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ABSTRACT 
 
A growing array of mouse and human pluripotent stem cell lines has been 
derived from the early embryo as well as from adult cells reprogrammed by ectopic 
expression of transcription factors – i.e. induced pluripotent stem (iPS) cells. These cell 
lines share the expression of key pluripotency markers and are able to self-renew and 
to generate differentiated progenies when induced. Their relationship to each other and 
whether they correspond to different pluripotent states with distinct developmental 
capacities and affiliations in vivo remains unclear, however. Profiling chromatin in a 
particular cell line has proven to be a valuable signature for cell identity and 
developmental stage. One approach has been to assay the timing of DNA replication 
across a panel of loci, as an indicator of chromatin accessibility. Of interest, this 
replication timing profiling was capable of discriminating pluripotent mouse ES (mES) 
cells from cells with a more restricted differentiation capacity. 
In this study, I have addressed whether distinct pluripotent states could be 
reliably discriminated at the chromatin level. In particular, I characterised the replication 
timing profile of a number of human ES (hES) cell lines alongside mES and mouse 
epiblast-derived stem (mEpiS) cell lines. I showed that mES cells have a steady and 
mostly early-replicating profile, regardless of their genetic background. In contrast, the 
profile of undifferentiated H1, H7 and H9 hES cell lines harboured an increased 
proportion of late-replicating loci during S-phase. Moreover, hES cell replication profile 
greatly varied between cultures and cell lines; a level of replication timing variability 
also observed among mEpiS cells, as opposed to mES cells. These results highlighted 
that hES and mEpiS cells share a common unstable or transitional state: primed on the 
verge of differentiation. 
This view was, however, further challenged by exploring how hES cell cultures 
could be modulated towards an ES-like versus epiblast-like state under different 
conditions. In particular, extensive and dynamic shifts of replication timing, from late to 
early, were consistently observed at many target loci in hES and hiPS cells upon 
increased Smad2/3 and p300 histone acetyltransferase activity. Importantly, these 
alterations were reversible and associated with differential gene expression profiles 
and functional properties of hES cells. Collectively, these data revealed the existence 
of distinct but interchangeable pluripotent hES cell states and proposed a key role for 
TGF-β/Activin signalling and the HAT p300 in modulating the balance between a naive 
versus primed state in hES cell cultures. 
 4 
ACKNOWLEDGEMENTS 
 
I would first like to give my sincere thank you to Veronique for giving me the 
opportunity to work in her lab, for her teaching, support and help on the demanding 
challenges of a PhD. It was very exciting to be part of the Epigenetics and 
Development group foundations. 
I would like to thank Olivia for being the perfect “desk and lab-neighbour” in the 
world, for all her friendship, advice and help (especially in filling up paperwork). I would 
additionally like to thank past and present members of the Epigenetics and 
Development Group (Anne, Fabrice, Kavita and Patrick) for being great colleagues, for 
all the scientific (and not that scientific) coffee discussions and for making work in the 
lab so much fun. In particular, I would like to specifically thank Matias for all his help in 
the lab, lost weekends in tissue culture room and for being a good colleague and a 
“stubborn” friend. I would like to thanks our collaborators: Neil Harrison and Peter 
Andrews (University of Sheffield, UK), Catherine Flores (Imperial College, London), 
Ludovic Vallier (University of Cambridge, UK) and especially to Wei Cui (Imperial 
College, London) for all her help and teaching with the human embryonic stem cells. 
Thanks also to everyone in IRDB first floor for being great colleagues and for creating a 
friendly atmosphere to work. 
A special acknowledgement goes to the GABBA PhD Program for giving me the 
privilege of becoming one of their students, for the scientific training and above all for 
the freedom of choice. I am indebted to all my friends and teachers from the 8th edition 
for an amazing year of learning and scientific discussions. This work would not be 
possible without the generous financial support from the funding bodies FCT, Portugal, 
and the IOG Trust Fund, UK. I also want to thank all my housemates and friends in 
London that made this city a fantastic place to live and so difficult to leave.  
My very special thank you goes to Filipe for always being present, for believing 
in me, for his patience, and for the constant help and support throughout these years. It 
is a privilege to have you by my side. 
Finalmente agradeço aos meus pais Ana Maria e Manuel, às minhas irmãs 
Paula e Rosa e aos meus avós pelo amor e apoio incondicional que sempre me deram 
e por me ajudarem a concretizar os meus sonhos, mesmo quando isso implica a 
minha ausência. Obrigada. 
 5 
TABLE OF CONTENTS 
 
STATEMENT OF ORIGINALITY 2 
ABSTRACT 3 
ACKNOWLEDGEMENTS 4 
TABLE OF CONTENTS 5 
FIGURES AND TABLES 8 
ABBREVIATIONS 11 
CHAPTER 1. INTRODUCTION 15 
1.1. Epigenetic levels of gene regulation and epigenetic inheritance 16 
1.1.1. Chromatin structure 16 
1.1.2. DNA methylation 19 
1.1.3. Covalent histone modifications and their impact on chromatin dynamics 21 
1.1.4. Spatial constraints – nuclear organisation 27 
1.1.5. Temporal constraints – DNA replication timing 29 
1.2. Early mammalian development 33 
1.2.1. Early embryo development and pluripotency 33 
1.2.2. Embryo-derived stem cells 34 
1.2.3. Signalling pathways required for ES cells self-renewal and pluripotency 39 
1.2.4. Transcriptional networks that control pluripotency 42 
1.2.5. Epigenetic control of pluripotency 42 
1.2.6. Reprogramming to pluripotency 43 
1.3. Aims of this study 47 
CHAPTER 2. MATERIALS AND METHODS 48 
2.1. Materials 48 
2.1.1. Primary antibodies 48 
2.1.2. Secondary antibodies 49 
2.1.3. Cell lines 50 
2.2. Methods 52 
2.2.1. Cell culture 52 
2.2.2. Human ES cells differentiation 54 
2.2.3. Replication Timing analysis 56 
2.2.4. Reverse transcription (RT) polymerase chain reaction (PCR) 57 
2.2.5. Genomic context analysis 59 
2.2.6. Immunofluorescence analysis and alkaline phosphatase activity 59 
 6 
2.2.7. Fluorescence activated cell sorting analysis 60 
2.2.8. Western blot analysis 61 
2.2.9. Chromatin immunoprecipitation analysis 62 
2.2.10. Methylated DNA immunoprecipitation analysis 64 
2.2.11. Cell fusion and experimental heterokaryons 64 
2.2.12. Analysis of DNA content and BrdU incorporation following acid denaturation of DNA 65 
CHAPTER 3. CHARACTERIZATION OF THE CHROMATIN STATUS OF HUMAN ES 
CELLS ALONGSIDE MOUSE ES AND EPIS CELLS 67 
3.1. Replication timing analysis of hES, mES and mEpiS cells using a candidate 
based approach 67 
3.2. Replication timing profiles are conserved between independent mES cell lines 72 
3.3. Pluripotent mouse and human ES cells have distinct replication timing profiles 74 
3.4. Human ES cell replication profiles can be reliably discriminated from that of cells 
with more restricted differentiation capacity 76 
3.4.1. Replication timing comparison of hES and hES-derived neural progenitor cells 76 
3.4.2. Replication timing comparison of human ES and CD34+ haematopoietic stem cells 80 
3.5. Analysis of the gene expression status and chromosomal context of replication 
timing variable genes 81 
3.5.1. Gene expression and histone acetylation analysis of genes shifting replication timing across 
H1, H7 and H9 hES cells 81 
3.5.2. Genomic features analysis of genes shifting replication timing across H1, H7 and H9 hES cells
 84 
3.5.3. DNA methylation analysis at promoters of replication timing variable genes across H1, H7 and 
H9 hES cells 86 
3.6. Human ES and mEpiS cells share a common unstable or transitional state: 
primed on the verge of differentiation 87 
CHAPTER 4. IDENTIFICATION AND CHARACTERIZATION OF DISTINCT 
PLURIPOTENT STATES WITHIN HUMAN ES CELL CULTURES: NAIVE VS 
PRIMED 91 
4.1. Undifferentiated hES cell replication timing profile is prone to extensive 
alterations upon different cell culture conditions 91 
4.1.1. Replication profile of H9 hES cells grown in two different laboratories 91 
4.1.2. Dynamic equilibrium and heterogeneity of hES cells in distinct epigenetic states 92 
4.1.3. Fully reprogrammed hiPS cell replication profiles matches hES cells dramatic late to early 
shifts in response to alterations in culture conditions 95 
4.2. Phenotypic and functional characterization of distinct populations of 
undifferentiated hES cells in CM and CDMactivin growth conditions 97 
4.2.1. CDM
activin
 conditions maintain H1 hES cells in an undifferentiated state supporting their self-
renewal 97 
4.2.2. H1 CM and CDM
activin
 form embryoid bodies containing tri-germ layer differentiation 98 
4.2.3. H1 hES cells in CM and CDM
activin
 conditions have different kinetics of in vitro differentiation
 100 
4.2.4 CDM
activin
 conditions tip the balance towards a more stable, ICM-like cell phenotype within hES 
cell cultures 102 
4.3. Generation of inter-species heterokaryons by cellular fusion 104 
 7 
4.3.1. Mouse EpiS cells are not able to reprogram human B-lymphocytes for pluripotency in contrast 
to mES cells 106 
4.3.2. Both H1 CM and CDM
activin
 hES cells are able to reprogram mouse B-lymphocytes for 
pluripotency 108 
CHAPTER 5. EPIGENETIC AND MOLECULAR MECHANISMS UNDERLYING 
DISTINCT PLURIPOTENT STATES WITHIN HUMAN ES CELLS 110 
5.1. A possible role for TGF-β/Activin signalling in defining a hES cell naive versus 
primed state in culture 110 
5.2. Shift from early to late replication is accompanied by an increased recruitment of 
active p300 at the promoter of target genes in CDMactivin cells 111 
5.2.1. Global increase of p300-mediated histone H3 acetylation in CDM
activin
 hES cell cultures 111 
5.2.2. Recruitment of active p300 complexes at target loci is enhanced in response to CDM
activin
 
growth conditions 113 
5.3. Inhibition of p300 acetyltransferase activity leads to early to late replication 
timing alterations in H1 CDMactivin hES cells 115 
CHAPTER 6. DISCUSSION 118 
6.1. Human and mouse ES cells have distinct replication timing profiles 118 
6.2. Replication timing variability is a hallmark of hES cells in CM conditions and 
mEpiS cells 120 
6.3. Identification and characterization of distinct pluripotent states within hES cell 
cultures: naive vs primed 122 
6.4. Investigating the mechanisms that specify distinct pluripotent states within 
human ES cell cultures: a pivotal role for TGF-/Activin signalling and the histone 
acetyltransferase p300 126 
REFERENCES 129 
APPENDIX I – PRIMER SEQUENCES 151 
APPENDIX II – COMPLETE DATA SETS 160 
 
 
 
 
 8 
FIGURES AND TABLES 
 
Figure 1.1. Epigenetic levels of gene regulation. 17 
Figure 1.2. Post-translational modifications of human histones. 22 
Figure 1.3. Replication timing foci patters during early, middle and late S-phase of cell 
cycle. 30 
Figure 1.4. Schematic representation of the early stages of mouse development and 
derivation of stem cell types. 34 
Figure 3.1. Characterization of the undifferentiated state of hES cells alongside mES 
and mEpiS cells. 68 
Table 1. Candidate genes selected for the replication timing analysis. 69 
Figure 3.2. The principle of replication timing analysis 71 
Figure 3.3. Replication timing analysis controls. 72 
Figure 3.4. Independently derived mES cell lines from distinct genetic backgrounds 
have similar replication timing profiles. 73 
Figure 3.5. Pluripotent mouse and human ES cells have distinct replication timing 
profiles. 74 
Figure 3.6. Replication timing variability between established hES cell lines. 75 
Figure 3.7. Human ES cell cultures analysed by replication timing display 
homogeneous expression of pluripotency-associated markers. 77 
Figure 3.8. H7 undifferentiated hES cells can be clearly distinguished by replication 
timing analysis from neural progenitors (NP) H7-derived. 79 
Figure 3.9. Replication timing variability is not observed across human CD34+ 
haematopoietic stem cells. 80 
Figure 3.10. Human ES cells replication timing variability is not associated with gene 
expression or histone acetylation specific patterns. 83 
Table 2. Genomic features of replication timing analysed genes. 85 
Figure 3.11. Human ES cells replication timing variability is not associated with DNA 
methylation specific patters. 86 
Figure 3.12. Mouse EpiS and hES cells have identical cell cycle kinetics and variable 
replication timing profiles across many genes. 88 
Figure 4.1. Human ES cells grown under different culture conditions in different 
laboratories show dramatic replication timing late to early shifts. 92 
Figure 4.2. H1 hES cells grown under CM and CDMactivin conditions show dramatic 
replication timing late to early shifts. 93 
Figure 4.3. Loci subjected to replication timing shift towards early S-phase in CDMactivin 
conditions overlap between different hES cell lines. 94 
Figure 4.4. Fully reprogrammed hiPS cells replication profile also display dramatic late 
to early shifts in response to alterations in culture conditions. 96 
Figure 4.5. Human ES cells transferred from standard CM cell culture conditions to 
CDMactivin conditions retain their undifferentiated characteristics. 97 
 9 
Figure 4.6. Human ES cells in CDMactivin conditions show a slight increase in the 
percentage of cells in S and G2 compared to cells grown under standard CM 
conditions. 98 
Figure 4.7. Human ES cells in CM and CDMactivin conditions are able to differentiate in 
vitro into derivatives of the three germ layers. 99 
Figure 4.8. Human ES cells cultured in CDMactivin differentiate more slowly by EBs 
differentiation than hES cells cultured in CM. 100 
Figure 4.9. Human ES cells cultured in CDMactivin differentiate more slowly into 
neuroectoderm derivatives than hES cells cultured in CM. 101 
Figure 4.10. Differential gene expression profiles in H1 CM and CDMactivin hES cell 
populations. 102 
Figure 4.11. Transient increase in the expression levels of Nanog in H1 CDMactivin hES 
cells. 103 
Figure 4.12. Generation of inter-species heterokaryons by cell fusion. 105 
Figure 4.13. Mouse EpiS cells are not able to reprogram human B-lymphocytes for 
pluripotency by cellular fusion in contrast to mES cells. 107 
Figure 4.14. Both H1 CM and CDMactivin hES cells are able to reprogram mouse B-
lymphocytes for pluripotency by cellular fusion. 109 
Figure 5.1. H1 CDMactivin hES cells are characterized by higher levels of activated 
Smad2/3 complexes in comparison to H1 CM cell cultures. 111 
Figure 5.2. The histone acetyltransferase p300 is highly expressed in H1 CDMactivin hES 
cells in contrast to H1 CM cells. 112 
Figure 5.3. Loci changing replication timing from late in CM to early in CDMactivin hES 
cells have higher levels of p300 and histones acetylation at their promoter regions in 
CDMactivin hES cells. 114 
Figure 5.4. Inhibition of p300 activity in H1 CDMactivin hES cells by curcumin leads to a 
reduction in the levels of histone acetylation without inducing cell differentiation. 116 
Figure 5.5. Inhibition of p300 acetyltransferase activity in curcumin-treated H1 CDMactivin 
hES cells induces replication timing changes towards a CM-like profile. 117 
Figure 6.1. Proposed model for the maintenance of distinct pluripotent states within 
hES cell cultures 123 
Table A1. Primers for the amplification of human or mouse transcripts by real time 
quantitative PCR 151 
Table A2. Primers used for the amplification of human transcripts by semi-quantitative 
RT-PCR 154 
Table A3. Primers for the selective amplification of human or mouse genomic regions 
by real time quantitative PCR 155 
Figure A1. Comparison of replication timing profiles between mES (E14tg2A, B6 and 
Dc7), mEpiS (129, B6/CBA and NOD) and hES (H1, H7 and H9) cell lines. 160 
Figure A2. Comparative replication timing analysis of mES (E14tg2A, B6 and Dc7), 
mEpiS (129, B6/CBA and NOD) and hES (H1, H7 and H9) cell lines. 161 
Figure A3. Replication timing analysis of H1 hES cells re-swapped to CM conditions 
after growing in CDMactivin . 162 
Figure A4. Human ES cell populations grown under CDMactivin conditions are more 
homogeneous than cells grown under standard CM conditions. 162 
 10 
Figure A5. Differential gene expression of mES and mEpiS cell populations. 163 
Figure A6. Cell culture adaptation and karyotype abnormalities are not associated with 
earlier replication timing profiles in hES cells. 163 
 
 
 11 
ABBREVIATIONS 
 
α-MEM minimal essential medium 
µ micro 
AP alkaline phosphatase 
APC allophycocyanin 
AT adenine-thymine 
ATP adenosine tri-phosphate 
BMP bone morphogenetic protein 
bp base pair 
BrdU 5-bromo-2-deoxyuridine 
BSA bovine serum albumin 
cDNA complementary DNA 
CDM chemically defined medium 
ChIP chromatin immunoprecipitation 
CM conditioned medium 
C(T) threshold cycle 
CpG cytosine-guanine dinucleotide 
CTD carboxy-terminal domain 
DAPI 4,6-diamidino-2-phenylindole 
DiD 1,1’-dioctadecyl-3, 3, 3’, 3’ tetramethylindodicarbocyanine  
DiI 
1,1'-dioctadecyl-3, 3, 3', 3'-tetramethylindocarbocyanine 
perchlorate 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
Dnmt DNA methyltransferase 
dpc days post-coitum 
DTT dihiothreitol 
EB embryoid body 
EDTA ethylene-dinitrilo tetraacetic acid 
EC embryonic carcinoma 
EG embryonic germ 
EGF epidermal growth factor 
ES embryonic stem 
 12 
FACS fluorescence-activated cell sorter 
FBS foetal bovine serum 
FISH fluorescent in situ hybridisation 
FITC fluorescein isothiocyanate 
FGF fibroblast growth factor 
g gram 
GC guanine-cytosine  
GFP green fluorescent protein 
GMEM Glasgow’s modified Eagle’s medium 
Gy gray 
H histone 
HAT histone acetyltransferase 
hB Epstein-Barr virus-transformed human B lymphocytes 
HDAC histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hES Human embryonic stem 
HMT histone methyltransferase 
HRP horseradish peroxidase 
HP haematopoietic progenitor 
ICM inner cell mass 
IF immunofluorescence 
IL interleukin 
IMDM Iscove's modified Dulbecco's medium 
IP immunoprecipitation 
iPS induced pluripotent stem 
ISWI imitation switch family of chromatin remodelling ATPases 
K lysine 
Kb kilobase pair 
kDa kiloDalton 
KSR knockout serum replacement 
L litre 
LIF leukaemia inhibitory factor 
LINE long interspersed nuclear element 
m milli 
M molar 
Mb mega base pair 
 13 
MBD methyl-CpG binding domain 
me methylated 
MeDIP methylated DNA immunoprecipitation 
MEF mouse embryonic fibroblast  
mEpiS mouse epiblast stem 
mES mouse embryonic stem 
MgCl2 magnesium chloride 
min minute 
mRNA messenger RNA 
NaCl sodium chloride 
NEAA non-essential amino acids 
NGS normal goat serum 
NP neural progenitor 
NP-40 nonidet P-40 
P phosphorylated 
PBS phosphate buffered saline 
PcG polycomb group 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PEV position effect variegation 
PFA paraformaldehyde 
PGC primordial germ cell 
PI propidium iodide 
PK proteinase K 
PMSF phenylmethylsulphonyl fluoride 
Pol polymerase 
PRC polycomb repressive complex 
PRE polycomb response element 
PrE primitive endoderm 
qPCR real-time quantitative PCR 
RIPA radio immuno precipitation assay 
RNA ribonucleic acid 
RNAse ribonuclease 
rpm rotations per minute 
RPMI Roswell Park Memorial Institute medium 
RT-PCR reverse transcription PCR 
 14 
S. cerevisiae Saccharomyces cerevisiae, budding yeast 
SDS sodium dodecyl sulphate 
SET Su(var)-Enhancer of zeste-Trithorax 
SSEA stage-specific embryonic antigen 
SWI/SNF 
(mating-type) switch / sucrose non-fermenting family of 
chromatin remodelling ATPases 
TBS-T tris-buffered saline with tween20 
TGF transforming growth factor 
TE trophectoderm 
Tra tumor rejection antigen 
Tris (hydroxymethyl)methylamine 
TrxG trithorax group 
TS trophoblast stem 
TSS transcriptional start site 
U units 
WB western blot 
XEN extra-embryonic endoderm stem 
 
 15 
CHAPTER 1. INTRODUCTION 
 
 Mammalian development is a remarkable process underlined by a progressive 
loss of cell developmental potential and the acquisition of lineage-specific functions. 
This process begins with the fusion of germ cells, two highly differentiated cells, leading 
to the formation of a single totipotent zygotic cell and ends with the establishment of 
more than 200 specialised cell types of the mammalian body. Elucidating the 
mechanisms by which genetically identical cells acquire different cell identities during 
development and how those are stably maintained has been a major challenge in 
developmental biology for many years.  
 With the completion of the human genome sequencing (Lander et al., 2001; 
McPherson et al., 2001) it became clear that sequences are only the tip of the iceberg 
for understanding how genetic information is interpreted. Superimposed upon the DNA 
sequence exist several layers of heritable information that we are only beginning to 
understand. The vast majority of cells in a multicellular organism share the same 
genetic information, yet a multitude of specialised cell types each using a unique 
subset of genes is generated throughout development. Current evidence points to the 
importance of a close coordination between genetic and epigenetic programs in the 
control of cellular determination during development. Epigenetic factors include 
modifications in chromatin structure, methylation of the DNA cytosine residues, DNA 
replication timing, regulation by small interfering RNAs and the spatial positioning of the 
genomic region within the nucleus. These genetic and epigenetic programs are, in turn, 
regulated by signaling molecules, which together with interactions among neighboring 
cells induce appropriate and differential transcriptional and epigenetic responses that 
are essential for cell fate determination. In addition, epigenetic mechanisms contribute 
to the repression of inappropriate developmental programs in time and space while 
ensuring heritability of existing or newly acquired phenotypic states. These extrinsic 
and intrinsic regulators determine the developmental origin and subsequent 
maintenance of lineage commitment throughout rounds of cell division (Hochedlinger 
and Plath, 2009; Surani et al., 2007). 
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1.1. Epigenetic levels of gene regulation and 
epigenetic inheritance 
 
The term “epigenetic” was initially introduced by Conrad Waddington in 1942 
(Waddington, 1942) to describe how genes of a genotype bring about a phenotype. 
Currently, the most widely accepted definition designates epigenetics as the study of 
heritable changes in gene function that occur without alterations to the DNA sequence 
(Russo et al., 1996). Epigenetic inheritance refers to the transmission of information 
beyond the DNA sequence during cell division and from one generation to the next. 
Inheritance of epigenetic information is crucial for maintaining differential gene 
expression patterns in differentiation, development and disease (Haig, 2004). The key 
players in epigenetic inheritance are now beginning to be revealed. These include 
heritable but potentially reversible modifications in chromatin structure, methylation of 
DNA, regulation by small interfering RNAs and higher-order genome organisation 
(Figure 1.1). Histone-modifying enzymes, DNA methyltransferases, chromatin-binding 
proteins, non-coding RNAs and many other regulators may act together with sequence-
specific transcriptional factors to establish and convey gene expression patterns during 
development, ensuring the stability of the “committed” state. Uncoupling the chromatin 
changes that are “locked” and stably propagated throughout cell division from those 
that are transiently regulated constitutes a big challenge to define the epigenetic value 
of chromatin (Turner, 2002). 
 
1.1.1. Chromatin structure 
 
In the nuclei of all eukaryotic cells, the genomic information is divided between 
a set of different chromosomes. The genome is large, each human cell contains around 
three meters of DNA that needs to be highly compacted and ordered to fit within the 
nucleus. This is achieved by the interaction of DNA with histone and non-histone 
proteins to form a dynamic polymer called chromatin (Figure 1.1). The dynamic 
organization of chromatin is dependent on the higher order structuring of nucleosomes, 
the basic repeating unit of chromatin. The nucleosome includes the compact octameric 
histone complex consisting of two copies of each of the four core histones H2A, H2B, 
H3 and H4 wrapped by 147 basepairs (bp) of DNA (Luger et al., 1997). In addition to 
the canonical histones, several histone variants have been identified for example, the 
histone variant H3.3, which differs in only four amino acids from H3, but has different 
biological properties. While the canonical H3 is synthesised exclusively in dividing cells 
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and integrated into chromatin during DNA replication, H3.3 is constitutively expressed 
and deposited into chromatin throughout the cell cycle (Ahmad and Henikoff, 2002a, b). 
It has been proposed that the replication-independent histone replacement can be 
involved in the propagation of active chromatin states. Several variants have also been 
described for histone H2A. For example, H2AZ has emerged as a key regulator of 
chromatin function and necessary for embryonic stem (ES) cell differentiation 
(Creyghton et al., 2008).  
 
 
 
Figure 1.1. Epigenetic levels of gene regulation. Schematic representation of different levels of genome 
organisation that have an impact on gene regulation and epigenetic inheritance. (a) The DNA double helix 
carries the genetic information used for development and functioning of all known living organisms. DNA 
itself is covalently modified by methylation (Me) of cytosine residues, providing the most direct epigenetic 
mechanism of gene regulation. (b) DNA is wrapped around histones to form a “beads on a string” structure 
that is folded into higher order chromatin domains. Histones are also post-translationally modified at 
specific amino acids within their histone tails for example, by acetylation (Ac), methylation (Me) and 
phosphorylation (P), and each mark constitutes a signal that is read alone or in combination with other 
modifications on the same or neighbouring histones as a “histone code”. The nucleosome particles that 
comprise chromatin are represented as spheres and DNA as blue lines. (c) Nucleosomal arrays are 
packed into several levels of condensed, higher-order chromatin domains and organised in functional 
nuclear compartments. These three-dimensional structures along with temporal constraints (DNA 
replication timing) provide additional levels of regulation. Together these mechanisms provide some 
molecular clues on how a single genome can produce such a diversity of cell types. Adapted from (Probst 
et al., 2009; Sparmann and van Lohuizen, 2006). 
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While the length of DNA wrapped around the nucleosome is constant, the 
length of DNA separating nucleosomes varies between 10 and 80 bp. Although 
nucleosome mapping experiments did not reveal any strongly preferred DNA sequence 
consensus for nucleosome assembly it was suggested that nucleosome positioning is 
non-random and has a functional significance in several cellular processes including 
transcriptional regulation, chromosome segregation, DNA replication and DNA repair 
(Henikoff, 2008; Li et al., 2007; Schones et al., 2008). Several chromatin remodeling 
complexes (remodelers) that alter the positioning and/or nucleosome structure were 
identified. Many proteins of these complexes are ATPases that use energy of ATP 
hydrolysis to move, destabilise, eject, or restructure nucleosomes, including the 
SWI/SNF, ISWI, CDH and INO80 complexes (Clapier and Cairns, 2009). Together with 
additional chromatin associated proteins, including histone H1, nucleosomal arrays are 
packed into several levels of condensed, higher-order chromatin structures, which are 
organised in specific nuclear compartments (Figure 1.1) (Maresca and Heald, 2006; 
Tremethick, 2007). This folding can compact DNA by a factor of 30-40 fold (Widom, 
1989). 
The packaging of eukaryotic DNA must meet two requirements - DNA must be 
sufficiently compacted to fit inside the nucleus, and yet the DNA of transcriptionally 
competent or active genes must remain accessible to transcription factors and the RNA 
polymerase complex. These opposing requirements can be met by varying the mode of 
packaging. Early studies in 1928 by Emil Heitz suggested that the interphase chromatin 
is present in two distinguishable states: a less condensed form, euchromatin, and a 
more condensed form, heterochromatin, which stained intensely with specific dyes 
(Heitz, 1928). Euchromatin is the lightly packaged form of chromatin. Because of its 
unfolded structure, euchromatin is highly accessible to transcription factors and RNA 
polymerases. It is enriched for active genes replicating earlier in the S-phase of cell 
cycle than heterochromatin (Holmquist and Ashley, 2006; Shahbazian and Grunstein, 
2007). In contrast, the higher-order structures of the tightly packed heterochromatin are 
thought to favor gene silencing (Holmquist and Ashley, 2006), as was first 
demonstrated by the phenomenon of position effect variegation (PEV). In this 
phenomenon, the integration of genes that are normally found in euchromatin, close to 
heterochromatic regions, often results in sporadic gene silencing, giving rise to a 
mosaic pattern of expression within a given tissue. This heritable silencing 
phenomenon was first identified in Drosophila where chromosomal rearrangements 
that resulted in the positioning of an eye color gene into a close proximity to 
centromeric heterochromatin resulted in a colorless (silencing) eye phenotype (Muller 
and Altenburg, 1930). Some chromosomal regions developmentally regulated have 
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long been known to be “naturally” present in both euchromatic and heterochromatic 
forms depending on the cell type. Such regions were termed facultative 
heterochromatin and one of the most extensive examples of facultative 
heterochromatin formation is the inactivation of one of the two X-chromosomes in early 
embryonic development (Heard, 2005). As opposed to facultative heterochromatin, the 
constitutive heterochromatin is generally silenced in all cell types and includes 
centromeres, telomeres, pericentric regions, repetitive DNA elements and transposons 
(Arney and Fisher, 2004).  
 
1.1.2. DNA methylation 
 
DNA methylation is an epigenetic repression pathway, which, in vertebrates, 
occurs only at cytosines in the context of CpG dinucleotides (Figure 1.1). It is catalyzed 
by three essential DNA (cytosine-5) methyltransferases (Dnmt1, Dnmt3a and Dnmt3b) 
(Goll and Bestor, 2005). Dnmt1- or Dnmt3b-deficient mouse embryos die by embryonic 
day 10.5 and Dnmt3a-deficient mice are born occasionally but suffer serious 
malformations especially at the germ cell level and die within weeks (Goll and Bestor, 
2005). CpG methylation, especially within the promoter region of genes, is associated 
with stable transcriptional repression and plays important roles for X-chromosome 
inactivation, genomic imprinting, cell differentiation and carcinogenesis (Bird, 2002; 
Farthing et al., 2008; Jones and Baylin, 2002; Reik, 2007). Methylation patterns are 
propagated in mitotic cells by maintenance methylation activity that takes place in 
concert with DNA replication. The methyltransferase Dnmt1 performs this maintenance 
function (Bestor et al., 1988; Li et al., 1992). Dnmt1 is the most abundant DNA 
methyltransferase present in mammalian cells and has a substrate preference for 
hemimethylated DNA in vitro and is usually associated with replication foci in the S-
phase of dividing cells (Chuang et al., 1997; Leonhardt et al., 1992).  
During mammalian development, the genome goes through cycles of genome 
wide reprogramming that dramatically alter the overall patterns of DNA methylation 
(Reik, 2007). In early embryonic development parental methylation is lost, presumably 
due to the exclusion of Dnmt1 from the nucleus (Carlson et al., 1992) but methylation 
levels are restored at the blastocyst stage (Santos et al., 2002). Methylation patterns 
that are established at imprinted loci at this stage, such as the Igf2/H19 locus, are 
preserved in all cells of the adult organism, except for the germ line (Edwards et al., 
2007). The purpose of methylation reprogramming in preimplantation embryos is not 
well understood; one possible explanation is that demethylation in the early embryo is 
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needed for the parental genomes to lose their epigenetic marks so that the genome 
can return to totipotency (Reik et al., 2001). Genome-wide hypomethylation at the 
morula stage is then followed by lineage specific de novo methylation beginning at the 
blastocyst stage (Santos et al., 2002), presumably carried out by Dnmt3a and Dnmt3b 
(Okano et al., 1999). It is possible that this de novo methylation leads to epigenetic 
silencing of key promoters during early development. Indeed some regulators of 
pluripotency are hypomethylated in ES cells but become methylated upon 
differentiation in both mouse and human. A well characterised example of a locus 
regulated by DNA methylation is the ES cell-specific factor Oct4, which undergoes 
stable repression with cell differentiation (Farthing et al., 2008; Feldman et al., 2006; 
Gidekel and Bergman, 2002; Yeo et al., 2007).  
DNA methylation is thought to interfere with gene transcription by at least two 
independent mechanisms. Firstly, methyl-CpGs can directly prevent transcription 
factors from binding to their recognition sites on the DNA (Bird and Wolffe, 1999). 
Secondly, methyl-CpGs can recruit a protein family sharing the methyl CpG-binding 
domain (MBD), which was shown to indirectly induce silencing by further recruiting co-
repressor complexes to methylated DNA (Boyes and Bird, 1991), including histone 
deacetylases or methyltransferases (Bird, 2002). The links between DNA and histone 
methylation are thought to be important for propagating (hetero-) chromatin states 
through mitosis. Accordingly, it was suggested that DNA methylation is not a primary 
silencing mechanism, but rather one that makes silencing more stable and potentially 
irreversible (Jones and Takai, 2001; Li, 2002; Pannell et al., 2000) apart from the 
exceptional occasions when DNA methylation is broadly erasured (upon fertilisation, 
during germ cell development and/or somatic cell reprogramming) (Reik, 2007). 
However, this view has been recently challenged with evidence that DNA methylation 
can be dynamically regulated by active CpG demethylation. Cyclical methylation and 
demethylation of CpG dinucleotides, with a periodicity of 1-2 hours, was shown to be a 
characteristic of the oestrogen (E2)-responsive pS2 gene, in human cells 
(Kangaspeska et al., 2008). The DNA deaminases Aid and Apobec1 have been shown 
in vitro to deaminate 5-methylcytosine in DNA to thymine (Morgan et al., 2004); this 
results in T-G mismatches, which can be repaired by the base-excision repair pathway. 
Indeed, Aid and Apobec1 are highly expressed by oocytes, stem cells and germ cells 
(Morgan et al., 2004). Another DNA-damage-responsive gene, Gadd45 (growth arrest 
and DNA-damage-inducible 45), has also been implicated in DNA demethylation 
(Barreto et al., 2007; Rai et al., 2008) but despite intensive research, the mechanism 
for active erasure of the methylation mark remains largely unknown and controversial 
(Jin et al., 2008). 
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1.1.3. Covalent histone modifications and their impact on 
chromatin dynamics 
 
Histones are highly evolutionarily conserved proteins with a flexible amino-
terminal tail and a characteristic histone fold, a globular domain that mediates 
interactions between histones to form the nucleosome scaffold (Figure 1.1). Structural 
studies confirm that the histone N-terminal tails protrude outward from the nucleosome 
and can thus influence interactions with other nucleosomes, as well as with regulatory 
factors (Luger et al., 1997). The N-terminal tail of histones, as well as more recently 
defined positions in the globular domain, can carry post-translational modifications 
such as acetylation (of lysine residues), phosphorylation (serine and threonine), 
ubiquitination (lysine), methylation (lysine and arginine), sumoylation (lysine) and ADP 
ribosylation (Figure 1.2) (Kouzarides, 2007). Acetylation and methylation are two of the 
most extensively studied post-translational histone modifications. These modifications 
were first discovered in the 1960s but were considered by many to be artifactual 
(Allfrey et al., 1964). Only in the last decade has it become clear that covalent histone 
modifications have crucial regulatory functions in gene regulation by altering DNA-
histone interactions within and between nucleosomes and, thus, affect higher-order 
chromatin structures (Kouzarides, 2007). In this regard, histone covalent modifications 
can collaborate to influence a multitude of cellular processes, including transcription, 
DNA replication timing, DNA repair and cell cycle progression (Bhaumik et al., 2007). 
Note that a large number of residues within histones can be simultaneously modified, 
with different types of modifications occuring in distinct patterns. For instance lysine 
acetylation correlates with chromatin accessibility and transcriptional activity that is the 
case of the acetylation of lysine 9 or 14 (H3K9ac or H3K14ac) while lysine methylation 
can have different effects depending on which residue is modified. The di- and 
trimethylation of lysine 4 (H3K4me2/3) are marks of active chromatin, conversely other 
lysine methylations such as H3K9me3 or H3K27me3 correlates with a repressed 
chromatin state (Bernstein et al., 2007; Peterson and Laniel, 2004). Moreover, these 
modifications regulate one another, providing regulatory cross-talk. That is, one 
modification can influence the occurrence of one or more subsequent modifications 
either in cis - on the same histone molecule, or in trans - between histone molecules or 
across nucleosomes (Campos and Reinberg, 2009). Histone modifications may even 
form an informational “code” that is read by the binding of effector proteins, driving the 
transition between transcriptionally active and silent chromatin states as well as distinct 
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downstream biological processes (Jenuwein and Allis, 2001; Latham and Dent, 2007; 
Strahl and Allis, 2000; Turner, 2000).  
 
 
 
Figure 1.2. Post-translational modifications of human histones. Different covalent post-translational 
modifications of the four core histone (H2A, H2B, H3 and H4) have been identified and are here 
represented above the corresponding amino acid residue in the N-terminal tails of histones. These include 
acetylation (ac), phosphorylation by (ph), ubiquitylation (ub1) and methylation (me). Globular domains of 
each core histones are represented as ovals. Acetylation of lysines 9 or 14 of histone H3 (H3K9ac or 
H3K14ac) or dimethylation of lysine 4 (H3K4me2) are generally associated with open genomic regions and 
transcription, whereas others, such as H3K9me3 or H3K27me3, are indicative of a repressed chromatin 
state. Covalent histone modifications, alone or in combination, can influence nucleosome mobility and 
function as a platform for the recruitment of effector proteins (from Bhaumik et al, 2007). 
 
 
1.1.3.1. Histone acetylation 
 
Histone acetylation plays key roles in modulating chromatin structure and 
function (Shahbazian and Grunstein, 2007). Transcriptionally active chromatin was 
initially shown to be enriched in acetylated histones (Hebbes et al., 1988; Pogo et al., 
1966), whereas heterochromatic regions of the genome were shown to be 
hypoacetylated (Jeppesen and Turner, 1993; Maison et al., 2002). These associations 
have been more recently explored and confirmed by numerous large-scale studies 
mapping histone modifications across the genome (Birney et al., 2007; Koch et al., 
2007; Wang et al., 2009). Histone acetylation is a modification that neutralizes the 
positive charge of the target lysine. It can occur at specific lysines on the four core 
histones (Figure 1.2), however, modifications of histone H3 and H4 have been more 
extensively characterized. It has been proposed that histone acetylation promotes a 
“open” chromatin configuration by decreasing interactions between nucleosomes, 
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releasing the histone tails from the linker DNA, reducing fiber-fiber interactions and 
thus facilitating transcription machinery accessibility (Shahbazian and Grunstein, 
2007). In addition, acetylation may promote transcription by providing binding sites for 
proteins involved in gene activation, such as those containing bromodomains. The 
chromatin remodelling complex SWI/SNF, which mobilizes nucleosomes and is 
important for transcriptional activation, is an example of a protein complex that binds to 
acetylated histones through a bromodomain (Hassan et al., 2002).  
The acetylation state of a given chromatin locus is controlled by two classes of 
antagonizing histone modifying enzymes, histone acetyltransferases (HATs) and 
deacetylases (HDACs), which add or remove acetyl groups to/from target histones, 
respectively (Wade et al., 1997). Despite the general correlation between histone 
acetylation and gene transcription, it is not a stably increased level of acetylation that is 
important for transcription but rather a high level of acetylation, coupled with rapid 
deacetylation. It has been known for some time that the turnover of histone acetylation 
can be quite rapid. Remarkably, the fastest rates of acetylation turnover (with half-lives 
between 1-5 min) are associated with transcriptionally active regions, whereas slower 
rates of turnover (with half-lives between 30-60 min) do not correlate with 
transcriptional activity (Covault and Chalkley, 1980; Waterborg, 2002). Recent 
genome-wide studies showed that the dynamic cycle of acetylation and deacetylation 
by the transient binding of HATs and HDACs at promoters occupied by H3K4 
methylation, may poise inactive genes for future activation (Wang et al., 2009). While 
this makes continuous demands on cell energy resources, it also offers an advantage 
to primed genes whose expression may need to be up- or downregulated relatively 
quickly, in respond to hormonal cues or growth factor stimulation, for example. 
Three major groups of HATs have been identified as transcriptional 
coactivators: Gcn5-related N-acetyltransferases (GNATs), E1A-associated protein of 
300 kDa (p300)/CREB-binding protein (CBP), and MYST proteins (Lee and Workman, 
2007; Yang and Seto, 2008a). In contrast, histone deacetylation is generally associated 
with transcriptional repression, and HDACs have been identified as transcriptional 
corepressors. Known HDACs are divided into the Rpd3/Hda1 and sirtuin families. In 
humans, the former contains HDAC1, -2, -3, and -8 (class I, similar to yeast Rpd3); 
HDAC4, -5, -6, -7, -9, and -10 (class II, homologs of yeast Hda1); and HDAC11 (class 
IV) (Yang and Seto, 2008b). Within the sirtuin family, there are seven members in 
humans (SIRT1– 7, related to yeast Sir2; also known as class III HDACs) (Haigis and 
Guarente, 2006). Similar to HATs, HDACs have critical functions in many cellular 
pathways, and their misregulation has been linked with tumorogenesis. Thus chemicals 
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that inhibit HDAC activity are currently among the most promising drugs in anticancer 
therapies (Bolden et al., 2006). 
Although histone acetylation is generally associated with actively transcribed 
genes, there are some reported exceptions to this rule. For example, acetylation of 
lysine 56 on histone H3 (H3K56ac) was shown to be dispensable for transcription but 
required for genome stability functions like DNA replication and repair (Li et al., 2008; 
Masumoto et al., 2005). More recently, H3K56ac was linked to the core transcriptional 
network of human ES cells, being enriched at active regulators that contribute to ES 
cell pluripotency and self-renewal, but also at inactive, lineage-specific genes that are 
poised for activation upon differentiation (Xie et al., 2009). 
 
1.1.3.2. Histone methylation 
 
Histone methylation at lysine and arginine residues in the N-terminal tails of 
histones H3 and H4 (Figure 1.2) has been linked to a number of cellular processes 
including DNA repair, replication, transcriptional activation and repression. Arginine 
residues can accept one or two methyl groups while lysine residues can be modified 
with one, two or three methyl groups. The enzymes that catalyse these modifications 
are known as histone methyltransferases and are either lysine (PKMTs) or arginine 
(PRMTs) specific. In contrast to acetylation (which broadly correlates with 
transcriptional activation), histone methylation is associated with different outcomes 
depending on the site and also the extent of methylation (Kouzarides, 2007). 
There are at least eight human PRMTs for which some level of 
methyltransferase activity has been shown and implicated in both negative and positive 
regulation of transcription. These proteins share a canonical sequence domain that is 
associated with the binding sites for cofactor and substrate (arginine), yet the sequence 
conservation among these proteins is low. Estimates of the total number of PRMTs that 
are encoded by the human genome vary, depending on the method of sequence 
alignment and the level of alignment stringency that is applied (Copeland et al., 2009). 
Two PRMTs, PRMT1 and CARM1 were shown to be associated with transcriptional 
activation by methylating H4R3 (Strahl et al., 2001; Wang et al., 2001) or H3R2, H3R17 
and H3R26 (Bauer et al., 2002; Schurter et al., 2001) respectively. Contrasting with 
this, PRMT5, that can methylate H3R8 and H4R3, was shown to act as a 
transcriptional repressor (Fabbrizio et al., 2002; Pal et al., 2003). In vivo, CARM1 has 
also been described as having an important role in the choice between embryonic and 
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extraembryonic commitment of blastomeres in early mouse development (Torres-
Padilla et al., 2007).  
Methylation of lysine residues is known to occur on histone H3 at lysines 4, 9, 
27, 36 and 79 and on histone H4 at lysine 20 (Figure 1.2). Histone H3 lysine 4, 36 and 
79 methylation has been correlated with transcriptional activity being mostly found in 
euchromatic regions, whereas methylation of H3K9 and H4K20 are found 
predominantly but not exclusively at constitutive heterochromatin (Martin and Zhang, 
2005; Peters et al., 2003). Methylated H3K27, in turn, is enriched at facultative 
heterochromatin, including the inactive X-chromosome (Peters et al., 2003; Rougeulle 
et al., 2004). Several proteins have been shown to specifically recognise and interact 
with methylated lysines (including chromodomain-, tudordomain- and WD40-repeat 
domain proteins), giving rise to diverse outcomes in terms of transcription (Martin and 
Zhang, 2005). Generally, proteins that associate with methylated H3K4 are involved in 
transcriptional activity (Pray-Grant et al., 2005; Wysocka et al., 2005), whereas those 
that bind methylated H3K9 or H3K27 are implicated in transcriptional repression 
(Fischle et al., 2003; Thiagalingam et al., 2003).  
With the exception of DOT1-like histone H3 methyltransferase, all human 
PKMTs contain a ~130 amino acid domain, referred to as the SET domain, which 
constitutes the catalytic domain of these enzymes (Schneider et al., 2002). SET 
domain–containing enzymes can catalyze methylation of specific lysines on histones 
H3 and H4. The mammalian versions of H3K9 methyltransferases include Suv39h1, 
Suv39h2, G9A and ESET. PR-Set7 and two other SET domain proteins, Suv4-20h1 
and Suv4-20h2, catalyze histone H4K20 methylation (Bhaumik et al., 2007; Shilatifard, 
2006; Sims and Reinberg, 2006). Enhancer of zeste homologue 2 (Ezh2) is a SET 
domain protein that forms the catalytic subunit of the protein core of polycomb 
repressive complex 2 (PRC2). Ezh2 is a PKMT that catalyses the methylation H3K27. 
Although Ezh2 contains the catalytic active site, all members of PRC2 complex are 
required for full PKMT activity (see below). The methylation of H3K4 is catalysed by the 
Trithorax/MLL complex (Copeland et al., 2009; Lachner and Jenuwein, 2002; Milne et 
al., 2002). 
Trithorax (TrxG) and Polycomb (PcG) group proteins were discovered in 
Drosophila as genes that, when mutated, would affect the spatially restricted 
expression pattern of Hox genes and developmental patterning (Lewis, 1978). These 
proteins are part of a widely conserved “cell memory” system that stabilises cell identity 
by restricting or maintaining transcription patterns set in the first stage of embryonic life, 
throughout development and in adulthood (Ringrose and Paro, 2004; Simon and 
Kingston, 2009). It is now accepted that PcG proteins regulate many genes in addition 
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to the Hox genes and several cellular processes, including proliferation, X-inactivation 
and pluripotency by regulating developmental genes such as transcription factors and 
signalling proteins (Azuara et al., 2006; Bernstein et al., 2006; Boyer et al., 2006; 
Heard, 2005; Lee et al., 2006; Schwartz et al., 2006; Spivakov and Fisher, 2007). PcG 
proteins are involved in gene repression and silencing, whereas TrxG proteins 
counteract repressive PcG functions and maintain gene activity (Orlando and Paro, 
1995; Pirrotta, 1998).  
As previously mentioned, TrxG protein complexes were found to methylate 
H3K4 (Milne et al., 2002), a modification typically associated with active chromatin 
(Ruthenburg et al., 2007). The recruitment of the mammalian TrxG protein MLL is 
facilitated by basal transcriptional machinery as well as sequence-specific transcription 
factors (Ruthenburg et al., 2007). H3K4 methylation can also be catalyzed by several 
MLL unrelated methyltransferases and the recruitment of one of them, Ash1, was 
shown to be mediated by non-coding RNAs (Sanchez-Elsner et al., 2006). H3K4 
methylation is also known to recruit transcriptional activators and nucleosome 
remodelling factors, such as the HAT-containing complexes SAGA and the ISWI-
containing complex NURF (Pray-Grant et al., 2005; Wysocka et al., 2006). 
The methylation of H3K27 is associated with PcG proteins, a family of multiple 
proteins involved in the epigenetic maintenance of the transcriptionally silent state. 
Progress over the past decade has defined two main protein complexes, Polycomb 
repressive complex 1 (PRC1) and PRC2, with fundamental roles in PcG-mediated 
silencing. The mammalian PRC2 complex contains the histone methyltransferase Ezh2 
and also two other proteins, Eed (embryonic ectoderm development) and Suz12 
(suppressor of zeste-12) that are essential for the catalytic activity of the complex (Cao 
and Zhang, 2004). This complex by catalysing the trimethylation of H3K27, creates a 
binding site for PRC1, that comprises Ring1A/Ring1B, Bmi-1, Polycomb and 
Polyhomeotic proteins (Wang et al., 2004a). In addition, Ring1A/B in cooperation with 
Bmi-1 were shown to act as ubiquitin ligases catalysing the ubiquitylation of lysine 119 
of H2A (de Napoles et al., 2004), an event that was implicated in preventing active 
transcription of a number of developmental genes in ES cells (Jorgensen et al., 2006; 
Stock et al., 2007). This suggests that PRC1 and PRC2 collaborate in maintaining 
silent chromatin. 
Histone methylation was regarded as a more permanent mark compared to 
other histone modifications such as acetylation or phosphorylation (Bannister et al., 
2002). But with the discovery of novel histone arginine and lysine demethylases it is 
now considered a dynamic modification. Arginine demethylation is catalyzed by 
deiminases (Bannister et al., 2002). Members of the peptidyl arginine deiminase family, 
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including PADI4 deiminate arginine residues by converting them into citrulline 
(Nakashima et al., 2002; Wang et al., 2004b). The first histone demethylase to be 
identified was the lysine-specific demethylase 1 (LSD1), a protein previously found to 
be part of several HDAC complexes, that catalyses mono (me1)- or dimethylated (me2) 
H3K4 demethylation by an oxidative reaction (Shi et al., 2004). LSD1 has now been 
demonstrated to associate with both transcriptional repressors and activators. It 
demethylates H3K4me2/me1 when associated with the Co-REST complex at neuronal 
genes, or H3K9me2/me1 when associated with the androgen receptor (Metzger et al., 
2005; Shi et al., 2004). Unlike LSD1, a structurally unrelated family of enzymes has 
been found capable of removing both mono-, di- and trimethyl marks (Tsukada et al., 
2006). These proteins share a JmjC conserved motif and are thought to demethylate 
histones through a hydroxylation reaction. The methylation marks removed by these 
family of demethylases include H3K9, H3K27 and H3K36 (Klose and Zhang, 2007). Of 
interest, both H3K27 demethylases, JMJD3 and UTX, were found to be recruited with 
the H3K4 methylation machinery (Trithorax complex), resulting in the concerted 
demethylation of H3K27 (repression mark) and methylation of H3K4 (activation mark) 
at homeotic (Hox) loci during developmental activation (Agger et al., 2007; Lan et al., 
2007). Conversely, functional interplays between PRC2 complexes (that methylate 
H3K27) and the H3K4 demethylase Rbp2 were also recently demonstrated in mouse 
ES cells upon differentiation (Pasini et al., 2008). 
 
1.1.4. Spatial constraints – nuclear organisation 
 
The nucleus is a highly organized entity with complex substructures that in 
addition to the regulation provided by DNA and histone modifications have the capacity 
to influence a variety of cellular processes, including gene expression (Dillon, 2008).  
A striking feature of nuclear architecture is the non-homogeneous distribution in 
the nucleoplasm of components of the machinery required for gene transcription or 
repression (Iborra et al., 1996; Jackson, 1995; Negre et al., 2006). The positioning of a 
gene in the eukaryotic nucleus is also constrained by a variety of different parameters. 
The most basic constraint is the location of the gene as part of the linear sequence that 
forms each chromosome. Individual chromosomes form distinct territories in the 
nucleus (Figure 1.1). As a result of different compaction levels, different chromosome 
segments can adopt a complex organisation and topography within their chromosome 
territory (Croft et al., 1999; Edelmann et al., 2001). For example, a polarised 
intranuclear distribution of gene-rich and gene-poor chromosomal segments has been 
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shown to be an evolutionarily conserved principle of nuclear organisation (Cremer et 
al., 2003; Tanabe et al., 2002). Gene-rich regions tend to be oriented towards the 
nuclear interior, whereas gene-poor regions tend to be oriented towards the periphery 
(Foster and Bridger, 2005). Although these territories were thought to be relatively 
discrete and separate, recent data has provided evidence of extensive intermingling 
between chromosomes (Branco and Pombo, 2006), which would make it easier for 
genes on different chromosomes to come into contact with one another. Importantly, 
chromosomes can also be dynamically repositioned during development and cell 
differentiation, implying that nuclear organisation vary between cell types (Parada et 
al., 2004). One example of such is the clustering of heterochromatin in distinct foci in 
the nucleus of mammalian cells, which can undergo morphological changes during 
differentiation. For instance, when ES cells differentiate towards neural progenitor cells, 
the number of heterochromatic foci per nucleus decreased while the average cluster 
size increased, suggesting a global reorganisation of chromatin upon differentiation 
(Williams et al., 2006).  
Another parameter that can affect genes positioning in the nucleus is folding of 
the DNA into higher-order chromatin by trapping them within large aggregates of 
condensed heterochromatin. There is increasing evidence that gene repositioning to 
specific nuclear compartments is important for regulating gene expression (Gasser, 
2002). In many cell types, heterochromatin has been shown to localize preferentially to 
the nuclear periphery, which raises the possibility that proximity to the nuclear envelope 
facilitates silencing. For example, the inactive X-chromosome is often observed at the 
nuclear periphery of female cells (Burke and Stewart, 2002). A mutation of the human 
nuclear lamin A protein has also been found to result in reduced amounts of 
constitutive and facultative heterochromatin and associated H3K9 and H3K27 
methylation (Lammerding et al., 2005; Shumaker et al., 2006). However, there is not 
always a strict correlation between movement away from the periphery and gene 
activation. Indeed, the nuclear pores are important sites of transcription in yeast and 
genome-wide analysis has shown that nuclear pore-associated proteins bind 
preferentially to active genes (Casolari et al., 2004). 
The corollary to large-scale chromatin condensation is that escape from regions 
of condensed chromatin could be involved in regulating transcriptional activation 
(Dillon, 2008). The mouse Hoxb locus provides an example of such chromatin looping. 
Fluorescent in situ hybridization (FISH) analysis showed how Hoxb1 gene selectively 
“loops out” from its chromosome territory, moving towards the center of the nucleus, in 
Hoxb1-expressing cells during retinoic acid-induced differentiation of ES cells into 
neural progenitors (Chambeyron and Bickmore, 2004). Conversely, chromatin loops 
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can spatially separate genomic regions and contribute to gene silencing (Horike et al., 
2005). 
 
1.1.5. Temporal constraints – DNA replication timing 
 
The eukaryotic cell cycle consists of an orderly series of events in which cells 
grow, replicate their chromosomes, and segregate the duplicated genome to the 
daughter cells (Aladjem, 2007). DNA replication is central to this process and occurs by 
a complex series of events involving the activation of thousands of replication initiation 
zones that are spaced every 100 Kb on average (Huberman and Riggs, 1968). 
Activation of replication origins does not occur synchronously. Usually this process 
occurs in a defined sequential order during the S-phase of the cell cycle - some origins 
fire early and some fire late in S-phase (Camargo and Cervenka, 1982). This pattern is 
clonally inherited through subsequent cell divisions, but it can change at genes 
undergoing developmental activation or silencing (Cimbora and Groudine, 2001; Perry 
et al., 2004). 
Replication origins in S. cerevisiae are known to be DNA sequence-specific 
(Van Houten and Newlon, 1990). This sequences are designated autonomously 
replicating sequences (ARSs) and when inserted into a plasmid are able to confer 
autonomous replication (Stinchcomb et al., 1979). Although the time of firing during S-
phase has been defined for many ARSs, comparative sequence analyses at these 
sites has revealed no clear differences between early and late firing origins 
(Wintersberger, 2000). In metazoans, no consensus motifs that direct DNA replication 
from specific sites have been found and current evidence indicate that origin 
recognition complexes do not rely on sequences to be targeted to origins. The increase 
in genome size and the diversification of transcriptional programmes required for 
cellular specialisation in metazoans seem the most plausible explanations for the 
differences observed in S. cerevisiae and metazoan replication origin specification 
(Mechali, 2001). 
The time at which a locus replicates during S-phase (locus replication timing) is 
likely to be regulated at two levels; locally by the regulation of origin activity as 
described above and more globally by the mechanisms that determine the replication 
timing of entire chromosomal domains (Mendez, 2009). Chromosome replication 
domains were originally detected in the 1970s by pulse-labelling cells with nucleotide 
analogue 5-bromo-2-deoxyuridine (BrdU) at different times during S-phase and 
visualizing its incorporation into discrete areas of condensed mitotic chromosomes 
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(Latt, 1973; Stubblefield, 1975). It was then noted that the banding patterns observed 
after Giemsa staining overall coincide with early and late replicating domains; the dark 
G-bands tend to be late replicating, whereas early-replicating regions map to reverse 
(R) light bands (Dutrillaux et al., 1976). These correlations were further confirmed by 
replication timing high resolution maps of human chromosomes using microarray 
technology (Costantini and Bernardi, 2008; Woodfine et al., 2004). The dynamics of 
DNA replication can also be monitored by the detection of BrdU incorporation onto 
newly synthesized DNA during S-phase. Replication foci appear as intranuclear 
punctuated structures, which form different patterns as the S-phase progresses. In 
early S-phase many small foci are distributed all over the nuclei, in middle S foci are 
preferentially assembled around the nucleoli and nuclear periphery while late S is 
characterized by clusters of foci that correspond to heterochromatic regions (Figure 
1.3) (Dimitrova and Gilbert, 1999; O'Keefe et al., 1992). 
 
 
Figure 1.3. Replication timing 
foci patters during early, middle 
and late S-phase of cell cycle. 
Replication foci were visualized by 
30 min pulse-label with 5-bromo-2-
deoxyuridine (BrdU) and 
immunofluorescence detection. 
DNA was stained with Hoeschst 
(from Mendez, 2009).  
 
 
 
The temporal order of gene replication during S-phase has been proposed to be 
important for maintaining gene expression patterns (Gilbert, 2002). Early replication is 
generally associated with accessible chromatin carrying acetylated histones (Lin et al., 
2003; Perry et al., 2004; Vogelauer et al., 2002), whereas late replication is a 
characteristic of constitutive heterochromatin and some facultative heterochromatin, 
formed through gene repression (Gilbert, 2002; Peters and Schubeler, 2005). In 
accordance, housekeeping genes constitutively replicate early in S-phase, whereas 
many tissue-specific genes are developmentally regulated so that they replicate later in 
most cell types but earlier in the tissue of expression (Goren and Cedar, 2003). In the 
case of imprinted genes in which only one of the two parental alleles is active, the 
expressed allele replicates early and the repressed allele replicates late (Simon et al., 
1999). However, there are also many inactive genes that replicate early. For example 
genes involved in stress response and apoptosis, which are not expressed during 
normal proliferation but need to be accessible for rapid transcription in special 
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circumstances. These results suggest that a correlation may exist between early 
replication timing and the potential for gene expression rather than actual expression. A 
small number of late replicating genes with strong promoters that may render 
regulatory elements accessible was also shown to be expressed (Hiratani and Gilbert, 
2009; Mendez, 2009). 
As previously mentioned, genome-wide studies in Drosophila and mammalian 
cells suggested that replication timing might also correlate with its genomic context. 
More specifically, GC-rich, gene-dense regions tend to replicate early in S-phase, while 
AT-rich, gene-poor regions with high LINE (linear interspersed nuclear element) 
content tend to replicate later (Hiratani et al., 2004; Schubeler et al., 2002; Woodfine et 
al., 2004). The nature of such correlation between replication timing and genomic 
features remains unclear, however. Interestingly, candidate-based and genome-wide 
approaches have begun to define possible cross-tables between replication timing and 
histone marking. In particular, early-replicating domains map to regions enriched in 
histone modifications that are characteristic of active chromatin (Hiratani et al., 2008; 
Karnani et al., 2007; Perry et al., 2004). The presence of repressive chromatin marks in 
late replication timing domains was conversely reported in human (Karnani et al., 2007) 
but not in mouse replication timing maps (Hiratani et al., 2008), although the reason for 
this discrepancy is not clear. Interestingly, the chromatin modification that correlates 
most strongly with early replication timing is histone acetylation (Mendez, 2009). In 
particular, Cedar and colleagues demonstrated how the recruitment of HATs to the 
human β-globin locus in a non-erythroid cell line would change its replication timing 
from late to early. Conversely, tethering an HDAC to the locus in an erythroid cell line, 
where β-globin is normally expressed, was sufficient to change its replication timing 
from early to late (Goren et al., 2008). A correlation between histone acetylation and 
replication timing was further supported by the fact that the use of HDAC inhibitors 
(sodium butyrate or trichostatin A) was sufficient to remove the replication imprinting 
signals in two loci (Wt1 and Igf2) on human chromosome 11p (Bickmore and 
Carothers, 1995). It was hypothesised that histone acetylation renders replication 
origins more efficiently or specifically orchestrates earlier firing leading to earlier 
conclusion of locus replication (Aparicio et al., 2004; Vogelauer et al., 2002). Besides 
histone acetylation, the influence of other DNA or histone modifications on replication 
timing determination is less certain and may be restricted to specific chromosome 
structures (Jorgensen et al., 2007; Mendez, 2009). 
Single-cell microinjection experiments in mammalian cells further suggested 
that replication timing might, in turn, play a key role in maintaining heritable epigenetic 
states through mitosis. A reporter gene microinjected into early S-phase nuclei was 
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preferentially assembled into nucleosomes with acetylated histones and expressed 
with higher efficiency than the same DNA microinjected in late-S nuclei, which was 
packed into deacetylated histone nucleosomes (Zhang et al., 2002). This result, which 
strongly suggests that the timing of replication can influence on chromatin structure, 
has been supported by the recent demonstration that DNA sequences packaged in 
nucleosomes characteristic of late replication (i.e. containing deacetylated histones) 
can be reassembled with acetylated histones if replicated in early S-phase, and vice 
versa (Lande-Diner et al., 2009). The presence at replication forks of different sets of 
chromatin assembly factors and histone-modifying enzymes in early or late S-phase is 
consistent with this function (McNairn and Gilbert, 2003). Although these different sets 
of experiments strongly suggest a link between replication timing and chromatin 
structure, how this relationship is precisely regulated remains unclear. So far, indirect 
evidence have supported two rather intuitive models in which open chromatin dictates 
early replication or early replication dictates open chromatin. Combining these models 
creates an attractive scenario in which DNA replication provides a means to inherit 
chromatin states that, in turn, regulate replication timing in the subsequent cell cycle, 
so that once a timing program is established, it forms a self-reinforcing auto-regulatory 
loop that is very stable for many generations (Hiratani and Gilbert, 2009).  
Replication timing is also subject to developmental control. A study comparing 
the replication timing of a panel of approximately 50 tissue-specific genes in 
undifferentiated ES cells and ES-derived neural progenitors revealed that neural 
commitment results in dynamic changes in the replication timing of many genes. The 
replication of several ES-associated genes was delayed upon neural induction, 
alongside with an advance in replication of a number of neural-associated genes 
(Hiratani et al., 2004; Perry et al., 2004). Moreover, these replication timing “shifts” from 
early (in ES cells) to late S-phase (in neural progenitors), was coupled to significant 
deacetylation of loci, for example, at the Rex1 promoter region (Perry et al., 2004). In a 
subsequent study, the replication timing of a panel of loci encoding transcription factors 
associated with lineage specification was analysed in pluripotent ES cells and in 
differentiated cell types such as haematopoietic progenitors (HP) and T lymphocytes 
(T) (Azuara et al., 2006). In ES cells, many loci were early-replicating, whereas in HP 
and T many genes replicated later. This difference in the replication timing of neural-
associated genes was detected despite the fact that these genes were not expressed 
by ES, HP or T cells. Thus, these changes were not merely reflecting differences in 
gene activity. Additionally, the replication timing analysis of a subset of genes in two 
different embryonic carcinoma (EC) cell lines (F9 and P19) with a more restricted 
differentiation capacity than ES cells, showed that EC replication profiles were distinct 
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from that of ES cells, reflecting their distinct potentials. Together, these data suggested 
that replication timing profiles can be used to identify the lineage potential and 
developmental stage of a given cell population. 
 
1.2. Early mammalian development 
 
1.2.1. Early embryo development and pluripotency 
 
The combination of the oocyte and sperm in the zygote represents the climax of 
cellular potency. The zygote is the only unequivocally totipotent cell in the life cycle with 
potential to form every cell type of the organism (including specialised extraembryonic 
cells) (Hemberger et al., 2009). Progressively, throughout development specific 
programmes of gene expression are established and early progenitor cells gradually 
become more restricted in their potential while they commit to different cellular lineages 
(Morgan et al., 2005).  
The access to human embryos and in vivo tissues from postimplantation stages 
is clearly very limited. Consequently the steps leading towards the earliest lineage 
decisions in mammals have been best studied in mice (Pera and Trounson, 2004). 
Following fertilization, the mouse zygote undergoes a series of sequential cleavage 
divisions during the first two days of development to produce a 4-cell embryo that 
progresses to an 8-cell embryo. At this point the cells (or blastomeres) maximise cell-
cell contact, giving rise to a compacted morula (Figure 1.4). Asymmetrical cell divisions 
at the morula stage along a basolateral cleavage plane accompanies the first 
differentiation event in the mouse embryo that gives rise to an internal cavity, the 
blastocoel and two visibly distinct subpopulations - the inner cell mass (ICM) 
surrounded by an epithelial cell layer that will become allocated to the extraembryonic 
trophectoderm (TE) lineage (Arnold and Robertson, 2009). This typical embryonic 
structure characterises the early blastocyst stage that corresponds to embryonic day 
3.5 (E3.5) of development. Cell fate studies (mostly using mouse chimeras) have 
shown that ICM cells are pluripotent, giving rise to all tissues of the foetus. In contrast, 
TE cells are more restricted in their potential (multipotent) and solely contribute to 
placenta formation (Rossant, 2001). Around the time of implantation in the late 
blastocyst, the ICM further differentiates into the epiblast or primitive ectoderm and 
another extraembryonic lineage, the hypoblast or primitive endoderm (PrE) (Figure 1.4) 
(Ralston and Rossant, 2005). Epiblast cells are also pluripotent, giving rise to the three 
germ layers (ectoderm, mesoderm and endoderm) upon gastrulation as well as 
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primordial germ (PGC) cells. Cells from the PrE (like the TE) are multipotent, being 
able to exclusively differentiate into the visceral and parietal endoderm layers that will 
line the yolk sac (Bielinska et al., 1999; Rossant, 2001). Besides providing growth 
support and protection within the uterus, the extraembryonic TE and PrE lineages are 
sources of signals to the embryonic lineages to promote correct patterning and 
differentiation (Rossant and Tam, 2004). The germ cells represent the end point of a 
differentiation cascade and can be considered highly specialised. At the same time, 
however, they have the capacity to return to totipotency (as a consequence of germ 
cell-specific epigenetic reprogramming) when the gametes come together in the zygote 
(Hemberger et al., 2009).  
 
 
 
Figure 1.4. Schematic representation of the early stages of mouse development and derivation of 
stem cell types. Following fertilization the mouse zygote undergoes two rounds of cleavage division that 
leads to the 4-cell stage embryo. The next round of cells division leads to the eight-cell embryo or early 
morula where the cells become more compact. Subsequent divisions lead to the generation of distinct 
inside and outside cell populations and formation of an internal cavity, the blastocoel. Two distinct lineages 
are apparent in the early blastocyst stage: the trophectoderm (TE) and the inner cell mass (ICM) from 
where the trophoblast stem (TS) cells and the embryonic stem (ES) cells are derived, respectively. The TE 
is also present in the late blastocyst, but the ICM has meanwhile segregated into two lineages: the epiblast 
and the primitive endoderm (PrE). Epiblast stem (EpiS) cells can be derived from the epiblast immediately 
after implantation and extraembryonic endoderm (XEN) cells from the PrE. The TE and PrE lineages will 
give rise to extraembryonic tissues that support the embryo, while the epiblast will give rise to the three 
germ layers (ectoderm, mesoderm and endoderm) during gastrulation that will differentiate into all cell 
types of the adult organism. Recent breakthroughs in dedifferentiation techniques allow the 
reprogramming of fully differentiated somatic cells into induced pluripotent stem (iPS) cells, which closely 
resemble ES cells in their developmental potency. 
 
 
1.2.2. Embryo-derived stem cells 
 
1.2.2.1. Mouse embryo-derived stem cell 
 
In mammalian blastocysts, three distinct cell lineages can be discriminated 
before implantation: the ICM, TE and PrE lineages. Different populations of stem cell 
lines were successfully derived from each of these lineages, namely ES cells from the 
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ICM (Evans and Kaufman, 1981; Martin, 1981), trophoblast stem (TS) cells from the TE 
(Tanaka et al., 1998) and extraembryonic endoderm (XEN) cells from the PrE (Kunath 
et al., 2005) (Figure 1.4). All of these cells share a similar characteristic: they can self-
renew without differentiating in culture while faithfully retaining the developmental 
competence of their cognate lineage. Even though they share this property, all these 
stem cells are remarkably different in terms of their morphology, gene expression 
patterns and growth factor requirements that typify the lineage from where they are 
derived (Rossant, 2008). Pluripotent mouse ES cells contribute to all tissues of the 
foetus, but poorly to PrE and rarely to TE lineages (Beddington and Robertson, 1989); 
TS cells only contribute to the trophoblast lineages of the placenta (Tanaka et al., 
1998) and XEN cells contribute exclusively to the parietal and visceral endoderm 
lineages (Kunath et al., 2005). Although, the molecular mechanisms underlying self-
renewal and lineage restriction are not fully understood, several factors have been 
clearly identified as key regulators of cell fate in the early embryo. The expression or 
combination of key lineage-specific transcription factors, such as Oct4/Sox2/Nanog, 
Cdx2/Eomes/Gata3 and Gata6/Gata4/Sox7 was shown to be determinant in the 
maintenace of ES, TS and XEN cells, respectively (Home et al., 2009; Ralston and 
Rossant, 2005; Rossant, 2008).  
Recently, pluripotent epiblast stem (EpiS) cells have been established from the 
epiblast lineage, isolated from E5.5 to E6.5 postimplantation mouse embryos (Figure 
1.4) (Brons et al., 2007; Tesar et al., 2007). Although EpiS cells like ES cells are able 
to differentiate into the three embryonic germ layers, they have difficulties in 
contributing to the germ line and forming chimeras after introduction into blastocyst 
(Brons et al., 2007; Tesar et al., 2007). Embryonic germ (EG) cells can also be derived 
from early PGC cells between E8.5 and E11.5 postimplantation embryos (Matsui et al., 
1992; Resnick et al., 1992) and likewise ES cells, upon blastocyst injection they can 
contribute extensively to chimeric mice including germ cells (Labosky et al., 1994; 
Stewart et al., 1994). More recently, pluripotent stem cells were also derived from both 
neonatal and adult mouse testis (Guan et al., 2006; Kanatsu-Shinohara et al., 2004), 
suggesting that pluripotency can be maintained during germ cell development.  
 
1.2.2.2. Mouse and human embryonic stem (ES) cells 
 
Pluripotent cells are present only transiently in embryos in vivo, as they quickly 
differentiate into various somatic cells through development. However, it is possible to 
isolate ex vivo pluripotent mouse (mES) and human (hES) ES cells from the ICM under 
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defined growing conditions that promote proliferation in the absence of differentiation 
(Yu and Thomson, 2008).  
Mouse ES cells were first isolated in 1981 from blastocyst stage embryos 
(Evans and Kaufman, 1981; Martin, 1981) and exhibit two remarkable features in 
culture. First, under the appropriate conditions, they can be propagated indefinitely as a 
stable self-renewing population maintaining their cell identity. This immortalized 
phenotype allows ES cells to be cultured over extended periods of time. Upon 
differentiation, this feature is lost and progeny succumb to cellular aging mechanisms 
(Hayflick limit) as all other non-transformed primary cells. A second feature is that 
during extended culture, mES cells clonally derived from a single cell retain their 
pluripotency and differentiate into the same range of cell types as those formed by the 
ICM in vivo, when injected into blastocyst (Martin, 1981). Mouse ES cells have been 
derived from cleavage stage embryos and even from individual blastomeres of 2- to 8-
cell stage embryos (Chung et al., 2006; Wakayama et al., 2007). 
The derivation of hES cells provides a unique opportunity to study early human 
development and is thought to hold great promise for regenerative medicine (Pera and 
Trounson, 2004; Reubinoff et al., 2000; Thomson et al., 1998). There was a 
considerable delay however, between the derivation of mES cells in 1981 and the 
derivation of hES cells in 1998 (Thomson et al., 1998), in spite of several earlier 
attempts. This delay was primarily due to species-specific ES cell differences and 
suboptimal human embryo culture conditions (Yu and Thomson, 2008). For example, 
the isolation of ICMs from human blastocysts had been previously reported (Bongso et 
al., 1994), but subsequent culture in media supplemented with leukemia inhibitory 
factor (LIF) and serum, conditions that allow the derivation of mES cells, resulted in 
cells differentiation. Improvements in the culture conditions for human IVF embryos 
(Gardner et al., 1998) and experience in growing non-human primates cell lines 
(Thomson et al., 1995; Thomson et al., 1996) permitted the subsequent derivation of 
hES cells in 1998. A common alternate assay for ES cells potency, particularly for hES 
cells where embryo transfer is not permitted for research purposes, is to inject ES cells 
into immunocompromised mice where they form mixed cell tumours know as 
teratomas. Another approach is to grow the cells in non-adherent conditions leading to 
the formation of three-dimensional structures called embryoid bodies (EBs) (Vallier and 
Pedersen, 2005). Like mES cells, hES cells are capable of maintaining their 
developmental potential to contribute to derivatives of all three germ layers, even after 
prolonged undifferentiated proliferation and/or clonal derivation (Amit et al., 2000). In 
addition, and in contrast to mES cells (Beddington and Robertson, 1989), hES cells 
can give rise to extraembryonic lineages including TE (Thomson et al., 1998; Xu et al., 
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2002) and PrE-like cells (Pera et al., 2004). Similarly to mES cells, hES cells have 
been derived from morula, later blastocyst stage embryos (Stojkovic et al., 2004; 
Strelchenko et al., 2004), single blastomeres (Klimanskaya et al., 2006), and 
parthenogenetic embryos (Lin et al., 2007; Mai et al., 2007; Revazova et al., 2007). 
However, it is not known yet how similar or distinct pluripotent hES cell lines are 
between them, especially in terms of their developmental potential. Recently some 
studies using directed differentiation methods or EBs, suggested that independently-
derived hES cells may greatly differ in their developmental potential, with some cell 
lines showing marked differences in their differentiation propensity (Kim et al., 2007; 
Osafune et al., 2008). Gene expression profiling also revealed that distinct hES cell 
lines can display differences in the expression of specific genes (Abeyta et al., 2004; 
Allegrucci and Young, 2007; Skottman et al., 2006), although being clearly 
distinguishable from other cell types. In addition, epigenetic profiling showed that hES 
cells can display some degree of epigenetic variability and instability across lines and 
cultures (Allegrucci et al., 2007; Maitra et al., 2005). 
Nevertheless, mouse and hES cells share the expression of high levels of 
alkaline phosphatase (Adewumi et al., 2007) and key transcription factors that were 
identified as being important in the maintenance of the ICM/ES cell pluripotency. These 
include the POU-family transcription factor Oct4 (Nichols et al., 1998; Palmieri et al., 
1994), a homeodomain DNA-binding protein called Nanog (Chambers et al., 2003; 
Mitsui et al., 2003) and the SOX-family transcription factor Sox2 (Avilion et al., 2003). 
Embryos lacking Oct4 do not form ICM, consisting exclusively of TE tissue (Nichols et 
al., 1998). Similarly, the in vitro deletion of Oct4 leads to the conversion of ES to TS-
like cells (Niwa et al., 2000). Mouse ES cells deficient for Nanog are still able to self-
renew, but show an increased propensity to differentiate towards XEN-like cells and 
cannot give rise to mature germ cells (Chambers et al., 2003; Chambers et al., 2007). 
Functional studies further suggested similar roles for these transcription factors in 
maintaining the pluripotent stem cell state of hES cells. For example, reduced 
expression of Oct4 in hES cells by genetic manipulation also results in TE 
differentiation and Nanog gene expression inhibition also causes hES cells 
differentiation to extraembryonic cell lineages (Hyslop et al., 2005; Zaehres et al., 
2005). The function of Sox2 in early embryonic development is more difficult to study 
due to the presence of maternally-derived Sox2 protein, however after implantation (as 
the maternal contribution is largely lost), Sox2-null embryos generate exclusively TE 
and PrE lineages (Avilion et al., 2003). Similarly Sox2 deletion in ES cells also leads to 
their conversion in TS-like cells (Masui et al., 2007). Sox2 was shown to 
heterodimerise with Oct4, acting synergistically by regulating the expression of stem 
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cell-associated genes (Chew et al., 2005; Okumura-Nakanishi et al., 2005; Tomioka et 
al., 2002). Recently, it was suggested that Sox2 may stabilise pluripotent ES cells by 
maintaining the requisite level of Oct4 expression (Masui et al., 2007).  
Mounting evidence suggests that ES cells in culture may not all be identical but 
may exist in different, interconvertible substates that have significant consequences for 
their behaviour and ability to differentiate. In particular, undifferentiated mES cell 
cultures are likely to contain different interconvertible subpopulation of cells that either 
correspond to an ICM-like or epiblast-like identity (Enver et al., 2009). Expression 
levels of Rex1 (an ICM marker) (Toyooka et al., 2008), Nanog (Chambers et al., 2007) 
and Stella (an ICM and germ cell lineage marker) (Hayashi et al., 2008) are highly 
variable in mES cells, contrasting with the apparent homogeneity of Oct4 and Sox2. 
Although detailed studies of the dynamics of expression of these markers in hES cells 
have yet to be carried out, the patterns of cell surface marker expression present on 
pluripotent hES cells also points to the existence of interconvertible substates of the 
stem cell compartment (Enver et al., 2005; Stewart et al., 2006) a feature also evident 
in several adult stem cell systems (Booth and Potten, 2000; Hu et al., 1997; Jones et 
al., 2007). 
 
1.2.2.3. Embryonic equivalence of mouse and human ES cells – a 
developmental paradox 
 
 Despite the similarities of the intrinsic control of mouse and human pluripotent 
ES cells by Oct4, Nanog and Sox2, several phenotypic differences between mES and 
hES cells have been reported particularly in terms of cells morphology and cell-surface 
markers (Pera and Trounson, 2004). Mouse ES cells grow as three-dimensional dome-
shaped colonies whereas hES cells grow in colonies as thin and flat layers. The 
embryonic markers defined by the antibodies SSEA-1, -3 and -4 against cell surface 
glycolipids are expressed differently in undifferentiated mES (SSEA1+) and hES 
(SSEA3/4+) cells. Also the cell-surface proteoglycan recognised by several monoclonal 
antibodies, including TRA-1-60 and TRA-1-81 are reactive with hES cells but not 
detected in mES cells (Thomson et al., 1998). The question of whether differences 
between mES and hES cells are related to species differences or relate to differences 
in the stages of embryonic development from which they arise, remains open (Lovell-
Badge, 2007). On this line of thoughts, one study showed that ICM cells of human 
blastocysts and hES cells share the same pattern of antigen expression. SSEA3, 
SSEA4 and TRA-1-60 were all found to be expressed in the ICM of in vitro human 
preimplantation blastocysts cultured, although a limited number of embryos were 
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analysed. Note that these markers are not expressed in the mouse ICM, highlighting 
possible intrinsic species-specific differences in the expression of these markers as 
seen in mES and hES cells (Henderson et al., 2002). Consistent with this idea, mouse 
and human pluripotent cell lines harbour the same phenotypic differences whether they 
originate directly from embryos (ES cells) or from PGC cells through 
teratocarcinogenesis (embryonic carcinoma (EC) cells) (Pera et al., 2000). Thus, 
human EC cells resemble hES cells, mouse EC stem cells resemble mES cells, and 
the two cell-types show the same inter-species differences. An alternative view would 
be that hES cells are in a pre-epiblast stage of commitment, where all lineage 
pathways including TE are still open, whereas mES cells represent the already lineage-
restricted epiblast progenitor of the blastocyst. This could relate to the slower pace of 
lineage restriction in the early stages of human development compared with mouse 
(Pera and Trounson, 2004). Most recently, however, two groups have been able to 
derive several pluripotent cell lines (EpiS cells) directly from the early postimplantation 
epiblast in the mouse (Brons et al., 2007; Tesar et al., 2007). Like mES and hES cells, 
these novel pluripotent cell lines express the three key pluripotency transcription 
factors, Oct4, Sox2, and Nanog, yet are distinct from mES cells in their genetic and 
epigenetic state as well as the signals driving their differentiation. In contrast, mEpiS 
cells share a number of features with hES cells, leading to the suggestion that hES 
cells might in fact be an in vitro equivalent of early postimplantation epiblast cells. For 
example, mEpiS cells derivation failed in the presence of LIF and/or BMP4, the two 
factors required for the derivation and self-renewal of mES cells. In contrast, similar to 
hES, FGF and Activin/Nodal signalling appear critical for EpiS cell derivation and BMP4 
induces differentiation towards TE. EpiS cells were able to generate tissues from all 
three germ layers in vitro and to form teratomas. Data mining of the deposited gene 
expression arrays for mEpiS cells shows that they do express pluripotent markers but 
also seem to be expressing higher levels of mesoderm and definitive endoderm 
transcripts as compared to mES cells. This suggests that mEpiS cells, and by 
extension hES cells, may be in an unusual transition state as compared to mES cells: 
poised on the verge of differentiation into multiple directions (Rossant, 2008). 
 
1.2.3. Signalling pathways required for ES cells self-
renewal and pluripotency 
 
Although hES and mES cells share a number of intrinsic regulators, the 
extrinsic signals that drive ES cell self-renewal and pluripotency have undergone 
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significant species-specific deviation (Pera and Trounson, 2004). The undifferentiated 
state of mES cells can be maintained in culture by foetal calf serum in combination with 
LIF, a cytokine shown to sustain ES cell growth and self-renewal (Smith et al., 1988; 
Williams et al., 1988). LIF is known to act mainly via the JAK-STAT3 signalling pathway 
(Niwa et al., 1998; Yoshida et al., 1994). The activation of this pathway involves 
heterodimerisation of LIF receptor with the gp130 membrane protein (Yoshida et al., 
1994) that leads to the activation of JAK tyrosine kinase and subsequent recruitment 
and activation of STAT3, that translocates to the nucleus and regulates the expression 
of genes required for “stemness” (Niwa et al., 1998; Raz et al., 1999). Withdrawal of 
LIF triggers differentiation to a mixture of lineages (Nichols et al., 2001) and the 
provision of activated STAT3 renders mES cells independent of LIF (Matsuda et al., 
1999). In serum-free medium, LIF alone is insufficient to prevent mES cell 
differentiation, but in combination with bone morphogenetic protein (BMP; a member of 
the TGF-β superfamily), mES cells self-renewal is sustained (Ying et al., 2003). BMPs 
induce the expression of inhibitor of differentiation (Id) proteins through the activation of 
the Smad 1/5/8 pathway. However, studies indicate that BMPs might also act 
independently of Smads, through inhibition of the MAPK pathways. The latter is 
supported by the facts that ES cells can be derived from blastocysts lacking Smad4 
(the common partner for all Smads) (Sirard et al., 1998) and that inhibition of p38 
MAPK allowed derivation of ES cells from blastocysts lacking BMP type I receptor Alk-
3, which were previously refractory to ES cell derivation (Qi et al., 2004). Recently, it 
was shown that mES cells can be efficiently derived and maintained in minimal 
conditions without extrinsic requirements for growth factors or cytokines (Ying et al., 
2008). This work showed that ES cells can be maintained in their self-renewing “ground 
state” by blocking differentiation-inducing signalling using a cocktail of inhibitors (for 
FGF receptor tyrosine kinases, ERK and GSK3 pathway). In normal development, 
however, there is no apparent requirement for LIF, gp130 or STAT3 prior to 
gastrulation, this seems to be a specific requirement of embryos in diapause (Nichols 
et al., 2001). Also, homozygous Alk-3 mutant mouse embryos can develop normally to 
early postimplantation stage (Mishina et al., 1995). Thus, the pluripotent ICM/epiblast 
could use alternative signalling pathways for undifferentiated proliferation. 
Mitotically inactivated fibroblast feeder layers and serum-containing medium 
were used in initial attempts to derive hES cells, essentially the same conditions used 
for the derivation of mES cells prior to the identification of LIF (Thomson et al., 1998). 
However, it now appears largely to be a lucky coincidence that fibroblast feeder layers 
support both mES and hES cells, as the specific factors used to sustain mES cells do 
not support human. In contrast to mES cells, LIF signalling is not active in 
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undifferentiated hES cells (Daheron et al., 2004; Humphrey et al., 2004) and BMPs 
induce TE differentiation, either in the presence (Gerami-Naini et al., 2004; Pera and 
Trounson, 2004) or absence (Xu et al., 2002) of serum. Conversely, the MEK kinase 
pathway that promotes differentiation in mES cells (Nichols et al., 2001), is activated by 
fibroblast growth factor 2 (FGF2) and required to maintain the undifferentiated state of 
hES cells (Amit et al., 2000). At higher concentrations, FGF2 allows feeder 
independent growth of hES cells cultured in commercial serum replacement 
(Levenstein et al., 2006; Wang et al., 2005; Xu et al., 2005). The mechanism through 
which these high concentrations of FGF2 exert their functions is not fully understood, 
although one of the effects is suppression of BMP signalling (Xu et al., 2005) present in 
the serum and the widely used commercially available serum replacement. FGF2 is 
also able to up-regulate the expression of TGF- ligands in both feeder cells and hES 
cells, which in turn, could promote hES cell self-renewal (Greber et al., 2007). Several 
studies suggest that FGF and TGF-/Activin/Nodal signalling interactions are important 
for maintenance of hES cell pluripotency (Amit et al., 2004; Noggle et al., 2005; Wang 
et al., 2005; Xu et al., 2005), as recently described for mEpiS cells (Brons et al., 2007; 
Tesar et al., 2007). Both TGF-β and Activin A have strong positive effects on 
undifferentiated proliferation of hES cells in the presence of low or modest 
concentrations of FGF2, and based on inhibitor studies, it has been suggested that this 
signalling pathway is essential for hES cell self-renewal and pluripotency (Beattie et al., 
2005; James et al., 2005; Vallier et al., 2005; Xiao et al., 2006). The TGF-β/Activin 
signalling is transmitted by the phosphorylation of Smad2/3 (Schmierer and Hill, 2007). 
Inhibition of the TGF-β/Activin receptors by the chemical inhibitor SB431542 reduces 
Smad2/3 phosphorylation and induces differentiation (James et al., 2005; Vallier et al., 
2005; Xiao et al., 2006). Recently, it was shown that Smad2/3 bind directly to the 
Nanog proximal promoter in hES cells, modulating its expression (Vallier et al., 2009a; 
Xu et al., 2008). In contrast, BPM-responsive Smad1 also binds to the Nanog promoter 
(Xu et al., 2008). These suggest that an intricate balance of Smad2/3 and Smad1/5/8 
could modulate the expression of Nanog and potentially determine the choice between 
undifferentiated and lineage-committed fates. Although other growth factors have been 
reported to have a positive effect on hES cell growth including Wnt (Sato et al., 2004), 
IGF1 (Bendall et al., 2007), heregulin (Wang et al., 2007), sphingosine-1-phosphate 
(S1P), and PDGF (Pebay et al., 2005), there are clearly additional important pathways 
yet to be identified. Defining the molecular mechanisms of hES cells self-renewal and 
pluripotency will enable growth of hES cells under defined conditions and aid controlled 
differentiation of cells into specified lineages, thus providing cells suitable for 
therapeutic applications. 
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1.2.4. Transcriptional networks that control pluripotency 
 
A network of transcription factors including Oct4, Nanog and Sox2 have been 
shown to be crucial for development of pluripotent cells in the preimplantation embryo 
and for maintenance of pluripotency of human (Boyer et al., 2005) and mouse (Ivanova 
et al., 2006; Loh et al., 2006; Mathur et al., 2008) ES cells. To gain more insights into 
these transcriptional regulatory networks operating in ES cells, it was used chromatin 
immunoprecipitation (ChIP) assays to map the genome-wide binding sites for Oct4, 
Nanog and Sox2 in human and mouse. Despite the low overlap between human and 
mouse datasets, these authors found that Oct4 and Nanog (and in human ES cells, 
also Sox2) co-occupy a large number of developmental genes, including both 
transcriptionally active and inactive genes in ES cells. Interestingly, among the targeted 
genes Oct4, Nanog and Sox2 were shown to be able to regulate themselves. Other 
active targets were transcription factors, chromatin remodelling and components of 
signalling pathways identified to be important for ES cell biology, as for example, Cripto 
and Lefty2, two members of the TGF- pathway. In contrast, a large portion of the 
inactive targets identified encode developmentally important transcription factors, such 
as genes involved in the specification of ectoderm, endoderm, mesoderm and extra-
embryonic lineages. These findings have been collectively taken to suggest that Oct4, 
Sox2 and Nanog are as so-called “master regulators” of the pluripotent stem cell 
identity (Spivakov and Fisher, 2007). However, the network that control pluripotency is 
much more complex and many other players are currently being discovered (Dejosez 
et al., 2008; Kim et al., 2008). 
 
1.2.5. Epigenetic control of pluripotency 
 
The chromatin features of pluripotent ES cells seem to reflect a generalised 
“open” and transcriptionally “permissive” state (Meshorer and Misteli, 2006). In 
contrast, ES cell differentiation resulted in an increase in global levels of the 
heterochromatic mark H3K9me3 and a decrease of acetylated H3 and H4 (Lee et al., 
2004; Meshorer et al., 2006). ES cells have also been shown to have a characteristic 
replication timing profile (as discussed above in section 1.1.5.) in which many non-
expressed tissue-specific regulator genes replicate early in S-phase (Azuara et al., 
2006; Hiratani et al., 2008; Perry et al., 2004). A series of studies have shown that 
tissue-specific genes that were thought to be in a repressed state in pluripotent cells 
might in fact be poised for transcription in ES cells. Interestingly, the promoters of many 
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inactive genes are marked in ES cells by both repressive (H3K27me3) and active 
(H3K4me2 or H3K4me3) modifications - so-called bivalent domain (Azuara et al., 2006; 
Bernstein et al., 2006). It has been suggested that bivalent chromatin may allow tissue-
specific regulator genes to remain silent in pluripotent cells, but primed for rapid 
activation in response to developmental cues (Giadrossi et al., 2007; Spivakov and 
Fisher, 2007). Interestingly, this gene priming for transcription has been shown to 
correlate at the molecular level with the presence of poised RNA polymerase II 
complexes at bivalent promoter genes in ES cells (Stock et al., 2007). Although with 
some exceptions, in ES-derived neural and haematopoietic progenitors, bivalent 
chromatin profiles at many developmental genes were found to be resolved as lineage-
appropriate genes became activated and depleted for H3K27me3, while lineage-
inappropriate genes lost histone acetylation and H3K4m3 (Bernstein et al., 2006; 
Mikkelsen et al., 2007). In addition, ChIP studies in both mouse and human ES cells 
revealed that members of the PRC2 complex (Suz12 and Eed) bind to the promoters of 
many developmental genes that are not actively transcribed in ES cells, but are 
important for the regulation of lineage specification of extraembryonic lineages or in 
later stages of development (Boyer et al., 2006; Jorgensen et al., 2006; Lee et al., 
2006). Remarkably, Suz12 occupied many of non-expressed genes targeted by 
transcription factors Oct4, Sox2 and Nanog, suggesting that these regulators may 
specifically recruit PcG proteins to their repressed genes (Lee et al., 2006). In addition, 
many developmental PcG target genes become derepressed upon genetic disruption 
of the PRC2 components Eed or Suz12 (Azuara et al., 2006; Boyer et al., 2006; Lee et 
al., 2006) or the PRC1 component Ring1B (Jorgensen et al., 2006; Stock et al., 2007). 
Altogether these findings demonstrated a pivotal role for PcG-mediated silencing in 
stably maintaining an ES cell pluripotent state in culture. 
 
1.2.6. Reprogramming to pluripotency 
 
Epigenetic mechanisms ensure that once committed, the differentiated state of 
a cell is normally stable and can be inherited throughout cell divisions. However, under 
certain conditions cell fate can be modified or reversed. This exceptional change in 
cellular identity leading to the establishment of a novel gene expression program is 
designated reprogramming (Jaenisch and Young, 2008).  
Reprogramming is a phenomenon of particular interest by giving the opportunity 
to revert developmental programs, including the reprogramming of somatic cells to an 
embryonic state. This provides an exciting approach to address the functional 
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significance of epigenetic mechanisms implicated in cellular differentiation and 
establishment of pluripotency. In addition, reprogramming somatic cells to become 
pluripotent is an important goal in cell replacement therapy since it is an opportunity to 
generate patient-specific ES-derived cells as grafts (Hochedlinger and Plath, 2009; 
Jaenisch and Young, 2008). The increasing knowledge of how the undifferentiated 
state is maintained in mouse and human ES cells provided valuable clues for the 
understanding how re-orchestration of pluripotency occurs during reprogramming 
(Jaenisch and Young, 2008). Different experimental reprogramming strategies have 
been created including somatic cell nuclear transfer (SCNT) (Gurdon, 1962), cell fusion 
(Miller and Ruddle, 1976) and the forced expression of specific factors (Takahashi and 
Yamanaka, 2006). 
The transfer of a nucleus from a somatic cell to an enucleated oocyte can 
reprogram the differentiated state to that of a zygote, potentially generating a new 
organism with the genetic information of the donor nucleus (a clone). The cloning of 
Dolly demonstrated that trans-acting material in mammalian oocytes is sufficient to 
change the epigenetic status of a differentiated nucleus to a totipotent state (Wilmut et 
al., 1997). This discovery completely changed the mindset of developmental biologists 
who previously thought this was impossible in mammals (McGrath and Solter, 1984). 
Immediately following the derivation of hES cells, it was suggested that SCNT might be 
used to create patient-specific stem cells. Yet applying SCNT to human material has 
proven challenging, and has only very recently been achieved in non-human primates 
(Byrne et al., 2007) with very low efficiency that would make it impractical for 
widespread human clinical use.  
 Experimental cell fusion between different cell types has also been used to 
study the plasticity of differentiated cells. Cell fusion creates cells harbouring two or 
more nuclei sharing the same cytoplasm, termed heterokaryon if the fused cells 
originate from different tissues or species, or homokaryons if the parental cells belong 
to the same cell-type. If heterokaryons are maintained in culture for several days, 
hybrids will form, resulting from fusion between nuclei and subsequent cell division 
(Kikyo and Wolffe, 2000). In most cell hybrids, the phenotype of the less differentiated 
cell is dominant over the phenotype of the more differentiated fusion partner. 
Consistent with this, fusion of mouse myoblasts with human B-lymphocytes leads to 
the activation of muscle regulatory factors in human B-lymphocyte nuclei accompanied 
by declining expression of several lymphocyte-specific genes (Terranova et al., 2006). 
Spontaneous and experimental cell fusion between ES and somatic cells has also 
shown that the phenotype of ES cells is dominant, imposing an ES-specific gene 
expression pattern in the nuclei of the less differentiated cell type (Tada et al., 2001; 
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Ying et al., 2002). The ability to reprogram somatic cells seems to be conserved in hES 
cells (Cowan et al., 2005; Yu et al., 2006) and analysis of mouse and human hybrid cell 
transcriptome revealed global patterns of gene expression reminiscent of ES cells 
(Ambrosi et al., 2007; Cowan et al., 2005). Other stem cell populations such as EG and 
EC cells have also been described to reprogram somatic cells in vitro (Miller and 
Ruddle, 1976; Tada et al., 1997) towards their identity. The reason why undifferentiated 
cell-types usually dominate over more differentiated fusion partners remains unknown. 
Interestingly, the principle of phenotypic exclusion seen during normal development 
also applies to hybrid cells. When two differentiated cell types are fused, hybrid cells 
have the potential to express either one or the other phenotype, but not both (Fougere 
and Weiss, 1978). Cell fusion experiments might not be the best source of cells for 
therapy, due to the low efficiency and requirement to remove the ES-cell nucleus from 
the heterokaryon in order to generate diploid customised cells for transplantation 
therapy (Pralong et al., 2005). However, it provides a powerful in vitro system to test 
the contribution of individual factors to the reprogramming of somatic cells towards 
pluripotency. Recently, using genetically engineered mES cells, it was demonstrated 
that the successful reprogramming of human lymphocytes is independent of Sox2. In 
contrast, there is a distinct requirement for Oct4 in the establishment but not the 
maintenance of the reprogrammed state (Pereira et al., 2008). 
 In 2006, Takahashi and Yamanaka reported the reprogramming of mouse 
fibroblasts to a pluripotent-like state by viral transfection of four transcription factors, 
Oct4, Sox2, kruppel-like factor 4 (Klf4) and c-Myc (Takahashi and Yamanaka, 2006). 
These factors had been selected as being involved in maintaining pluripotency and 
reprogrammed cells designated induced pluripotent stem (iPS) cells (Figure 1.4). Since 
this ground-breaking report other combinations of factors that have been successfully 
used for the derivation of iPS cells include the oestrogen-related receptor-β (Esrrb) in 
conjunction with Oct4 and Nanog in mouse fibroblasts (Feng et al., 2009a), and Oct4, 
Sox2, Nanog and Lin-28 in human fibroblasts (Yu et al., 2007). Since Takahashi and 
Yamanaka initial report in 2006 the reprogramming field is in constant revise, iPS cell 
lines have been generated from human (Takahashi et al., 2007; Yu et al., 2007), 
monkey (Liu et al., 2008) and rat (Li et al., 2009b; Liao et al., 2009) somatic sources, 
as well as from multiple cell types including disease-specific iPS cells for research 
studies (Park et al., 2008b), using various vehicles such as doxycycline-inducible viral 
vectors, adenoviral and plasmid vectors, and excisable genetic inserts (transposon-
based and Cre-based), to deliver the exogenous genes (Colman and Dreesen, 2009). 
Furthermore, recombinant transcription factor proteins (Zhou et al, 2009), and small 
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chemicals that substitute for specific transcription factors and/or enhance the efficiency 
of the reprogramming process have been identified (Feng et al., 2009b).  
Mouse and human iPS cells are remarkably similar to mouse and human ES 
cells, respectively. Although the initial mouse iPS cells did not contribute to the 
germline in chimeras, subsequent modification of the procedure to select iPS cells 
based on the reactivation of Oct4 or Nanog promoter resulted in generation of 
postnatal chimeras and contribution to the germ line (Maherali et al., 2007; Okita et al., 
2007; Wernig et al., 2007). More recently, it was shown that iPS cells were able to 
generate adult mice trough tetraploid complementation, the most stringent test for 
developmental potency (Boland et al., 2009). In addition, iPS cells showed epigenetic 
features of ES cells, including the reactivation of somatically silenced X-chromosome, 
DNA demethylation of pluripotency-associated genes and acquisition of chromatin 
structure that closely resemble ES cells (Maherali et al., 2007; Okita et al., 2007; 
Wernig et al., 2007). Human iPS cells are morphologically similar to hES cells, express 
typical cell surface antigens and genes, differentiate into multiple lineages in vitro, and 
form teratomas containing differentiated derivatives of all three primary germ layers 
when injected into immunocompromised mice. Interestingly, generation of human iPS 
cells was dependent on FGF2 (Park et al., 2008c) rather than LIF (required to generate 
mouse iPS). Derivation of human iPS cells in mES cell media with LIF was fruitless 
(Takahashi et al., 2007).  
These pioneering studies have illustrated the importance of several factors in 
reprogramming somatic cells to pluripotency. However, iPS cells are generated at very 
low efficiency and different types of reprogrammed cells (full and partially) are usually 
obtained (Chan et al., 2009). A better understanding of the reprogramming 
mechanisms and the true lineage identity of pluripotent mouse and human ES cells as 
well as the development of new and more efficient defined cell culture conditions 
should improve the efficiency of derivation and maintenance of iPS cells with full 
potential and clinically safe. 
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1.3. Aims of this study 
  
A growing panel of mouse and human pluripotent stem cell lines has been 
derived from the early embryo. Their relationship to each other and whether they 
correspond to different pluripotent states with distinct developmental potencies and 
affiliations in vivo remains unclear, however. The overall aim of this project is to define 
the developmental status of embryo-derived pluripotent cell lines using a chromatin-
based approach. Here I will take advantage of replication-timing assay as a tractable 
approach to investigate how chromatin shutdown contributes to lineage restriction and 
cell fate identity through development. 
Initially I will focus in the comparison of the replication timing status of a large 
panel of key developmental genes in several hES cell lines alongside mES and mEpiS 
cells to determine whether distinct pluripotent states can be delineated at this level. 
Further I will explore how hES cell cultures can be modulated towards a self-renewing 
(ICM-like) versus primed for cell differentiation (epiblast-like) state under different 
growth conditions. Finally, I will investigate the molecular and epigenetic mechanisms 
that underlie hES cell self-renewal and differentiation, and evaluate the influence of 
TGF-β/Activin signalling pathway on favouring a self-renewing and homogeneous state 
within hES cell cultures. This is with the ultimate aim of defining optimal conditions to 
stably maintain hES cells and fully competent human iPS cells generated by 
reprogramming. 
This study might contribute in the advance of our understanding of early 
development but is also important for developing stem cell-based therapies, as 
responses to differentiation protocols are likely to vary depending on the initial position 
of cells in a developmental hierarchy. 
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1. Materials 
 
2.1.1. Primary antibodies 
 
SSEA1 Allophycocyanin (APC) –conjugated mouse monoclonal anti-SSEA1 (FAB2155A; R&D 
Systems Inc. Minneapolis, MN). Used for immunofluorescence (IF) and fluorescence 
activated cell sorting (FACS) at 1:200 dilution. 
SSEA4 Mouse monoclonal anti-SSEA4 (MC-813-70; Developmental Hybridoma Studies Bank, 
Iowa City, IA). Used for IF and FACS at 1:3 dilution. 
TRA-1-60 Mouse monoclonal anti-TRA-1-60 (MAB4360; Chemicon/Milipore, Temecula, CA). 
Used for IF and FACS at 1:12 dilution. 
TRA-1-81 Mouse monoclonal anti-TRA-1-81 (MAB4381; Chemicon). Used for FACS at 1:20 
dilution. 
Nanog Rabbit polyclonal anti-human Nanog (ab21624; Abcam Ltd., Cambridge, UK). Used for 
IF at 1:500 and western blot (WB) at 1:1000 dilution. Rabbit polyclonal anti-mouse 
Nanog (REC-RCAB0002P-F; Cosmo Bio Co., Ltd., Japan) used for IF at 1:500, FACS 
at 1 µg/1x10
6
 cells and WB at 1:1000 dilution. 
Oct4 Goat polyclonal anti-Oct4 (N19 sc-8628; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA). Used for IF at 1:100, FACS at 1 µg/1x10
6
 cells and WB at 1:1000 dilution. 
Sox2 Rabbit polyclonal anti-Sox2 (ab15830; Abcam). Used for IF at 1:1000 and WB at 
1:1500 dilution. 
Nestin Mouse monoclonal anti-Nestin (MAB5326; Chemicon/Milipore). Used for IF at 1:500 
dilution. 
Pax6 Rabbit polyclonal anti-Pax6 (AB5409; Chemicon/Milipore). Used for IF at 1:1000 
dilution. 
Musashi Rabbit polyclonal anti-Musashi (AB5977; Chemicon/Milipore). Used for IF at 1:200 
dilution. 
H3 Rabbit polyclonal anti-histone 3 carboxy terminal (ab1791; Abcam). Used for WB at 1:2 
500 and ChIP at 5 µg/IP dilution. 
H3Ac Rabbit polyclonal anti-histone 3 acetylation (17-615; Upstate Biotechnology /Milipore, 
Lake Placid, NY). Used for WB at 1:10 000 and ChIP at 5 µg/IP dilution. 
H3K9Ac Rabbit polyclonal anti-histone 3 lysine 9 acetylation (07-352; Upstate). Used for WB at 
1:2 500 and ChIP at 5 µg/IP dilution. 
H3K14Ac Rabbit polyclonal anti-histone 3 lysine 14 acetylation (06-911; Upstate). Used for ChIP 
at 5 µg/IP dilution. 
H3K18Ac Rabbit polyclonal anti-histone 3 lysine 18 acetylation (07-354; Upstate). Used for WB at 
1:10 000 and ChIP at 5 µg/IP dilution. 
H3K56Ac Rabbit monoclonal anti-histone 3 lysine 56 acetylation (2134-1; Epitomics, Inc., 
Burlingame, CA). Used for WB at 1:750 and ChIP at 10 µg/IP dilution. 
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H3K27me3 Rabbit polyclonal anti-histone 3 lysine 27 trimethylation (07-449; Upstate). Used for 
WB at 1:2500 dilution. 
H3K4me2 Rabbit polyclonal anti-histone 3 lysine 4 dimethylation (07-030; Upstate). Used for WB 
at 1:5000 dilution. 
H4 Rabbit monoclonal anti-histone 4 pan (05-858; Upstate). Used for ChIP at 5 µg/IP 
dilution. 
H4Ac Rabbit polyclonal anti-histone 4 acetylation (06-866; Upstate). Used for ChIP at 5 µg/IP 
dilution. 
BrdU Mouse monoclonal anti-BrdU antibody (347580; Becton Dickinson Biosciences, San 
Jose, CA). Used for replication timing at 80 µl/reaction dilution. 
Methyl-C Mouse monoclonal anti-5-methylcytidine (33D3; Eurogenetec, Belgium). Used for 
methylated DNA immunoprecipitation (MeDIP) at 10 µl/reaction dilution. 
IgG Rabbit anti-IgG (whole molecule) fraction of antiserum antibody (M-7023; Sigma 
Aldrich Company Ltd., Gillingham, UK). Used for ChIP at 5 µg/IP and replication timing 
35 µg/reaction dilution. 
β-actin Rabbit polyclonal anti-β-actin antibody (ab8227; Abcam). Used for WB at 1:5000 
dilution. 
P-Smad2/3 Rabbit monoclonal anti-Phospho Smad2/3 (serines 465/467) (3108; Cell Signalling 
Technology, Inc., Boston, MA). Used for WB at 1:1000 and ChIP at 10 µl/IP dilution. 
Smad2/3 Rabbit polyclonal anti-Smad2/3 (3102; Cell Signalling Technology). Used for WB at 
1:1000 and ChIP at 10 µl/IP dilution. 
p300/CBP Rabbit polyclonal anti-P300/CBP (C-20 sc-585; Santa Cruz). Used for WB at 1:1000 
and ChIP at 2 µg/IP dilution. 
 
2.1.2. Secondary antibodies 
 
Alexa 488 Goat anti-mouse IgG (A11029; Molecular Probes Invitrogen, Ltd., Paisley, UK). Used 
for IF at 1:500 and FACS at 1:1000 dilution. 
Alexa 488 Goat anti-rabbit IgG (A11034; Molecular Probes). Used for IF at 1:500 and FACS at 
1:1000 dilution. 
Alexa 568 Goat anti-mouse IgG (A11031; Molecular Probes). Used for IF at 1:500 dilution. 
Alexa 568 Goat anti-rabbit IgG (A11036; Molecular Probes). Used for IF at 1:500 dilution. 
FITC Goat anti-mouse IgM (F9259; Sigma). Used for IF at 1:200 and FACS at 1:500 dilution. 
FITC Goat anti-rat IgM (F6258; Sigma). Used for IF at 1:100 dilution and FACS at 1:500 
dilution. 
HRP-conjugated Goat anti-mouse IgG HRP (sc-2005, Santa Cruz). Used for WB at 1:2000 dilution. 
HRP-conjugated Goat anti-rabbit IgG HRP (sc-2004, Santa Cruz). Used for WB at 1:5000 dilution. 
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2.1.3. Cell lines 
 
H1 (WA-01) Male human ES cell line (Thomson et al., 1998); grown in collaboration with Dr Wei Cui 
(IRDB, Imperial College London, UK). 
H1-BH1 Male human ES cell line clonally derived from H1 cells. Cell number passages with ≥ 
100 are karyotypicaly abnormal. Cells were grown and kindly provided by Dr Peter 
Andrews’s laboratory (Centre for Stem Cell Biology, University of Sheffield, UK). 
H7 (WA-07) Female human ES cell line (Thomson et al., 1998); grown in collaboration with Dr Wei 
Cui (IRDB, Imperial College London, UK). 
H9 (WA-09) Female human ES cell line (Thomson et al., 1998); grown in collaboration with Dr Wei 
Cui (IRDB, Imperial College London, UK). 
iPS 40 Human iPS cell line (Vallier et al., 2009b) derived from neonatal foreskin fibroblasts by 
retroviral infection and expression of four reprogramming factors (Oct4, Sox2, c-Myc and 
Klf4). These cells were obtained from Dr Ludovic Vallier (Laboratory for regenerative 
medicine, University of Cambridge, UK). 
CD34+ Human CD34+ stem cells isolated from peripheral blood of 3 healthy volunteers 
following informed consent. These cells were kindly provided by Dr Catherine Flores 
(Department of Haematology, Imperial College London, UK). 
NP7 Human neural progenitor cells derived from H7 ES cells (Gerrard et al., 2005). 
ReNcell VM Human immortalized neural stem cell line derived from a 10-week fetal brain (SCC008; 
Chemicon/Milipore). 
hB Human Epstein-Barr Virus transformed adult B cell clones (Eden et al., 2002) obtained 
from Dr Filipe Pereira (MRC Clinical Sciences Centre, London, UK). 
Oct4-GFP B Abelson transformed mouse B cell line derived from the transgenic mice GOF18PE 
(Palmieri et al., 1994); C5BL/6 genetic background. This cell line was kindly provided by 
Dr Filipe Pereira (MRC Clinical Sciences Centre, London, UK). 
E14tg2A Hprt deficient mouse ES cell line derived from Lesch-Nyhan embryos (Hooper et al., 
1987); feeder-independent; 129 genetic background. 
B6  Mouse ES cell line (Kontgen et al., 1993); feeder-dependent; C57BL/6 genetic 
background; a gift from Dr Colin Steward (National Cancer Institute, Frederick, 
Maryland, USA). 
Dc7 Mouse ES cell line newly derived; feeder-independent; 129/castaneus mixed genetic 
background; a gift from Dr Tatyana Nesterova (MRC Clinical Sciences Centre, London, 
UK). 
Oct4GiP Mouse ES cell line derived from embryos carrying an Oct4GiP (eGFPiresPuro) 
transgene (Ying et al., 2002) feeder-independent; MF1/129 genetic background; a gift 
from Dr Jennifer Nichols (Wellcome Trust Centre for Stem Cell Research, University of 
Cambridge, UK). 
EpiS 129 Mouse EpiS cell line derived from the dissection of the late-epiblast layer from pre-
gastrula E6.5 embryos (Vallier et al., 2009a); 129 genetic background; a gift from Dr 
Ludovic Vallier (Department of Surgery and Laboratory for Regenerative Medicine, 
University of Cambridge, UK). 
EpiS B6/CBA Mouse EpiS cell line derived from the dissection of the late-epiblast layer from pre-
gastrula E5.75 embryos (Brons et al., 2007); B6/CBA F1 genetic background; a gift from 
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Dr Ludovic Vallier (Department of Surgery and Laboratory for Regenerative Medicine, 
University of Cambridge, UK). 
EpiS NOD Mouse EpiS cell line derived from the dissection of the late-epiblast layer from pre-
gastrula E6.5 embryos (Brons et al., 2007); NOD genetic background; a gift from Dr 
Ludovic Vallier (Department of Surgery and Laboratory for Regenerative Medicine, 
University of Cambridge, UK). 
EpiS Oct4GiP Mouse EpiS cell line derived from E5.75 embryos carrying an Oct4GiP (eGFPiresPuro) 
transgene (Ying et al., 2002); feeder-independent; MF1/129 genetic background; a gift 
from Dr Jennifer Nichols (Wellcome Trust Centre for Stem Cell Research, University of 
Cambridge, UK). 
MEFs Mouse embryonic fibroblasts isolated from wild type CF-1 embryos (E13.5).  
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2.2. Methods 
 
2.2.1. Cell culture 
 
All tissue culture reagents used were from Invitrogen (Invitrogen Ltd, Paisley, 
UK), unless otherwise stated. H1, H7 and H9 hES cell lines were cultured under 
feeder-free conditions on matrigel-coated (Becton Dickinson) 6 well plates as 
previously described (Xu et al., 2001). According to these conditions, cells were 
maintained in an undifferentiated state in mitotically inactivated primary MEF cells-
conditioned medium (CM) [KnockoutTM Dulbecco's Modified Eagle Medium (DMEM) 
medium supplemented with 20% (v/v) KnockoutTM Serum Replacement (KSR), 1 mM 
L-glutamine, non-essential amino acids (NEAA), 0.1 mM β-mercaptoethanol and 
antibiotics (50 U/ml Penicillin/Streptomycin)] supplemented with 8 ng/ml basic fibroblast 
growth factor (FGF2) (PeproTech EC Ltd., London, UK). CM was prepared by 
incubating hES cells medium on flasks (0.5 ml/cm2) with 40 Gy irradiated MEFs at 56 
000 cells/cm2 during 24 hours. The CM was filtered (0.2 µm) and stored at -20C. 
MEFs were cultured in high-glucose DMEM supplemented with 10% foetal bovine 
serum (FBS; Globepharm, Esher, UK), 2 mM L-glutamine and antibiotics, grown until 
80-85% confluence, dissociated with trypsin-EDTA before irradiation and plated onto 
0.5% gelatine-coated surfaces (Sigma). 
For feeder and Serum Replacer free culture, H1 and H9 hES cell lines were 
transferred from CM conditions to a chemically defined medium (Johansson and Wiles, 
1995; Wiles and Johansson, 1999) supplemented with 10 ng/ml activin (R&D Systems) 
and 12 ng/ml FGF2 (PeproTech) as previously described (Vallier et al., 2005) and here 
designated as CDMactivin. The composition of CDM was 50% Iscove's Modified 
Dulbecco's Medium (IMDM) plus 50% F12 NUT-MIX, supplemented with 7 µg/ml of 
insulin (Roche Ltd., West Sussex, UK), 15 µg/ml of transferrin (Roche), 450 µM of 
monothioglycerol (Sigma), 1% chemically defined lipid concentrate100x, 5 mg/ml of 
batch tested bovine serum albumin (BSA) fraction V (Sigma) and antibiotics. To allow 
hES cells adhesion in CDMactivin, plates were pre-coated with adhesion media 
(KnockoutTM DMEM medium supplemented with 10% batch tested FBS and 2 mM L-
glutamine), for 24 hours at 37°C and then washed twice in phosphate buffered saline 
(PBS) to eliminate any serum. A range of concentrations (10, 25 and 50 µM) of 
curcumin (a gift from Dr Matthew J Fuchter, Department of Chemistry, Imperial College 
London, UK) solution in dimethyl sulfoxide (DMSO) (Sigma) was added to CDMactivin 
media of H1 hES cells when indicated. Medium was daily changed and cells routinely 
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passaged at a 1:3 split ratio by treatment with 200 U/ml collagenase type IV in 
KnockoutTM DMEM followed by mechanical dissociation with 5 ml pipette in both CM 
and CDMactivin conditions. Nomenclature for culture conditions is according to the 
following convention: cell line, number of passages in CM culture, plus additional 
passages in CDMactivin conditions, plus number of passages of cells returned to CM 
here labelled as re-swapped (RS) cells, if applied. Thus, H1p40(CDM6;RS5) would be 
H1 grown for 51 passages overall, 40 initial passages were in CM, passages 41-46 
were in CDMactivin  and passages 47-51 were again in CM. Since hES cells are 
susceptible to genetic anomalies on prolonged passages (Draper et al., 2004), unless 
otherwise stated only hES cells earlier passages (p30-p80) were used for these 
experiments. 
Multiple passages of H1-BH1 consisting of early and karyotypicaly abnormal 
late adapted cultures separated by at least 100 passages (early-passage hES 
duplicates ranged from p11-p26, and late-passage hES duplicates ranged from p145-
p162) were cultured as previously described (Baker et al., 2007). Briefly cells were 
maintained on 600 cells/cm2 MF-1 mitomycin C (Sigma) inactivated MEFs, in 
KnockoutTM DMEM medium supplemented with 10% KSR and 4 ng/ml of FGF2. Cells 
were harvested for passaging by scraping with glass beads after brief incubation with a 
solution of 1% collagenase type IV in DMEM/F12. Early passage cells were typically 
passaged using 1:2 to 1:3 split ratios, every 5-6 days; later passage, adapted cells 
grew more robustly and were split at 1:5 to 1:10 split ratios. 
Human iPS 40 cells (Vallier et al., 2009a) were grown under CM or CDMactivin 
conditions as described for hES cells. 
Human CD34+ hematopoietic stem cells were isolated by Dr Catherine Flores 
from blood samples of three healthy volunteers after informed consent and under the 
local research ethics committee approval. Briefly, peripheral blood mononuclear cells 
(PBMCs) obtained by leukapherese processed samples were isolated with the help of 
Lymphoprep (Axix-Shield; Oslo, Norway) gradient. CD34+ cells were isolated from the 
pool of PBMCs using the MiniMacs CD34+ isolation kit (MACS Miltenyi Biotec; 
Camberley, UK) as detailed in the manufacturer protocol. Isolated CD34+ cells were 
plated on 35 mm2 Petri dishes with α-minimal essential medium (α-MEM) 
supplemented with 30 %FBS and cytokines (R&D Systems) [20 ng/ml stem cell factor, 
1 ng/ml granulocyte-macrophage colony stimulating factor, 5 ng/ml interleukin (IL)-3 
and 100 ng/ml granulocyte colony-stimulating factor]. 
EBV-transformed hB clones were maintained in RPMI-1640 supplemented with 
10% FBS, 2 mM L-glutamine and antibiotics. The Oct4-GFP B-cell line was grown in 
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RPMI-1640 supplemented with 20% FBS, 1x NEAA, 2 mM L-glutamine, 50 µM β-
mercaptoethanol, antibiotics and IL-7 (5 ng/ml; R&D systems).  
Human ReNcell VM cells were cultured in N2B27 medium (1:1 mix of 
DMEM/F12 supplemented with N2 and Neurobasal medium supplemented with B27) 
with 20 ng/ml FGF2 and 20 ng/ml epidermal growth factor (EGF) (R&D Systems) onto 
poly-L-lysine/laminin (Sigma) coated culture dishes. ReNcell VM cells were plated at 
1x105 cells/cm2 in 6 well plates and expanded by disassociation into single cells with 
TrypLE express. 
Mouse ES cells were grown and maintained in an undifferentiated state either 
on 0.1% gelatin-coated surfaces (E14tg2A and Oct4GiP) or on irradiated MEF feeder 
layers (B6 and Dc7), and dissociated with trypsin-EDTA. With the exception of the 
newly derived Dc7 cell line, all mES cells were grown in Minimal Eagle medium 
(GMEM-BHK 21) supplemented with 15% batch tested FBS (Sigma), 1x NEAA, 1 mM 
sodium pyruvate, 0.075% sodium bicarbonate, 0.1 mM β-mercaptoethanol, 2 mM L-
glutamine, antibiotics, and 1000 U/ml of LIF (ESGRO-LIF, Chemicon/Millipore). Dc7 
cells were cultured and analyzed in derivation medium with DMEM supplemented with 
5% batch tested FBS (Sigma), 15% KSR, 1x NEAA, 50 µM β-mercaptoethanol, 2 mM 
L-glutamine and 2000 U/ml LIF. Differentiated cells could be eliminated from Oct4GiP 
cultures by puromycin (1 μg/ml) selection for expression of the Oct4GiP transgene. 
Mouse EpiS cell lines (129, B6/CBA, NOD and Oct4GiP) were cultured as 
previously described (Brons et al., 2007) in CDMactivin media supplemented with 20 
ng/ml activin and 12 ng/ml FGF2 on pre-coated adhesion medium plates in the same 
way that hES cells in CDMactivin conditions. Cells were propagated as small clumps by 
scraping with 5 ml pipette after incubation with 1% collagenase type IV in KnockoutTM 
DMEM using 1:5 to 1:15 split ratios depending on proliferation ratio. Differentiated cells 
could be eliminated from Oct4GiP mEpiS cultures by puromycin (1 μg/ml) selection for 
expression of the Oct4GiP transgene. Unless otherwise stated all cells were 
maintained at 37°C and 5% CO2. 
 
2.2.2. Human ES cells differentiation 
 
2.2.2.1. Embryoid body formation 
 
Human ES cells differentiation was achieved by promoting embryoid body (EB) 
outgrowths from hES cells CM and CDMactivin conditions, as previously described 
(Osafune et al., 2008). Briefly, 2 wells from a 6 well plate of hES cells at 80-90% 
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confluence were rinsed with PBS and treated with 1 mg/ml collagenase type IV in 
KnockoutTM DMEM for 10 min at 37 °C. The collagenase was rinsed away with PBS 
and replaced with undifferentiation CM or CDMactivin medium (as described above). 
Cells were then scraped off with a cell scraper, dissociated by pipetting, and distributed 
into ultra-low attachment 10 cm plates (Corning Incorporated, NY, USA) containing 
KnockoutTM DMEM supplemented with 20% KSR, 0.1 mM NEAA, 2 mM L-glutamine, 
500 U/ml Penicillin/Streptomycin and 0.55 mM β-mercaptoethanol. On day 7, EBs were 
transferred back to 0.1% gelatinized-tissue culture plates, which allow the cells to 
adhere and further differentiate into different cell lineages. Media was changed every 3 
days and EBs were collected for real-time quantitative PCR analysis at culture day 3, 6, 
9 and 30. Primer pairs used for this analysis are listed in Appendix I, Table A1. 
 
2.2.2.1. Neural progenitor cell differentiation 
 
 Neural differentiation of hES cells was achieved using two different 
methodologies as previously described (Gerrard et al., 2005) and (Chambers et al., 
2009) with slight modifications.  
 
Human neural progenitor (NP) cells derived from undifferentiated H7 cells from 
CM conditions were derived according to Gerrard et al. Briefly, confluent hES cells 
were split with 0.5 mM EDTA/PBS in 1:5 ratios into culture dishes coated with poly-L-
lysine/laminin and cultured in N2B27 medium (as described above), supplemented with 
100 ng/ml mouse recombinant noggin (R&D Systems). Cells were consistently split at 
1:3 ratios by collagenase into small clumps, similar to hES cells CM culture. After 24 
days in culture cells were disassociated into single cells by TrypLE express, and 
noggin was withdrawn from N2B27 medium, while 20 ng/ml FGF2 and 20 ng/ml EGF 
were added after an extra 8 days in culture. NP cells were plated at 1x105 cells/cm2 in 
6 well culture plates. Media was changed every 2 days. The neural progenitor 
phenotype was confirmed by immunostaining and semi-quantitative PCR (as described 
in the Results section). Primer pairs used for this analysis are listed in Appendix I, 
Table A2. 
Chambers et al., neural differentiation protocol was applied to H1 hES cells 
grown under CM and CDMactivin conditions. Briefly, undifferentiated hES cells expanded 
in their regular cell culture conditions for 2 days, were incubated with N2B27 medium 
supplemented with 10 µM SB4341542 (TOCRIS/Sigma), 500 ng/ml noggin and 10 
ng/ml FGF2. Media was daily changed, and cells collected for real-time quantitative 
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PCR analysis at culture day 2, 4 and 6. Primer pairs used for this analysis are listed in 
Appendix I, Table A1. 
 
2.2.3. Replication Timing analysis 
 
2.2.3.1. BrdU labelling and cell cycle fractionation by flow cytometry 
 
All reagents used in this analysis were from Sigma unless otherwise stated. The 
replication timing of individual loci was assessed using a previously described method 
(Azuara, 2006). Exponentially growing non-synchronized cells were incubated with 50 
µM 5-bromo-2-deoxyuridine (BrdU) for 30 min (mES and mEpiS cells) or 90 min (hES, 
iPS 40, NPs and CD34+ cells) at 37C, washed in cold PBS (Invitrogen) without 
calcium and magnesium, fixed in 70% ethanol and stored at 4C in the dark for at least 
24 hours. Ethanol was removed by washing the cells twice with PBS and collected by 
centrifugation at 1700 rpm for 10 min, 4C. BrdU-labelled cells were resuspended in 
staining buffer (40 mM Tris pH 7.4, 0.8% NaCl, 21 mM MgCl2 and 0.05% NP-40) with 
50 µg/ml propidium iodide (PI) and 1 mg/ml RNAse A, carefully disaggregated with the 
help of a 40 µm cell strainer (Becton Dickinson) and allowed to stain on ice, in the dark 
for 20 min prior to separation on a FACS Vantage flow cytometer, Diva. Equal numbers 
of cells (ranging from 20 000 to 50 000) were collected for each of six fractions (G1, 
S1, S2, S3, S4 and G2) into Lysis buffer I [1 M NaCl, 10 mM EDTA, 50 mM Tris-HCL 
pH 8.0, 0.5% SDS, 0.2 mg/ml proteinase K (PK), 0.25 mg/ml salmon sperm DNA 
(Invitrogen)] and stored at -20C following incubation for 2 hours at 50C. 
 
2.2.3.2. Isolation of newly-replicated DNA by immunoprecipitation 
 
Equal amounts of Drosophila melanogaster S2 BrdU-labelled DNA were added 
to each sorted cell cycle fraction (7.5 ng per 104 sorted cells). DNA was then purified by 
phenol, chloroform/isoamylalcohol extraction and ethanol precipitation. Precipitated 
DNA was dissolved in 480 µl of Tris-EDTA (TE) with 0.2 mg salmon sperm DNA 
(Invitrogen) at 37C for 1 hour in the dark. Samples were then sonicated 45 sec on a 
Vibra-CellTM VC130 (Sonics & Materials, Inc, Newtown, USA) (130W, 30Hz) using a 
microtip ultrasonic probe in order to generate fragments of an average size of 700 bp. 
After denaturation for 5 min at 95C and cooling down on ice for 2 min, it was added 50 
µl of Adjusting buffer [10 mM sodium phosphate (pH 7), 0.14 M NaCl, and 0.05% Triton 
X-100] to each fraction and incubated with 80 µl anti-BrdU antibody for 30 min at room 
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temperature with constant rotation. Secondary antibody (rabbit anti-mouse IgG) was 
added (35 µg) and incubated at room temperature with constant rotation for additional 
30 min. DNA-protein complexes were collected by centrifugation at 15 300 rpm for 20 
min, 4C, washed once with Washing buffer (10 mM sodium phosphate buffer pH 7.0, 
0.14 M NaCl, 0.05% Triton X-100) and resuspended in 200 µl Lysis buffer II (50 mM 
Tris-HCL pH 8, 10 mM EDTA, 0.5% SDS, 0.25 mg/ml PK) and incubated 2 hour, 55C. 
BrdU-labelled DNA was then extracted by phenol/chloroform/isoamyl alcohol and 
ethanol precipitation before resuspension in Tris-EDTA (TE; 10 mM Tris-Hcl pH 8.0, 1 
mM EDTA) at a concentration of 150/200 cell equivalents per microlitre. The 
abundance of newly replicated DNA in each cell-cycle fraction was determined by real-
time quantitative PCR. Primer pairs used for this analysis are listed in Appendix I, 
Table A3. 
 
2.2.4. Reverse transcription (RT) polymerase chain 
reaction (PCR) 
 
2.2.4.1. RNA extraction and cDNA synthesis 
 
RNA extraction was performed using RNeasy protect mini kit (Qiagen, Valencia, 
CA) and residual DNA eliminated with RNase-free DNase set (Qiagen) according to 
manufacturer’s instructions. RNA was then reverse transcribed using the SuperscriptTM 
first-strand synthesis system. 1.5 µg of total RNA was diluted in RNase free water to a 
final volume of 11 µl and supplemented with 1 µl of 10 mM dNTP mix (Invitrogen) and 1 
µl of oligo (dT)12-18 (Invitrogen). The mixture was incubated at 65°C for 5 min and put 
on ice for 1 min, when 1 µl of 0.1 M DTT, 4 µl of 5X first strand buffer, 1 µl of 
RnaseOUT (Invitrogen) and 1 µl of 200 U/µl Superscript III were added. A reaction 
mixture without the enzyme was also set up as a control (designated “-RT”). The 
mixture was then incubated at 50°C for 1 hour and at 70°C for 15 min in order to stop 
the reaction. 180 µl of RNase-free water was then added to each cDNA sample. 
cDNAs of interest were then detected by semi-quantitative PCR or real-time PCR. 
 
2.2.4.2. Semi-quantitative PCR analysis (RT-PCR) 
 
Semi-quantitative PCR analysis was performed in 50 µl reaction volume with 
1.25 U of HotStarTaqTM DNA polymerase (Qiagen) using 0.4 µM specific primers, with 
the following program: 95°C for 15 min, then cycles of 94°C for 15 sec, 60°C for 30 
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sec, 72°C for 30 sec. PCR products were separated by electrophoresis on 1.5% 
agarose (Invitrogen) gels and visualised by ethidium bromide staining. β-actin was 
used to normalize input. The primers and conditions used for this analysis can be found 
in Appendix I, Table A2. For each reaction of PCR amplification, conditions were 
maintained within the dynamic range. 
 
2.2.4.3. Real-time quantitative PCR analysis (qPCR) 
 
Real-time PCR analysis was performed in 30 µl reaction volume with 2X Sybr-
Green PCR Mastermix (Qiagen), 300 nM primers and 2 µl of template. A reaction 
without DNA was included to control for the formation of primer dimers and each 
measurement was performed in duplicate. PCR reactions were carried out on a DNA 
Engine OpticonTM II using Opticon Monitor 3 software (MJ Research Inc., Waltham, 
MA), running the following program: an initial denaturating step at 95°C for 15 min, 40 
cycles of denaturation at 94°C for 15 sec, annealing at 60°C for 30 sec, elongation at 
72°C for 30 sec at which point the fluorescence was read at 72°C, 75°C, 78°C, 80°C 
and 83°C. The melting curve was determined from 70°C to 90°C, at 0.1°C intervals. 
For analysis of the qPCR data the relative abundance of sequences was calculated 
using the C(T) method (Pfaffl et al., 2001). Gene expression data was normalized to 
the average of two housekeeping genes: Gapdh and Hprt for human data and for 
mouse Actin and L19 as previously described (Vandesompele et al., 2002). Primer 
sequences can be found in Appendix I, Table A1. 
 
2.2.4.4. Primer design and testing for real-time quantitative PCR 
 
Replication timing, ChIP and methylated DNA immunoprecipitation (MeDIP) 
primers were designed with the Primer Express software (Applied Biosystems, 
Warrington, UK) while gene expression primers designed with PerlPrimer software 
(Marshall, 2004) using sequences from the mouse and human Ensemble Genome 
Browser (http://www.ensembl.org/index.html) database. The following design criteria 
were used: amplicon size of 100-200 bp, GC content of 40-60%, melting temperature 
55-65°C. All primer pairs were tested for predicted products using in silico PCR tools 
such as PUNS (http://okeylabimac.med.utoronto.ca/PUNS) or the UCSC genome 
browser (http://genome.ucsc.edu). Primers yielding a single predicted PCR product of 
the correct size were ordered from Sigma Genosys. 
The efficiency of amplification for each primer pair was determined by qPCR 
with sequential dilutions of cDNA or genomic DNA (see section 2.2.10.1.) and primers 
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yielding poor linear fits of the C(T) versus logarithm of concentration (R2<0.99) or 
efficiencies lower than 1.8 or greater than 2.2 were discarded. When species specificity 
was required (i.e. analysis in inter-species heterokaryons), primers were designed and 
tested to specifically amplify the human or the mouse sequences but not the orthologs. 
 
2.2.5. Genomic context analysis 
 
The GC content, long interspersed nuclear elements (LINE) density and gene 
density genomic features of the replication timing analyzed genes was obtained from 
the University of California, Santa Cruz, genome browser website 
(http://genome.ucsc.edu/), based on the May 2004 human genome assembly. For GC 
content and LINE density calculations it was analyzed, for each gene of interest a 200 
Kb surrounding DNA region (100 Kb upstream and downstream of the transcription 
start position). As previously described (Hiratani et al., 2004), regions with < 43% GCs 
are considered poor for this parameter and regions with > 6% LINE are highly dense. 
Gene density was defined as the number of transcriptional units in 1 Mb (500 Kb 
upstream and downstream of the middle position of the gene). Regions with ≤ 10 
genes were considered poor. 
 
2.2.6. Immunofluorescence analysis and alkaline 
phosphatase activity 
 
Undifferentiated hES, mES an mEpiS cells were cultured on coated glass 
coverslips according to their growth conditions and NP cells on poly-L-lysine/laminin 
coated Thermanox® coverslips (Nalge-Nunc Inc., Rochester, NY) for at least 24 hours. 
Coverslips were removed, washed in PBS and fixed in 4% paraformaldehyde (PFA) in 
PBS for 15 min. Fixed samples were washed in PBS and, for intracellular staining, 
permeabilised with 0.4% Triton X-100 for 15 min at room temperature. Samples were 
incubated sequentially in blocking solution [2.5% BSA, 0.05% Tween20, 10% Normal 
Goat Serum (Sigma) in PBS] for 30 min and in primary antibody diluted in blocking 
solution (2 h at room temperature) in a humid chamber. Coverslips were washed in 
wash buffer (0.2% BSA, 0.05% Tween20 in PBS; 3x5 min) and incubated with 
secondary antibodies coupled with appropriated fluorophores diluted in blocking 
solution for 45 min. Finally, cells were washed twice in wash buffer (5 min), once in 
PBS (3 min) and mounted in Vectashield (Vector) with DAPI (1 µg/ml). For SSEA1 
staining, cells were incubated with APC-coupled anti-SSEA1 antibody, washed twice in 
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wash buffer (5 min), once in PBS (3 min) and mounted in Vectashield (Vector) with 
DAPI (1 µg/ml). A list of primary and secondary antibodies used for IF as well as 
quantities and suppliers is shown in section 2.1.1. and 2.1.2. 
Alkaline Phosphatase staining was carried out on cells grown for 2 days under 
their standard culture conditions, using a kit from Sigma (86R-1KT) according to the 
instructions. 
Samples were visualised using a Nikon Eclipse TE2000-U microscope and 
images processed using QCapture Pro software and Adobe Photoshop CS2, or a TCS 
SP5 Leica laser-scanning confocal microscope using the Leica Confocal software and 
Adobe Photoshop CS2. Microscope settings and laser power were kept constant 
between the controls and samples.  
 
2.2.7. Fluorescence activated cell sorting analysis 
 
The analysis of cell surface antigens (SSEA4, SSEA3, SSEA1, Tra-1-60 and 
Tra-1-81) was performed as follows: cells were harvested by trypsinisation and 1.5x106 
cells were washed twice in FACS buffer (PBS, 2% FBS), resuspended in primary 
antibody diluted in FACS buffer and incubated 30 min at 4ºC. The cells were then 
washed twice and incubated for an additional 30 min with a secondary antibody also 
diluted in FACS buffer. Finally, cells were washed twice and then resuspended in 100 
µl of FACS buffer for analysis. For SSEA1 staining, cells were incubated with APC-
coupled anti-SSEA1 antibody, washed twice and resuspended directly in 100 µl of 
FACS buffer. For intracellular staining (Oct4 and Nanog) cells were harvested by 
trypsinisation, washed in FACS buffer and 1.5x106 cells fixed (10 min, 37°C) with 0.1% 
PFA in PBS. Cells were then washed and permeabilised (30 min, 4°C) with cold 90% 
methanol. After washing once, cells were incubated for 30 min at room temperature 
with primary antibody diluted in FACS buffer with 0.1% Triton X-100. Cells were again 
washed twice before incubating for 30 min with secondary antibody diluted in FACS 
buffer with 0.5% Triton X-100. The cells were finally washed twice and resuspended in 
600 µl of FACS buffer before analysis on a FACScalibur flow cytometer (BD 
Biosciences) with CellQuest software. The profile of stained cells was compared to 
unstained cells and cells stained with the secondary antibody only. A list of primary and 
secondary antibodies used for FACS as well as quantities and suppliers is shown in 
section 2.1.1. and 2.1.2. 
For cell fusion efficiency (see section 2.2.11.) assessment it was used the cell 
labelling solutions VibrantTM 1,1’-dioctadecyl-3, 3, 3’, 3’ tetramethylindodicarbocyanine 
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(DiD) and 1,1'-dioctadecyl-3, 3, 3', 3'-tetramethylindocarbo cyanine perchlorate (DiI) 
(Molecular Probes; emission spectra: DiI λ=565nm, DiD λ=665nm). Human B-
lymphocytes were labelled with DiI while mES and mEpiS cells with DiD using the FL2 
and FL4 FACS detection channels, respectively.  
 
2.2.8. Western blot analysis 
 
Whole cell extracts were prepared by direct lysis of cells with cold Radio 
Immuno Precipitation Assay (RIPA) buffer [150 mM NaCl, 50 mM Tris pH 8.0, 0.5% 
Deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40 plus protease 
inhibitors]. Cells were scrapping, incubated on ice for 20 min and centrifugated at 13 
000 rpm for 20 min at 4˚C and the supernatant collected. For western blot analysis of 
modified histones, histone proteins were isolated from whole cells by acid extraction. 
10x107 cells were pelleted and resuspended in 1 ml PBS (4°C), centrifuged (500 g for 5 
min) and the supernatant removed. Cell pellets were resuspended in 180 µl of ice cold 
lysis buffer (100 mM HEPES pH 7.9, 1.5 mM MgCl2 10 mM KCl, 0.5 mM DTT and 1.5 
mM PMSF), 20 µl of 2 M HCl and incubated on ice for 30 min. Following acid lysis the 
solution was centrifuged 11 000 g for 10 min at 4°C, the supernatant of acid soluble 
proteins collected and sequentially dialyzed against 0.1 M acetic acid (twice for 1 hour) 
and water (1 hour, 3 hours and overnight, respectively). The protein solution was 
quantified and stored at -80°C. 
10-20 µg of protein sample was diluted 1:1 with Laemmli sample buffer 
(BioRad) with 5% β-mercaptoethanol and heated at 95˚C for 5 min. Cell lysates were 
resolved on 8-14% SDS polyacrylamide gel electrophoresis (SDS-PAGE) gels with 11 
µl Novex Sharp protein ladder (Invitrogen). Resolved acrylamide gels were blotted to 
Polyvinylidene fluoride (PDVF) membranes (Chemicon/Milipore) using a wet-blot 
method at 200 mA for 1 hour in transfer buffer (48 mM Trizma base, 39 mM glycine, 
0.037% SDS and 20% methanol). The membranes were then blocked with 5% 
skimmed milk (Sigma) in Tris-Buffered Saline with 0.5% Tween20 (TBS-T) for 1 hour at 
room temperature, followed by primary antibody incubation diluted in blocking buffer or 
5% BSA in TBS-T, overnight at 4˚C, with agitation. Membranes were washed, to 
remove any excess antibody, for 10 min three times in TBS-T under agitation before 
incubating with the appropriate HRP-conjugated secondary antibody in blocking buffer, 
for 1 hour at room temperature. Excess secondary antibody was then removed by 
washing the membrane for 10 min three times in TBS-T buffer under agitation. The blot 
was treated by enhanced chemiluminescence western blotting detection reagents 
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(Amersham Pharmacia Biotech, Little Chalfont, UK) for HRP-conjugated antibody 
detection before being exposed to X-ray films (CL-XPosure Film, Thermo Scientific, 
UK) and using the OPTIMAX IGP developer. A list of primary and secondary antibodies 
used for WB as well as quantities and suppliers is shown in sections 2.1.1. and 2.1.2. 
 
2.2.9. Chromatin immunoprecipitation analysis 
 
2.2.9.1. Histone modifications ChIP 
 
All reagents used were from Sigma unless stated otherwise. Approximately 0.5-
1x108 exponentially growing cells were harvested, washed twice in PBS and cross 
linked with 1% PFA for 10 min at room temperature. After quenching of PFA with 
glycine at a final concentration of 125 mM, cells were washed twice with ice-cold PBS 
and lysed in 1 ml of ice cold lysis buffer (50 mM Tris-HCL pH 8.1, 10 mM EDTA pH 8.0, 
1% SDS) with protease inhibitor cocktail (Roche). Using a BioruptorTM 200 (Diagenode, 
SA, Liège, Belgium), the chromatin was sonicated to an average size of 300 to 1000 bp 
as analysed on 1.5% agarose gels. Insoluble proteins were discarded after 
centrifugation of the lysate at 15 000 rpm for 15 min at 18ºC and DNA concentration 
quantified using a NanoDrop ND-1000. 100-150 µg of fragmented chromatin was 
diluted 1/10 in dilution buffer (1% Triton X-100, 2 mM EDTA pH 8.0, 150 mM NaCl, 20 
mM Tris-HCL pH 8.1) with protease inhibitors and incubated at 4ºC for 2 hours, with 30 
µl of blocked protein A-sepharose beads to pre-clear the solution of any non-specific 
binding. Beads were overnight blocked at 4ºC in dilution buffer supplemented with 10 µl 
of BSA (New England Biolabs, 10 mg/ml) and 4 µl salmon sperm DNA (10 mg/ml) and 
then resuspended in dilution and lysis buffer in a 10:1 ratio. Pre-cleared chromatin was 
then immunoprecipitated (4°C, overnight) with primary antibodies for histone’s 
modification, a negative anti-IgG control and an anti-H3 or -H4 total antibody for data 
normalization, on a spinning wheel. A list of antibodies used for ChIP as well as 
quantities and suppliers is shown in section 2.1.1. Immune-complexes were collected 
by adding 30 μl of blocked beads once again and left immunoprecipitating 2 hours on a 
spinning wheel, at 4ºC. Unbound chromatin was removed by washing four times in 1 ml 
of cold wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM 
Tris.Cl pH 8.1 and protease inhibitors) and once in final high salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris.Cl pH 8.1 and protease 
inhibitors). After adding elution buffer (1% SDS, 0.1 M NaHCO3) to elute the 
immunocomplexes from the beads, these were treated with 100 µg/ml RNase A and 
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500 µg/ml PK, 2 hours at 37ºC and 6 hours of incubation at 65ºC to reverse the cross-
links. Finally, the DNA was sequentially extracted with 
phenol/chloroform/Isoamylalcohol and precipitated in 50% isopropanol containing 5 
mM NaAc and 20 µg of glycogen carrier (Glycoblue, Ambion). After purification, DNA 
was resuspended in 100 µl of TE buffer. Histone’s modification levels were normalized 
against total H3 or H4 detected, and the ratio of DNA bound to modified-H3 or -H4 to 
total H3 or H4 was denoted as “relative abundance”. Quantification of precipitated DNA 
was performed using qPCR amplification and the primers listed on Appendix I, Table 
A3. 
 
2.2.9.2. p300 and Smad2/3 ChIP 
 
This protocol used has previously been described in detail by (Stock et al., 
2007) with minor modifications. Briefly, cells were treated with 1% formaldehyde (37°C, 
10 min) and quenched with 125 mM glycine. Cells were washed in ice-cold PBS and 
lysed at 4°C for 10 min in swelling buffer (25 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 
mM KCl and 0.1% NP-40). Cells were scraped from plates, nuclei extracted by 
homogenization, resuspended in sonication buffer (50 mM HEPES pH 7.9, 140 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate and 0.1% SDS) and 
sonicated to produce chromatin fragments with less than 1.6 kb in length. 500-600 µg 
of solubilised chromatin was pre-cleared with blocked Protein-A (rabbit antibodies) or 
Protein-G-sepharose beads (mouse antibodies) and incubated overnight at 4˚C with 
primary antibody on a rotating wheel. Smad2/3 ChIP was performed with a mixture of 
P-Smad2/3 and total Smad2/3 antibody. A list of antibodies used for ChIP as well as 
quantities and suppliers is shown in section 2.1.1. Antibody-chromatin complexes were 
collected with blocked beads for 3 hours at 4˚C before sequential washes: 1x 
sonication buffer, 1x sonication buffer containing 500 mM NaCl, 1x with 20 mM Tris pH 
8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40 and 0.5% Na-deoxycholate, and 2x TE 
buffer. All buffers were supplemented with 5 mM NaF, 2 mM Na3VO4, 1 mM PMSF, 
and protease inhibitor cocktail. Immunoprecipitated chromatin was eluted and DNA 
recovered by phenol/chloroform/Isoamylalcohol extraction and ethanol precipitation as 
previously described in 2.2.9.1. Final DNA concentrations were determined by 
PicoGreen fluorimetry (Molecular Probes, Invitrogen) and the amount of DNA 
precipitated by each antibody was normalized against the total input material. 
Quantification of precipitated DNA was performed using qPCR amplification and the 
primers listed on Appendix I, Table A3. 
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2.2.10. Methylated DNA immunoprecipitation analysis 
 
2.2.10.1. Genomic DNA extraction 
 
MeDIP was carried out in hES genomic DNA as previously described (Weber et 
al., 2005). Genomic DNA was isolated from cells by overnight incubation in 500 µl of 
Lysis buffer (200 mM NaCl, 100 mM Tris-HCl pH 7.4, 5 mM EDTA, 0.2% SDS, 250 µg 
PK) at 55ºC and subsequent phenol/chlorophorm/isoamylalcohol and 
chlorophorm/isoamylalcohol extractions. DNA was then precipitated with 50% 
isopropanol, followed by 70% ethanol wash, and resuspension in TE with 20 µg/ml 
RNAseA. DNA concentration was determined using a NanoDrop ND-1000. 
 
2.2.10.2. Sonication and immunoprecipitation of methylated DNA 
 
Genomic DNA was sonicated (VC 130 PB, Sonics & Materials, Inc) to produce 
random fragments ranging in size from 300 to 1000 bp. 5 µg of fragmented DNA was 
used for the MeDIP assay. After denaturation for 10 min at 95C and cooling down on 
ice for 2 min, samples were immunoprecipitated for 2 hours at 4C with 10 µl of Methyl-
C antibody in a final volume of 500 µl of immunoprecipitation buffer (10 mM Na-
Phosphate pH 7.0, 0.14 M NaCl, and 0.05% Triton X-100) with constant rotation. 
Chromatin-antibody complexes were then precipitated with 30 µl of Dynabeads® with 
M-280 sheep antibody against mouse IgG (Dynal Biotech, Oslo, Norway) for 2 hours at 
4C and washed three times with 700 l of immunoprecipitation buffer. Beads were 
then treated with 70 µg of PK for 3 hours at 50C and methylated DNA was recovered 
by phenol-chloroform extraction followed by ethanol precipitation at -20C and 
resuspended in 60 µl of TE buffer. The abundance of methylated DNA was determined 
by qPCR amplification with 25 ng of input DNA and 2 µl of the immunoprecipitated 
methylated DNA. Primer pairs used in this analysis are listed in Appendix I, Table A3. 
 
2.2.11. Cell fusion and experimental heterokaryons 
 
2.2.11.1. Mouse ES and EpiS-Human B-lymphocyte heterokaryons 
 
Heterokaryons were generated by fusing either mES (Oct4GiP) or mEpiS 
(Oct4GiP) cells and human B-lymphocytes using 50% polyethylene glycol, pH 7.4 
(PEG 1500, Roche) as previously described (Pereira and Fisher, 2009; Pereira et al., 
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2008). Mouse ES cells or EpiS cells were labelled with DiD and hB-lymphocytes with 
DiI cell labelling solutions (Molecular Probes), respectively. Cells were resuspended at 
1x106 cells/ml in DMEM and labelled with 5 µl/ml of dye at 37°C, 15 min. Mouse 
ES/EpiS and hB cells were then mixed at 1:1 ratio and washed twice in PBS. The 
supernatant was completely removed and 1 ml of PEG at 37°C was added to the pellet 
of cells over 60 sec and incubated at 37°C for 90 sec with constant stirring. Then, 4 ml 
of serum-free medium (DMEM) were carefully added over a period of 3 min, followed 
by 10 ml of DMEM and incubation at 37°C for 3 min. After centrifugation (1350 rpm, 5 
min), the pellet was allowed to swell in mES/mEpiS cell culture media for 3 min. Cell 
mixtures were then resuspended and cultured under conditions promoting the 
maintenance of undifferentiated mES or mEpiS cells at 0.5x106 cells/cm2. To eliminate 
unfused hB cells Ouabain (10-5 M) (g-strophanthin, Sigma) was added to the medium. 
Proliferating mES or mEpiS cells were eliminated by the addition of 10-5 M Ara-C 
(Cytosine-D arabino furanoside; Sigma) 6 hours after fusion and then removed after 16 
hours. Fused cells were cultured under conditions promoting the maintenance of 
undifferentiated mouse stem cells and heterokaryons collected for qPCR analysis at 
day 0, 1, 2 and 3. Cell fusion efficiencies were determined by FACS analysis at day 0. 
Primer pairs used in this analysis are listed in Appendix I, Table A1. 
 
2.2.11.2. Human ES CM and CDMactivin-Mouse B-lymphocyte heterokaryons 
 
Undifferentiated H1 hES from CM or CDMactivin culture conditions were fused 
with mouse B-lymphocytes (Oct4-GFP B) as described above. Cells were mixed for 
fusion at 1:1 ratio and cultured under conditions promoting the maintenance of 
undifferentiated hES cells in CM or CDMactivin conditions at 0.5x106 cells/cm2. 
Proliferating hES cells were eliminated by the addition of Ouabain (10-5 M) 6 hours after 
cell fusion. Heterokaryons were collected for qPCR analysis at day 0, 1, 2 and 3. 
Primer pairs used in this analysis are listed in Appendix I, Table A1. 
 
2.2.12. Analysis of DNA content and BrdU incorporation 
following acid denaturation of DNA 
 
All reagents used in this analysis were from Sigma unless otherwise stated. 
Exponentially growing non-synchronized H1 hES CM and CDMactivin cells were 
incubated with 30 µg/ml BrdU for 60 min at 37C. Cells were collected from plates by 
trypsinization, pooled with the floating cells in the medium and resuspended in room 
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temperature PBS at 1x106 cells/ml. With a Pasteur pipette 1 ml aliquots of the cell 
suspension were transferred into tubes with 10 ml of ice-cold 70% ethanol and fixed 
overnight at 4C, in the dark. Cells were collected by centrifugation (1200 rpm, 5 min) 
and pellets incubated in 250 µl of 2 M HCl for 20 min at room temperature. After this 
step it was added 5 ml of phosphate/citric acid buffer, pH 7.4 (182 mM Na2HPO4 and 9 
mM citric acid) to the suspension, cells were centrifugated and washed in another 5 ml 
of phosphate/citric acid buffer, pH 7.4. Cells were resuspended in 100 µl antibody 
dilution buffer (0.1% Triton X-100, 1 % BSA in PBS) with 0.5 µg mouse anti-BrdU 
antibody, gently vortexed and incubated 30 min, room temperature. Cells were then 
washed once with 5 ml antibody dilution buffer and resuspended in 100 µl antibody 
dilution buffer with 1 µg Alexa 488 goat anti-mouse antibody, gently vortexed and 
incubated 60 min at room temperature and 5 min on ice. After washing once, cells were 
finally stained in the dark with 2 ml PI staining solution (100 µg PI, 1 mg RNase A and 
10 ml PBS) for 30 min prior to FACS analysis. Cells that were not incubated with BrdU 
and cells incubated only with secondary antibody were used as a negative control. 
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CHAPTER 3. CHARACTERIZATION OF THE 
CHROMATIN STATUS OF HUMAN ES CELLS 
ALONGSIDE MOUSE ES AND EPIS CELLS 
 
 
3.1. Replication timing analysis of hES, mES and 
mEpiS cells using a candidate based approach  
 
Profiling chromatin in a particular cell type has proven to be a valuable 
signature for cell identity and developmental stage. One approach has been to assay 
the timing of DNA replication across a panel of loci, as an indicator of chromatin 
accessibility. Remarkably, this replication timing profiling was capable of discriminating 
pluripotent mES cells from cells with a more restricted differentiation capacity (Azuara 
et al., 2006; Hiratani et al., 2008; Perry et al., 2004). Here, DNA replication timing will 
be used to examine and compare human and mouse stem cell populations derived 
from the early embryo, this includes well-established hES (H1, H7 and H9), mES 
(E14tg2A, B6 and Dc7) and mEpiS (129, B6/CBA and NOD) cell lines derived from 
different genetic backgrounds (see section 2.1.3. for cell line details). As illustrated in 
Figure 3.1a, all three pluripotent stem cell types analysed (hES, mES and mEpiS) 
share the expression of key pluripotency markers (Nanog and Oct4) and can be 
progapagated and maintained in an undifferentiated state in vitro for an unlimited 
period of time under appropriate conditions. Despite the similarities, several differences 
between hES, mES and mEpiS cells have been reported, in particular in terms of cells 
morphology and cell-surface markers (Pera and Trounson, 2004). Undifferentiated 
mES cells typically grow in small, compact, domed colonies while in contrast, hES and 
mEpiS cell colonies are larger, flat and cells grow as a monolayer (Figure 3.1b). The 
expression of the cell surface marker SSEA1 is restricted to mES and mEpiS cells 
while AP activity can only be detected in mES and hES cells (Figure 3.1a and c). 
Importantly, the extrinsic signals that drive pluripotent mouse and human cells self-
renewal and pluripotency have undergone significant deviations. The undifferentiated 
state of mES cells depends on LIF/BMP signalling, while hES and mEpiS cells rely on 
Activin/FGF (Yu and Thomson, 2008). Altogether, this raises a developmental paradox, 
where the true lineage affiliation of hES cells is questionable. Are the differences 
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between mES and hES cells related to species divergence or to differences in the 
stages of embryonic development from which they arise? In this study, I will further 
investigate this developmental paradox, by investigating the cell identity and chromatin 
status of mouse and human pluripotent cell lines, using DNA replication timing. 
 
 
 
Figure 3.1. Characterization of the undifferentiated state of hES cells alongside mES and mEpiS 
cells. (a) Mouse ES (E14tg2A line, top panel), hES (H1 line, middle panel) and mEpiS (129 line, bottom 
panel) cells were analysed by immunofluorescence for the expression of Nanog (green), Oct4 (red) and 
SSEA1 (red). Nanog and Oct4 are highly expressed in mES, hES and mEpiS cells, while SSEA1 is not 
expressed in hES cells. Nuclei are shown by DAPI staining (blue). (b) Bright field (BF) pictures of 
representative undifferentiated mES, hES and mEpiS cell colonies. Mouse ES cells typically grow in small, 
compact, domed colonies, while hES and mEpiS cell colonies are larger and flat growing as a monolayer. 
(c) Alkaline phosphatase (AP) enzymatic activity (pink) is detected in both hES and mES cells and absent 
in mEpiS cells. Scale bars, 50 µm. 
 
 
For this analysis, it was selected a panel of 45 key regulatory genes mainly encoding 
human and mouse homologs, which are selectively expressed in embryonic 
(pluripotent) and extraembryonic (trophectoderm) tissues of the early embryo or are 
involved in specifying ectoderm, mesoderm, endoderm or germ-line lineages (Table 1). 
The POU transcription factor Oct4 (Nichols et al., 1998; Palmieri et al., 1994; Reubinoff 
et al., 2000; Rosner et al., 1990; Scholer et al., 1990) and the homeobox gene Nanog 
(Chambers et al., 2003; Clark et al., 2004; Mitsui et al., 2003) are examples of key 
pluripotency-associated genes in both human and mouse stem cell populations.  
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Table 1. Candidate genes selected for the replication timing analysis. 
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Other loci showing differentiated gene expression between ICM/ES cells (Rex1 and 
Gbx2) (Chapman et al., 1997; Rogers et al., 1991) and epiblast/EpiS cells (Fgf5, Psc1 
and Prce) (Brons et al., 2007; Haub and Goldfarb, 1991; Hebert et al., 1991; Pelton et 
al., 2002; Tesar et al., 2007) were also included in this analysis. Note that the selection 
of these markers could only be based on expression analysis of mouse embryos, as 
equivalent information is not available in human embryos. Genes involved in the 
trophectoderm lineage specification in both human and mouse embryos include the 
caudal-related gene Cdx2 (Beck et al., 1995; Hay et al., 2004) and the T-box gene 
Eomes (Babaie et al., 2007; Ciruna and Rossant, 1999; Russ et al., 2000). While Dazl 
(Ruggiu et al., 1997) and Sycp1 (Meuwissen et al., 1992) are typical examples of 
selected germ cell markers. 22 additional genes implicated in the specification of 
somatic lineages were also included among which are the ectoderm, neuronal-specific 
genes, Sox1 (Collignon et al., 1996; Malas et al., 1997) and Sox3 (Collignon et al., 
1996; Stevanovic et al., 1993) and the mesoderm, myogenic or haematopoietic genes 
Myf5 (Braun et al., 1989; Rudnicki et al., 1993) and Ikaros (Georgopoulos et al., 1992), 
respectively. The zinc-finger transcription factor Gata6 (Koutsourakis et al., 1999; 
Morrisey et al., 1998) is known to be involved in PrE development while the pancreatic 
Pdx1 (Ahlgren et al., 1996; Stoffers et al., 1997) is an example of definitive endoderm 
marker. The full list of selected loci as well as their chromosomal locations on mouse 
and human genomes is summarized in Table 1. 
The replication timing of individual loci was assessed using a previously 
described method (Azuara, 2006; Azuara et al., 2003; Hansen et al., 1993); an outline 
of this assay is shown in Figure 3.2. Briefly, non-synchronised exponentially growing 
cells were pulse-labelled with 5-bromo-2-deoxyuridine (BrdU), a thymidine analogue 
that is incorporated by DNA polymerase into newly replicating DNA. The cells are then 
stained with the DNA-binding dye propidium iodide (PI) and fractionated by flow 
cytometry into six fractions according to DNA content. The first fraction includes cells in 
G0 and G1, while S-phase is represented by four fractions (designated as S1 to S4) 
and the G2 fraction includes cells that have completed DNA replication. A 
representative cell cycle profile for mES cells is shown in Figure 3.2, where the non-
overlapping gates used to sort the six cell cycle fractions, are indicated. After DNA 
isolation and sonication, newly synthesised BrdU-labelled DNA, from an equal number 
of sorted cells, is purified by immunoprecipitation with anti-BrdU antibodies. Locus-
specific sequences are then quantified by real-time quantitative PCR (qPCR) using 
primers amplifying the regions around 600 bp upstream of the transcription start sites 
of the selected genes. The relative abundance of newly synthesized locus-specific 
DNA present in each sorted cell cycle fraction was represented as a percentage of the 
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total. Importantly, the replication timing of each 45 candidate genes and controls were 
analysed in parallel using the same cell cycle sorted, BrdU-labelled DNA template. 
Figure 3.2. The principle of replication timing analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Controls for this analysis included the α-globin locus, a constitutively early-replicating 
gene (Smith and Higgs, 1999) and pancreatic Amylase, a tissue-specific gene, which 
consistently replicates late in S-phase in several cell types (Azuara et al., 2003; Hatton 
et al., 1988; Mileham and Brown, 1996). In agreement with previously published data, 
the early replicating control α-globin showed peak abundance in S1/S2 fractions 
isolated from hES, mES and mEpiS cells, whereas the late replicating control Amylase 
was abundant in S3 and peaked in the S4 fractions (Figure 3.3). To ensure equivalent 
precipitation of BrdU-labelled DNA, each cell cycle fraction was spiked with a constant 
amount of Drosophila S2 BrdU-labelled DNA prior to immunoprecipitation. The 
detection of similar levels of Drosophila EMC PCR products in each fraction confirmed 
uniform recovery of BrdU-labelled DNA (Figure 3.3, right panel) as assessed in each 
experiment.  
Figure 3.2. The principle of 
replication timing analysis. 
Asynchronously growing cells 
are pulse-labelled with 5-
bromo-2-deoxyuridine (BrdU) 
which is incorporated into 
replicating DNA and sorted 
according to DNA content into 
six cell cycle fractions 
(designated as G1, S1-S4 and 
G2) using propidium iodide 
(PI) staining. DNA is then 
isolated from each of the 
sorted fractions and sheared 
by sonication. Newly 
synthesised BrdU-labelled 
DNA is then recovered by 
immunoprecipitation using 
anti-BrdU antibodies and the 
relative abundance of locus-
specific sequences analysed 
by qPCR. 
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Figure 3.3. Replication timing analysis controls. Histograms showing the relative abundance of PCR 
products for early and late replicating controls (α-globin and Amylase, respectively) in each cell cycle 
fraction for mES (E14tg2A, B6 and Dc7), hES (H1, H7 and H9) and mEpiS (129, B6/CBA and NOD) cells. 
The Drosophila melanogaster EMC gene provides an additional internal control to ensure uniform recovery 
of BrdU-labelled DNA. Mean and standard deviation of at least two independent experiments are shown 
for each cell type analysed. 
 
 
3.2. Replication timing profiles are conserved 
between independent mES cell lines 
 
Replication timing of each candidate gene was classified according to its peak 
of abundance in G1/S1 (early), S2 (middle-early), S2 and S3 (middle), S3 (middle-late) 
and S4/G2 (late) and shown as a gradation of colours from green (earliest) to red 
(latest) (see examples of replication timing assignment in Figure 3.4a).  
Three mES cell lines independently established from different mouse inbred 
strains were analyzed by DNA replication timing. Line E14tg2A was derived 22 years 
(Hooper et al., 1987) ago from a 129 mouse strain, while B6 was derived 16 years ago 
(Kontgen et al., 1993) from a C57BL/6 mouse strain. In contrast, Dc7 was more 
recently derived (2 years ago; Nesterova T., unpublished) from a mixed background 
129/castaneus hybrid mouse and is therefore genetically polymorphic. All the three 
mES cell lines were consistently cultured in the presence of LIF and serum; E14tg2A 
cells were grown on gelatin-coated surfaces while B6 and Dc7 required MEFs as a 
substrate for optimal propagation. Note that Dc7 cells were also maintained in a slightly 
different medium composition, as described in section 2.2.1. 
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Figure 3.4. Independently derived mES cell lines from distinct genetic backgrounds have similar replication timing profiles. 
 
 
Despite the disparate genetic, temporal and culture condition histories of these three 
cell lines, their replication profiles were remarkably consistent across many loci, with 
few exceptions (Bmp4 and Gata6) (Figure 3.4b). In agreement with previously 
published results (Azuara, 2006; Hiratani et al., 2008), I confirmed that mES cells have 
a largely early-replicating profile with a majority of genes replicating early (green) or 
middle-early (light green) S-phase (73 - 76%, see Appendix II, FigureA1). This included 
a number of key pluripotency-associated genes highly expressed in mES cells (such as 
Oct4, Rex1 and Nanog). However, many other genes that are selectively expressed in 
somatic lineages (such as Ikaros, Neurog1 and Sox17) but silent in ES cells were also 
found to be early replicating, consistent with a broadly accessible chromatin structure in 
ES cells (Azuara et al., 2006). In contrast, Foxa2, Mash1, Myf5, NeuroD, Sox3 and 
Zic1 replicated steadily in middle-late (orange) or late (red) S-phase, across the three 
cell lines, further highlighting that lineage induction in ES cells is likely to be regulated 
by selective gene derepression (Perry et al., 2004; Williams et al., 2006). 
Figure 3.4. Independently derived mES cell lines 
from distinct genetic backgrounds have similar 
replication timing profiles. (a) The replication timing 
of each gene was defined according to its peak 
abundance in G1/S1 (early), S2 (middle-early), S2 and 
S3 (middle), S3 (middle-late) and S4/G2 (late) phases 
and shown as a gradation of colours from green 
(earliest) to red (latest). (b) E14tg2A, B6 and Dc7 mES 
cell lines (derived from 129, C57BL/6 and 
129/castaneus backgrounds, respectively) show a very 
similar replication timing profile across a panel of 45 
candidate genes. Replication timing colour assignment 
is followed for all subsequent figures. 
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3.3. Pluripotent mouse and human ES cells have 
distinct replication timing profiles 
 
The replication timing of the same panel of loci examined in mES cells (most of 
them localized in synthenic regions between mouse and human genomes) were next 
analysed in H1, H7 and H9 hES cell lines. All these cell lines were simultaneously 
derived 11 years ago (Thomson et al., 1998) and expanded for this analysis using hES 
cell standard culture conditions (Xu et al., 2001) on matrigel-coated plates in MEFs-
conditioned media (CM), supplemented with FGF2, as previously described in section 
2.2.1. To facilitate a comparison between mouse and human cell lines, the relative 
proportion of genes replicating in early, middle-early, middle, middle-late or late S-
phase was here summarised as pie-charts shown in Figure 3.5a and Appendix II, 
Figure A1. Although many genes analysed in the three hES cell lines consistently 
replicated early or middle-early (53-58%), the replication profiles of hES cells were 
significantly distinct from that of mES cells. A profound difference was the increased 
proportion of genes replicating in middle or second half of S-phase in hES cells (42-
47%) when compared to mES cells (24-27%) (Figure 3.5b). Despite the similar 
temporal and culture condition histories of these three hES cell lines, their replication 
timing profiles were also significantly different among cell lines, with variable proportion 
of loci replicating in middle, middle-late and late fractions (Figure 3.5).  
 
 
 
Figure 3.5. Pluripotent mouse and human ES cells have distinct replication timing profiles. (a) The 
proportion of genes that replicate early (E), middle-early (ME), middle (M), middle-late (ML) or late (L) in S-
phase in mES cells (E14tg2A) and in three hES cell lines (H1, H7 and H9) are represented as a pie-chart. 
(b) Proportion of candidate loci that replicate in each S-phase fraction, expressed as a percentage of total 
as assessed in mES (E14tg2A, B6 and Dc7) and hES (H1, H7 and H9) cells. 
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 At the locus level, 11 out of the 45 genes analysed (Dppa4, Tert, Tle1, Sycp1, 
Bmp4, Ebf, Foxa2, Gata6, Sox17, Sox3 and Zic1) showed variable replication kinetics 
between H1, H7 and H9 hES cell lines (Figure 3.6a). Moreover, among these genes, 
Tert replication timing profiles also varied between cultures of the same cell line. Dppa4 
and Ebf showed the most dramatic replication timing changes from early to late, as 
seen in only one of the lines or across the three cell lines, respectively (Figure 3.6b). 
Other genes such as Gata6 and Tle1 displayed more subtle differences (from middle to 
middle-late). In contrast, Nanog and NeuroD are shown as examples of genes that 
consistently replicated in H1, H7 and H9 cells, in early and late S-phase, respectively 
(Figure 3.6c).  
 
 
 
Figure 3.6. Replication timing variability between established hES cell lines. (a) The replication timing 
of individual genes was compared between three hES cell lines (H1, H7 and H9). Genes showing 
differential replication kinetics are marked by asterisks. (b) Histograms showing the relative abundance of 
locus-specific DNA within each cell cycle fraction (G1, S1-S4 and G2 phases). Examples of loci that switch 
dramatically their replication timing, as seen in only one of the lines (Dppa4) or across the three lines (Ebf), 
or those who show slight temporal delays (Gata6 and Tle1) or (C) not changing at all their replication 
timing (Nanog and NeuroD), as assessed by qPCR in H1 (black), H7 (grey) and H9 (white) hES cell lines. 
Mean and standard deviation of two or more experiments are shown for each cell type analysed.  
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The observation that hES cells showed an increased proportion of late 
replicating loci, a feature that is normally found in differentiated cells (Azuara et al., 
2006), as well as high levels of variability across lines and cultures, was puzzling and 
prompted us to carefully verify the undifferentiated state of these cultures. To do so, I 
analysed the expression patterns of the pluripotency transcription factors Oct4, Nanog 
and Sox2, alongside the specific surface markers SSEA4, Tra-1-81 and Tra-1-60 by 
immunofluorescence and/or FACScan analysis. As shown in Figure 3.7a and b, hES 
cell cultures displayed homogeneous expression of Oct4, Nanog and Sox2 as seen 
across the three cell lines analysed. Tra1-60, Tra1-81 and SSEA4 were also highly 
expressed in H1, H7 and H9 cells, while SSEA1 (a marker of differentiation) was 
virtually undetectable. AP activity was also strongly detected in more than 90% hES 
cell colonies (Figure 3.7c). These observations exclude that high level of spontaneous 
differentiation within hES cell cultures can simply explain the higher proportion of late 
replication and variability observed in hES cell profiles, in contrast to that of mES cells. 
 
3.4. Human ES cell replication profiles can be 
reliably discriminated from that of cells with more 
restricted differentiation capacity 
 
3.4.1. Replication timing comparison of hES and hES-
derived neural progenitor cells 
 
To investigate whether pluripotent hES cells have a distinct chromatin profile 
from that of cells with a more restricted differentiation capacity, as previously 
demonstrated in mES cells (Azuara et al., 2006; Hiratani et al., 2008; Perry et al., 
2004), we compared the replication timing of 24 candidate genes in undifferentiated 
hES cells (H7 line) and H7-derived neural progenitors (NP7). Neural cells were induced 
using an in vitro adherent culture system, where inhibition of the BMP signalling by its 
antagonist Noggin at the initial stage of differentiation is sufficient to produce highly 
enriched and expandable populations of NP cells (Gerrard et al., 2005). Note that 
FGF2 and EGF growth factors were continuously added to NP cultures in order to keep 
them cycling, as requirement for the replication timing experiment. The replication 
profiles of NP7 cells were determined alongside a well-characterized NP cell line 
(ReNcell VM) derived from a 10-week human fetal brain, as a reference.  
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Figure 3.7. Human ES cell cultures analysed by replication timing display homogeneous 
expression of pluripotency-associated markers. H1, H7 and H9 hES cells were analyzed by (a) 
immunofluorescence and (b) flow cytometry for the hES differentiation surface marker SSEA1 (red) and 
the characteristic pluripotency and undifferentiation markers Oct4 (green), Nanog (red), Sox2 (red, 
immunofluorescence), SSEA4 (green), Tra-1-60 (green) and Tra-1-81 (FACS). Nuclei are shown by DAPI 
staining (blue). FACS analysis showed that 84.2-99.9% hES cells expressed markers of undifferentiation, 
while only 4.8-7.4% cells were positive for SSEA1, as indicated in the histograms. The profile of stained 
cells (black) was compared to cells stained with the secondary antibody only (dotted line). (c) Alkaline 
phosphatase (AP) activity (pink) was also strongly detected in all hES cell colonies. Scale bars, 50 µm. 
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As illustrated in Figure 3.8a, after >60 days of differentiation, a homogeneous 
population of hES-derived NP cells displaying a typical bipolar morphology is observed. 
In contrast to undifferentiated H7 cells, hES-derived NPs showed by 
immunofluorescence a drastic downregulation of Oct4 and a robust staining for Sox2 
and other neural precursor markers, including the intermediate filament Nestin 
(Hockfield and McKay, 1985; Lendahl et al., 1990), Musashi (Kaneko et al., 2000; 
Sakakibara et al., 1996) and Pax6 (Walther and Gruss, 1991) confirming their neural 
identity and the absence of contaminating undifferentiated cells (Figure 3.8b). Efficient 
neural induction was further confirmed in NP7 cells by RT-PCR (Figure 3.8c), which 
showed the upregulation of Nestin, Sox1 and Pax6 mRNA levels and a dramatic 
reduction in the expression of the pluripotency-associated markers Oct4 and Nanog. 
As expected Sox2 showed consistent levels in both hES and NP cell populations 
(Figure 3.8b and c) (Graham et al., 2003), while the endodermal and mesodermal 
markers, Gata6 (Morrisey et al., 1996) and T (Edwards et al., 1996) were undetectable 
(Figure 3.8c).  
As shown in Figure 3.8d, undifferentiated H7 hES cells have a distinct profile 
from that of NP7 and ReNcell VM cells. In particular, neuroectodermal markers either 
remain early (Nestin and Pax6) or late (Mash1) or undergo a shift towards early 
replication (NeuroD, Sox1 and Sox3) in NP7 as compared to H7 cells, suggesting an 
increase in the chromatin accessibility and transcriptional permissiveness of these 
genes. In contrast, trophoblast (Eomes), endodermal (Foxa2, Gata6 and Sox17) and 
mesodermal (Bmp4, Ebf, Ikaros and Myf5) markers, all undergo a shift towards late 
replication in NP7 cells, in accordance with ReNcell VM neural stem cell profile. This 
suggests that epigenetic changes associated with decreased chromatin accessibility at 
lineage inappropriate genes in neural committed cells have taken place, as previously 
seen in mES cells (Azuara et al., 2006; Hiratani et al., 2008; Perry et al., 2004). The 
pluripotency-associated markers (Nanog, Oct4 and Sox2) remained early replicating in 
H7 hES cells upon neural differentiation, while (Cripto, Dppa4 and Tle1) showed a 
dramatic delay of their replication timing in NP7 cells, consisted with their shut-down 
upon differentiation and loss of pluripotency. Tert was the only exception, its instable 
middle-early/middle replication profile across cultures become consolidated as a 
middle-early locus in NP7 differentiated cells, probably associated with the reactivation 
of Tert in late NP cultures (M. Sheldon, unpublished results). Altogether, these results 
suggest that pluripotent hES cells can be reliably discriminated from cells with a more 
restricted developmental capacity by DNA replication timing. 
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Figure 3.8. H7 undifferentiated hES cells can be clearly distinguished by replication timing analysis 
from neural progenitors (NP) H7-derived. (a) Phase-contrast images of undifferentiated H7 hES cells 
(top panel) grown on matrigel-coated plates in conditioned media and NP7 cells with typical bipolar 
morphology (bottom panel) after >60 days of differentiation, induced as previously described (Gerrard et 
al., 2005). Scale bar, 75 µm. (b) Undifferentiated H7 hES and NP7-derived cells were analysed for the 
expression of Oct4, Sox2, Nestin, Musashi and Pax6 by immunofluorescence staining. Nuclei were stained 
with DAPI. Magnification, 200X (c) RT-PCR analysis of the expression of ES-associated genes (Oct4, 
Nanog and Sox2), neural determinants (Nestin, Sox1 and Pax6), endodermal and mesodermal markers 
(Gata6 and T, respectively) in H7 hES and NP7 cells. β-actin was used to standardise input. (d) 
Replication timing comparison between H7 and NP7-derived cells alongside the well-characterized 
ReNcell VM human NP cell line derived from a 10-week human fetal brain, used as a reference for neural 
differentiation. The loci selected for this analysis included key pluripotency markers (Cripto, Dppa4, Nanog, 
Oct4, Rex1, Sox2, Tert and Tle1), trophoblast (Eomes), endoderm (Foxa2, Gata6 and Sox17), mesoderm 
(Bmp4, Ebf, Ikaros and Myf5) and neuroectoderm (Mash1, Nestin, NeuroD, Pax6, Sox1 and Sox3) 
markers. 
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3.4.2. Replication timing comparison of human ES and 
CD34+ haematopoietic stem cells 
 
The observation that hES cell lines display variable replication timing profiles, 
prompted us to ask if such level of plasticity is an exclusive feature of undifferentiated 
hES cells or could be due to the unique genetic identity of embryos from which hES 
cells are derived. If this is the case, other human cell types derived from the “outbred” 
human population should also display variability in their profiles. Here, the replication 
timing of the 11 loci targets of variability across hES cell lines, alongside other loci that 
were described as steady, was analyzed in human CD34+ haematopoietic stem cells 
isolated from peripheral blood of three healthy volunteers (Figure 3.9). 
 
 
 
Figure 3.9. Replication timing 
variability is not observed across 
human CD34+ haematopoietic stem 
cells. The replication timing of variable 
loci across different hES cell lines was 
analysed in CD34+ cells isolated from 
peripheral blood of three different healthy 
volunteers (here represented as a, b and 
c), alongside loci that showed steady 
replication timing. All the loci that were 
shown to be steady were maintained, 
while all other targets of variability in hES 
cells replicated at similar times across the 
three different sources of adult stem cells, 
with the exception of Bmp4 and Tle1 that 
were earlier in c.  
 
 
 
 
 
The replication timing of variable genes was shown to be remarkably similar (9 
out of 11 genes) across the three different populations of CD34+ cells, with the 
exception of Bmp4 and Tle1 (Figure 3.9). Consistently, all the analyzed genes that 
previously were described as steady remained constant across samples (Figure 3.9). 
Interestingly, some genes replicated at later times in S-phase in all the three CD34+ 
samples than previously seen in hES cells (Figure 3.6), that is the case of Eomes, 
Pax6 and Sox2 consistent with a progressive decline of chromatin accessibility in more 
lineage committed cells. In contrast, other genes replicate earlier in CD34+ cells than in 
hES cells. These differences are lineage and transcriptional dependent, as highlighted 
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by Ebf and Ikaros, two known haematopoietic genes (Medina and Singh, 2005), and 
Neuro D (Graf et al., 2001) that are all expressed and early replicating in CD34+ cells 
in contrast to hES cells. These observations further corroborate that hES cells have a 
distinct profile from cells with a more restricted developmental potential and that 
replication timing variability is a hallmark of undifferentiated hES cells under standard 
CM cultures, independently of the genetic variation across individuals. 
 
 
3.5. Analysis of the gene expression status and 
chromosomal context of replication timing variable 
genes 
 
3.5.1. Gene expression and histone acetylation analysis of 
genes shifting replication timing across H1, H7 and H9 hES 
cells 
 
Changes on DNA replication timing are thought to reflect variations in chromatin 
accessibility and transcriptional permissiveness (Donaldson, 2005). Although the 
precise relationship between DNA replication, chromatin structure and transcription is 
complex and remains largely unresolved, previous data in mES cells (Azuara et al., 
2006; Jorgensen et al., 2007; Perry et al., 2004) together with studies in other cell 
types (Lande-Diner et al., 2009; Lin et al., 2003; Schubeler et al., 2004; Zhang et al., 
2002) suggested a positive correlation between histone acetylation and early-
replicating active genes and between deacetylated histones and late-replicating, less 
active genes. Here it was investigated if the differential replication kinetics observed in 
hES cell lines at specific genes (Bmp4, Dppa4, Ebf, Foxa2, Gata6, Sox17, Sox3, 
Sycp1, Tert, Tle1 and Zic1) may reflect changes at the transcriptional and/or histone 
acetylation levels (Figure 3.10).  
Chromatin immunoprecipitation (ChIP) assays were performed to evaluate the 
levels of acetylated histones at the promoters of individual loci, in H1, H7 and H9 hES 
cell lines. Crosslinked chromatin isolated from hES cells was immunoprecipitated with 
antibodies against H3K9ac, H3K14ac, H3ac, H4ac and total H3 and H4 or with a rabbit 
anti-mouse IgG antiserum as a negative control (Figure 3.10c). DNA eluted after 
immunoprecipitation was analysed by qPCR using primers amplifying sequences in 
promoter regions looking at both steady (Oct4, Nanog, Sox2, Rex1, Myf5 and Eomes) 
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and variable (Bmp4, Dppa4, Ebf, Foxa2, Gata6, Sycp1, Sox17, Sox3, Tert, Tle1 and 
Zic1) replicating genes in H1, H7 and H9 hES cells. Primers for pericentric 
heterochromatin (satellite repeats) were also included, providing a negative control for 
active histone marks immunoprecipitations. To reduce potential bias that might arise 
from different nucleosomal densities, the data for each gene was expressed relative to 
the enrichment obtained with the antibodies against total histone H3 or H4 (Figure 
3.10). 
These ChIP data was compared with the DNA replication timing and expression 
status of selected genes across the three hES cell lines (Figure 3.10a). Highly 
expressed and early replicating genes across H1, H7 and H9 hES cells (such as Oct4, 
Nanog and Sox2) showed a correlation with higher levels of histone acetylation, as 
previously described for mES cells (Azuara et al., 2006; Jorgensen et al., 2007; Perry 
et al., 2004). In contrast, silent and late replication genes (such as Myf5) showed only 
background levels as seen at satellite repeats control region. Accordingly, Rex1, an 
ES-specific late replicating gene showing lower levels of expression (relatively to Oct4 
and Nanog) and Eomes, an early replicating but silent lineage-specific gene showed 
low but detectable levels of acetylated histones. These data, from steady replicating 
loci, are consistent with histone acetylation being correlated with early replication 
and/or active expression as previously reported. In contrast, no straightforward 
correlation between replication timing variability, histone acetylation patterns and/or 
expression could be drawn when analysing variable replicating genes across H1, H7 
and H9 cells. Dppa4, Tert and Tle1, are three variable replicating genes expressed in 
the three hES cell lines and showing high levels of both H3 and H4 acetylated histones, 
yet no correlation with their replication timing status is observed. Although the 
replication timing pattern of Dppa4 (early in H1 and H7 and late in H9 cells) may reflect 
its variable expression (up to three-fold lower in H9 when compared to H1 cells, Figure 
3.10a), no correlation was observed at the histone acetylation level since only H7 
seems to have higher levels of enrichment for H3K9ac, H3K14ac and H3ac in contrast 
to H1 and H9 hES cells (Figure 3.10b). Other genes expressed at low levels (Bmp4, 
Foxa2 and Gata6) and replicating in the second half of S-phase show however, 
different patterns; Bmp4 has substantial levels of acetylated histones in all three hES 
cell lines, relatively to Foxa2 or Gata6. Other silent genes (Ebf, Sycp1, Sox17, Sox3 
and Zic1) also show variable or absent patterns of acetylated histones across H1, H7 
and H9 cells, regardless of their replication timing status. Altogether, these data 
demonstrate that replication timing variability is not directly underlined by gene 
expression variability at these loci, across hES cell lines, or merely explained by 
distinct histone acetylation patterns. 
 83 
 
Figure 3.10. Human ES cells replication timing variability is not associated with gene expression or 
histone acetylation specific patterns. (a) Replication timing status and expression of variable loci 
(Bmp4, Dppa4, Ebf, Foxa2, Gata6, Sycp1, Sox17, Sox3, Tert, Tle1 and Zic1) and early (Oct4, Nanog, 
Sox2 and Eomes) or late (Rex1 and Myf5) steady control loci between H1, H7 and H9 hES cell lines. The 
replication timing of each locus is indicated in a colour coded way as previously designated. The relative 
expression of variable and steady replicating loci was assessed by qPCR and compared between H1 
(black), H7 (grey) and H9 (white) hES cell lines. Data was normalized to the expression of two 
housekeeping genes (Gapdh and Hprt). Values shown are the mean of three independent experiments 
and error bars indicate standard deviation. (b) Relative enrichments for acetylated histones (H3K9ac, 
H3K14ac, H3ac and H4ac) were assessed in H1, H7 and H9 hES cells using chromatin 
immunoprecipitation and qPCR. The colour code for different histone marks is indicated in each panel. 
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Primers for satellite repeats (Sat. rept.) were used as a negative control for active histone marks 
immunoprecipitations. To eliminate bias for different nucleosome density, data was normalized to 
enrichments obtained with antibodies recognizing total histone H3 or H4. Error bars indicate standard 
deviations of at least two independent experiments. Background levels (from control IgG antibodies) are 
shown as dashed grey lines. The red open box highlights the variable replicating cohort of genes across 
H1, H7 and H9. 
 
 
3.5.2. Genomic features analysis of genes shifting 
replication timing across H1, H7 and H9 hES cells 
 
Work from I. Hiratani and colleagues suggested that genes located within low 
GC content (<43% GCs) and high LINE density (>6% LINE) regions might be more 
likely to shift their replication timing during development, irrespectively of their 
expression status (Hiratani et al., 2004). To investigate whether genes showing 
differential replication kinetics in hES cell lines (Bmp4, Dppa4, Ebf, Foxa2, Gata6, 
Sox17, Sox3, Sycp1, Tert, Tle1 and Zic1) may also share common chromosomal 
features, GC content, LINE repeat and gene density were analysed in the vicinity of 
each of those loci (Table 2), (see section 2.2.5 for details). As previously outlined in 
Table 1, these genes are located in different chromosomes throughout the genome or 
very far apart from each other when located in the same chromosome. Although a 
substantial proportion of shifting genes (8 out of 11) were scored as low GC content 
and high LINE density (black boxes), other genes that remain early (such as Pax6) or 
late replicating (such as Ikaros) across H1, H7 and H9 cells showed similar genomic 
features. Hence, no clear correlation could be established between hES cell replication 
timing variability and chromosomal location or genomic features at target genes. 
Interestingly, however, all genes shifting replication timing, apart from Tert were located 
in gene-poor genomic regions (Table 2, grey boxes). Although this is not a unique 
feature of variable loci in hES cells, it implies that changes in replication timing as 
observed at those genes are unlikely to be influenced by the transcriptional status of 
neighbouring genes. 
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Table 2. Genomic features of replication timing analysed genes. 
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3.5.3. DNA methylation analysis at promoters of 
replication timing variable genes across H1, H7 and H9 hES 
cells 
 
Different studies have recently reported the existence of variability at the DNA 
methylation level across different hES cell lines, mostly at random sites across the 
genome (Allegrucci et al., 2007; Maitra et al., 2005). Based on these studies we 
decided to investigate whether replication timing variability observed in H1, H7 and H9 
hES cells at specific genes (Bmp4, Dppa4, Ebf, Foxa2, Gata6, Sox17, Sox3, Sycp1, 
Tert, Tle1 and Zic1; Figure 3.11, red open box) may be underlined by DNA methylation 
variability. 
 
 
Figure 3.11. Human ES cells replication timing variability is not associated with DNA methylation 
specific patters. Abundance of CpG DNA methylation at each promoter region of replication timing 
variable loci (Bmp4, Dppa4, Ebf, Foxa2, Gata6, Sycp1, Sox17, Sox3, Tert, Tle1 and Zic1) highlighted by 
the red open box, between H1 (black), H7 (grey) and H9 (white) hES cells. DNA methylation was assessed 
using methylated DNA immunoprecipitation (MeDIP) (Weber et al., 2005) and qPCR analysis. Error bars 
indicate the standard deviation of three independent experiments. Early (Oct4 and Eomes) and late (Myf5 
and NeuroD) steady replicating loci across H1, H7 and H9 hES cells were also analyzed. Controls for 
methylated (H19-Igf2 imprinting control region) and unmethylated (Oct4) regions were included. The 
enrichment indicates the ratio of methylated DNA over input DNA. The replication timing of each locus 
(steady and variable) in H1, H7 and H9 cells is indicated by a colour code as previously designated.  
 
 
For this analysis I used, a previously described assay, methylated DNA 
immunoprecipitation (MeDIP) (Weber et al., 2005) that allows the generation of DNA 
methylation profiles across large panel of genes. The principle of this assay relies on 
the immunoprecipitation of methylated genomic DNA using an antibody that specifically 
recognizes 5-methylcytidine (see section 2.2.10. for details). The methylated imprinted 
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control region H19-Igf2 was used as a positive control in the experiments. As shown in 
Figure 3.11, high levels of DNA methylation were only observed at the promoter of 
Myf5 (steady replicating) and Sycp1 (variable replicating), both genes replicate in the 
second half of S-phase in H1, H7 and H9 cells. In contrast, Neuro D (steady 
replicating) or Foxa2 and Gata6 (variable replicating) that also replicate in late or 
middle/middle-late S-phase were not significantly enriched relatively to control H19, 
excluding a direct link between DNA methylation and late replication at single-copy 
genes. This contrasts with previous reports showing a key role for DNA methylation in 
maintaining a late replicating status of repetitive sequences, including major satellite 
repeats, in mouse cell lines (Jorgensen et al., 2007; Selig et al., 1988). While Sox3 
showed variable enrichment levels across the three hES cell lines (undetectable in H1 
and H7 but high in H9 cells), this did not correlate with its replication timing profile in 
each of these cell lines, showing no clear relationship between DNA methylation and 
replication timing variability. 
Altogether, these data argue against a direct role for DNA methylation in 
regulating the timing of DNA replication at specific loci in hES cells. This is consistent 
with previous studies showing that the replication timing of individual loci did not 
change in DNA methyltransferase-deficient mES cells (Gribnau et al., 2003; Jorgensen 
et al., 2007).  
 
3.6. Human ES and mEpiS cells share a common 
unstable or transitional state: primed on the verge of 
differentiation 
 
As described above, hES cell replication timing profiles greatly vary between 
cell lines and cultures, a level of variability not observed among mES cell lines derived 
from different genetic backgrounds. In undifferentiated hES cells, replication timing 
variability was shown to be unrelated to genetic variation or any specific genomic 
features. Such a level of plasticity within these cultures could however indicate an 
unstable or transitional state: poised on the verge of differentiation into multiple 
directions. Interestingly, it has been proposed that hES cells more closely resemble 
mEpiS cells than mES cells, two stem cell populations representing the pluripotent 
progenitors in mouse gastrulating embryos (mEpiS) and blastocysts (mES), 
respectively (Brons et al., 2007; Tesar et al., 2007). In favour of this idea, Rex1 - an 
ICM-specific marker that is shutdown in the epiblast (Rogers et al., 1991), was found to 
 88 
replicate early during S-phase in mES cells but consistently late in H1, H7 and H9 hES 
cell lines grown under standard CM conditions, (Figure 3.4 and 3.6). This prompted us 
to further characterize the level of similarities and/or differences between hES, mES 
and mEpiS cells at the chromatin level. In particular, I asked whether higher levels of 
replication timing variability could also be observed in mEpiS cells, in contrast to mES 
cells. To do so, I analysed the replication timing profiles of three independently derived 
mEpiS cell lines from different genetic backgrounds (129, B6/CBA and NOD) and 
compared them with those previously obtained from mES and hES cell lines (Figure 
3.12 and Appendix II, Figure A2 for full analysis).  
 
 
 
Figure 3.12. Mouse EpiS and hES cells have identical cell cycle kinetics and variable replication 
timing profiles across many genes. (a) Representative cell cycle profiles of mES (E14tg2A), mEpiS 
(129) and hES (H1) cells. Cells were stained with propidium iodide (PI) and DNA content analyzed on a 
FACScalibur flow cytometer. The percentages of cells into each phase of the cell cycle were determined 
using the WinMDI 2.9 software. The cell cycle profiles of mEpiS cells and hES cells (middle and right 
panels, respectively) show a similar pattern, with a lower number of cells seen in the S-phase when 
compared with mES cells. (b) Comparative replication timing analysis of mES (E14tg2A, B6 and Dc7), 
mEpiS (129, B6/CBA and NOD) and hES (H1, H7, and H9) cell lines. Selected loci shown for comparison 
are either associated with pluripotency and self-renewal (Nanog, Oct4 and Sox2), selectively expressed in 
the inner cell mass (ICM) (Dppa4, Gbx2 and Rex1), and the epiblast (Fgf5, Prce and Psc1) or showing 
variable replication timing across lines and cultures with specific roles during development (Bmp4, Cxcr4, 
Dazl, Ebf, Foxa2, Gata6, Ikaros, Mash1, Sox17, Sox3, Sycp1, Tert, Tle1 and Zic1). Genes that are equally 
variable between mEpiS cell lines and also between hES cell lines are marked by asterisks. For full list of 
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genes analyzed see Appendix II, Figure A2. (c) Percentage of replication timing variable loci between cell 
lines of the same population relative to the total 45 analyzed loci in mES (4.4%), mEpis (22.2%) and hES 
(24.4%) cell lines. Mouse EpiS and hES cells have in common high percentages of variable replication 
timing loci in contrast to mES cells. This analysis was performed in collaboration with Kavita Mehta and 
Matias Autio in our laboratory. 
 
 
Initially it was assessed the replication timing of key ICM (Dppa4, Gbx2 and 
Rex1) (Bortvin et al., 2003; Chapman et al., 1997; Maldonado-Saldivia et al., 2007; 
Rogers et al., 1991) and epiblast-specific markers (Fgf5, Prce and Psc1) (Brons et al., 
2007; Haub and Goldfarb, 1991; Hebert et al., 1991; Pelton et al., 2002; Tesar et al., 
2007) alongside Nanog, Oct4 and Sox2, that are expressed in both pluripotent tissues. 
This analysis was further extended to loci previously studied in mES and hES cells, 
especially differentiation-associated or loci that were subjected to variable replication 
kinetics in human cells (see Figure 3.12). 
During the course of this analysis, we observed that mEpiS and hES cells share 
similar cell cycle profiles, with a relatively lower number of cells in S-phase (25% and 
26%, respectively) as compared to mES cells (41%), suggesting common growth 
properties (Figure 3.12a). Mouse EpiS cells showed a mostly early replication timing 
profile with 71-78% of loci analysed replicating in early or middle-early S-phase, a 
percentage similar to that found in mES cells (73-76%) (Appendix II, Figure A1). These 
two developmentally distinct but closely related stem cell populations could, however, 
be reliably discriminated using our replication timing-based approach. The ICM 
markers Rex1 and Dppa4 were found to replicate early and late during S-phase in mES 
and mEpiS cells, respectively consistent with dynamic changes in gene expression 
patterns. In contrast, the replication timing of Fgf5, an epiblast-specific marker, shifts 
from late in mES cells to early in mEpiS cells, underlying gene derepression (Figure 
3.12b). Further differences were observed among lineage-specific genes, such as Zic1 
late replicating in mES cells and early in mEpiS cells.  
As anticipated, Nanog, Oct4 and Sox2 were consistently expressed and early 
replicating in mouse (ES and EpiS) and hES cells. However, we could not confirm 
whether or not hES cells are indeed more closely related to an mES cell-like or mEpiS 
cell-like developmental state, based on ICM/epiblast marker replication timing profiles 
only. While Rex1 was found late replicating in both hES and mEpiS cell populations, 
Fgf5 remained late in hES cells as seen in mES. Gbx2, Psc1 and Prce were early 
replicating in all mouse and human cell types analysed, regardless of their 
developmentally regulated gene expression patterns. However, the selection of these 
markers is here based on gene expression analysis in mouse embryos, as equivalent 
information is not available in human embryos yet. Interestingly, however, I observed a 
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high level of replication timing variability among mEpiS cell lines (22.2% variable loci), 
as previously seen in hES cells (24.4%) and in contrast to the homogeneous and 
steady replicating mES cell (4.4%) profiles (Figure 3.12c). 
Altogether, these results suggest that both hES and mEpiS pluripotent cells 
share a common unstable or transitional state: primed on the verge of differentiation, 
opening more questions concerning the true nature and origin of hES cells during 
normal development as recently raised (Lovell-Badge, 2007). 
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CHAPTER 4. IDENTIFICATION AND CHARACTERIZATION 
OF DISTINCT PLURIPOTENT STATES WITHIN HUMAN 
ES CELL CULTURES: NAIVE VS PRIMED 
 
 
4.1. Undifferentiated hES cell replication timing 
profile is prone to extensive alterations upon different 
cell culture conditions 
 
4.1.1. Replication profile of H9 hES cells grown in two 
different laboratories 
 
As recently shown, mES cultures can toggle between distinct pluripotent states 
from a naïve ICM-like to a more primed epiblast-like states (Nichols and Smith, 2009) 
that can interconvert in response to different culture conditions (Bao et al., 2009; Chou 
et al., 2008; Guo et al., 2009; Hanna et al., 2009). The presence of activin A and/or 
FGF2 was shown essential to maintain a hES pluripotent state (Levenstein et al., 2006; 
Vallier et al., 2005; Xiao et al., 2006) however, since 1998 when the first hES cell lines 
were reported (Thomson et al., 1998), a plethora of techniques to stably maintain hES 
cells in culture have been developed in different laboratories (Adewumi et al., 2007). 
Here I asked whether hES cell replication timing profiles could be directly and 
dynamically altered by changing cell culture conditions.  
Initially the profiles of H9 hES cells grown in our laboratory using standard CM 
conditions [matrigel-coated plates and MEF-CM with KSR and FGF2 (Xu et al., 2001)] 
was compared with that of cultures of the same cell line that were, however, routinely 
maintained into CDMactivin conditions [FBS-coated plates and KSR-free defined medium 
supplemented with FGF2 and activin A (Vallier et al., 2005)], as provided by Dr Ludovic 
Vallier’s laboratory (Figure 4.1a). Interestingly, the replication timing profile of H9 hES 
cells was dramatically altered, from late to early, when cultured under CDMactivin 
conditions. As shown in Figure 4.1b, the proportion of genes replicating early or middle-
early was significantly increased in H9 cells grown for more than 20 passages in 
CDMactivin conditions [H9p50(CDM20)] when compared to H9 cells in CM (H9p35CM) 
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(from 55% to 75%). This suggested that hES cell culture can adopt different epigenetic 
states when grown under different culture conditions in different laboratories. 
 
 
 
Figure 4.1. Human ES cells grown under different culture conditions in different laboratories show 
dramatic replication timing late to early shifts. The proportion of genes that replicate early (E), middle-
early (ME), middle (M), middle-late (ML) or late (L) in S-phase are represented as a pie-chart. (a) The 
replication timing of H9 hES cells grown in our laboratory under standard matrigel-coated plates and 
irradiated mouse embryonic fibroblast – conditioned medium (CM) with Knockout
TM
 Serum Replacement 
(KSR) and fibroblast growth factor (FGF2) conditions (Xu et al., 2001) (H9p35CM) were compared with 
that of cells that have been cultured for more than 20 passages into FBS-coated plates, KSR-free 
chemically defined medium (CDM) supplemented with FGF2 and activin A (CDM
activin
) (Vallier et al., 2005) 
as provided by Dr Ludovic Vallier’s laboratory [H9p50(CDM20)]. (b) Proportion of candidate loci that 
replicate in each S-phase fraction, expressed as a percentage of the total for H9 cells grown under 
standard CM and CDM
activin
 conditions. Note that nomenclature for culture conditions is according to the 
following convention: cell line, number of passages in CM culture, plus additional passages in CDM
activin
 
conditions. This format is followed for all subsequent figures. 
 
 
4.1.2. Dynamic equilibrium and heterogeneity of hES cells 
in distinct epigenetic states 
 
 To directly address whether this was a reproducible and dynamically reversible 
process, the behaviour of other hES cell lines (H1 and H7) grown in our laboratory in 
CM conditions and transferred to CDMactivin conditions was compared and backwards. 
We observed differences among the two hES cell lines in their response to CDMactivin 
conditions. While H1 hES cells rapidly settled into CDMactivin conditions when platting at 
high densities and gradually exposed to increasing concentrations of CDMactivin media 
(25, 50 and 75%), H7 cells could not be maintained in an undifferentiated state when 
transferred into these conditions, despite several attempts using variable conditions 
(i.e. different platting densities and/or in the presence of MEFs). 
After 3 passages in CDMactivin H1 hES cells were readily stabilised, with little 
evidence of differentiation (see section 4.2.1). Remarkably, extensive replication timing 
alterations were already evident, with an increased proportion of early and middle-early 
replicating genes from 55% in H1p49CM to 64% in H1p47(CDM3) and up to 77% in 
H1p47(CDM6) cells (Figure 4.2). Some loci, such as Rex1 promptly and dramatically 
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shifted their replication timing (from middle-late to middle-early). Progressive changes 
were also noticed as seen for Bmp4 (from middle-late, middle to middle-early) over 6 
passages (Figure 4.3a and b). Interestingly, there is a significant overlap (11 loci) 
between the loci that consistently advanced their replication timing towards early S-
phase in H1 and H9 hES cell lines in CDMactivin conditions (Rex1, Tert, Cga, Sycp1, 
Bmp4, Foxa2, Gata6, Neurog1, Sox1, Sox17 and Sox3) as highlighted by asterisks in 
Figure 4.3a and summarised by the Venn diagram in Figure 4.3c. Moreover, all the loci 
that previously were described as variable replicating across H1, H7 and H9 hES cell 
lines grown in CM become earlier under CDMactivin conditions in both H1 and H9 cells, 
providing valuable indicators for the epigenetic state of hES cells. 
 
 
Figure 4.2. H1 hES cells 
grown under CM and 
CDM
activin
 conditions 
show dramatic replication 
timing late to early shifts. 
(a) The replication timing of 
H1 hES cells grown in 
standard CM (H1p49CM) 
conditions was compared to 
that of cells transferred to 
CDM
activin
 conditions after 3 
[H1p47(CDM3) and 6 
[H1p47(CDM6)] passages. 
(c) Proportion of candidate 
loci that replicate in each S-
phase fraction, expressed 
as a percentage of the total 
for H1 hES cells grown 
under standard CM and 
CDM
activin
 conditions. 
 
 
 
Importantly, the modulation of hES cell replication profile was demonstrated to 
be a reversible process as returning the cells from CDMactivin to CM conditions was 
sufficient to revert to a more unstable late-replicating profile. The proportion of early 
and middle-early genes decreased to 46% in H1 re-swapped [H1p47(CDM14;RS6)] 
cells (Figure 4.3a and Appendix II, Figure A3), further illustrating the epigenetic 
plasticity of hES cells. Consistently, the replication profiles of both Rex1 and Bmp4 
shifted back from middle-early to middle (Figure 4.3a and b). In contrast, Dppa4, a 
locus that was consistently early-replicating in H1 hES cells grown in either CM or 
CDMactivin conditions display a biphasic replication profile with two main peaks in S1 
and S3 fractions (Figure 4.3a and b), underlying high level of variability in re-swapped 
cultures. Altogether these data challenge the view that hES cells most closely resemble 
mEpiS cells and suggest that distinct but interchangeable subpopulations may exist 
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within hES cell cultures as delineated by a stable, early-replicating (mES-like) versus 
unstable, late-replicating (mEpiS-like) profile. 
 
 
Figure 4.3. Loci subjected to replication timing shift towards early S-phase in CDM
activin
 conditions 
overlap between different hES cell lines. (a) The replication timing of individual loci was compared 
between H1 and H9 hES cells grown under standard CM culture conditions with that of cells that have 
been cultured for different number of passages into CDM
activin
. Replication timing late to early shifts occur 
immediately in H1 cells after 3 passages [H1p47(CDM3)] and becomes even earlier after 6 passages 
[H1p47(CDM6)]. All these replication timing shifts can be reverted to some extent by re-swapping cells 
back to CM conditions [H1p47(CDM14;RS6)]. Loci that consistently advance their replication timing 
towards early across H1 and H9 hES cell lines when in CDM
activin
 conditions (Rex1, Tert, Cga, Sycp1, 
Bmp4, Foxa2, Gata6, Neurog1, Sox1, Sox17 and Sox3) are marked by asterisks. (b) Histograms showing 
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the relative abundance of locus-specific DNA within each cell cycle fraction (G1, S1-S4 and G2 phases). 
Examples of loci that switch dramatically and immediately (Rex1) or progressively in time (Bmp4) their 
replication timing towards early as assessed by qPCR in H1 cells in CM and CDM
activin
 and are able to 
delay it back again when in re-swapped conditions. Dppa4 is consistently early across cells grown in CM 
or CDM
activin
 conditions but becomes unstable and heterogeneous in terms of replication timing within the 
same population of cells in re-swapped conditions, displaying biphasic (S1 and S3) peaks. Mean and 
standard deviation of at least two experiments are shown for each cell type analysed. (c) Venn diagram 
illustrating the 11 common targets (overlap) between loci changing their replication timing towards early in 
CM to CDM
activin
 conditions across H1 (13 earlier loci) and H9 (16 earlier loci) hES cell lines.  
 
 
4.1.3. Fully reprogrammed hiPS cell replication profiles 
matches hES cells dramatic late to early shifts in response to 
alterations in culture conditions 
 
Human somatic cells can be reprogrammed into hiPS cells by the enforced 
expression of transcription factors (Takahashi et al., 2007; Yu et al., 2007) providing a 
long-sought strategy to generate patient and disease-specific pluripotent stem cells 
(Dimos et al., 2008; Park et al., 2008a). However, it is essential to completely 
understand the equivalence between hiPS and hES cells and clearly define appropriate 
cell culture conditions for the derivation and maintenance of hiPS cells with full 
developmental potential (Colman and Dreesen, 2009). Our results described above 
indicate that hES cell replication profiles can shift away from a mEpiS cell-like towards 
a mES cell-like profile in response to alterations in the culture conditions. Here, I 
analysed the effect of CM and CDMactivin conditions on hiPS cell replication profile to 
test whether these cells shown similar levels of epigenetic plasticity that hES cells. To 
do so, I took advantage of a previously established fully reprogrammed hiPS 40 cell 
line which was derived from neonatal foreskin fibroblasts by overexpression of Oct4, 
Sox2, c-Myc and Klf4 as described (Vallier et al., 2009b). Human iPS cells in CM 
conditions showed a profile very similar to the ones previously observed in H1, H7 and 
H9 hES cells, with a higher proportion of late replicating genes in contrast to mES cells 
(Figure 4.4a and b). Interestingly, hiPS cell replication profiles also shifted dramatically 
from late to early when cultured in CDMactivin conditions for more than 12 passages, 
with 57% and 77% of genes replicating in early or middle-early in CM and CDMactivin 
conditions, respectively (Figure 4.4b). This included Rex1, Tert, Cga, Bmp4, Foxa2, 
Sox17 and Sox3 loci previously seen to also shift their replication timing towards early 
in CDMactivin in H1 and H9 hES cells (Figure 4.4c). These results provide additional 
evidence that induced (iPS) and natural (ES) pluripotent cell lines share common 
properties and reiterate the impact of culture conditions in modulating or supporting 
different epigenetic states within pluripotent hES cell cultures. This is an important 
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consideration, as responses to differentiation protocols are likely to vary depending on 
where the cells stand in a developmental hierarchy (see section 4.3). 
 
 
 
 
Figure 4.4. Fully reprogrammed hiPS cells replication profile also display dramatic late to early 
shifts in response to alterations in culture conditions. (a) The proportion of loci that replicate early (E), 
middle-early (ME), middle (M), middle-late (ML) or late (L) in S-phase are represented as a pie-chart. The 
replication timing of fully reprogrammed hiPS 40 cells derived from neonatal foreskin fibroblasts by 
overexpression of four reprogramming factors (Oct4, Sox2, c-Myc and Klf4) (Vallier et al., 2009b) grown 
under CM conditions was compared to that of cells in CDM
activin
 conditions. (b) Proportion of candidate loci 
that replicate in each S-phase fraction, expressed as a percentage of the total for hiPS 40 cells grown 
under standard CM and CDM
activin
 conditions. (c) The replication timing of individual loci in hiPS 40 cells 
grown in CM or CDM
activin
 conditions is shown. Earlier replicating loci in CDM
activin
 conditions (Rex1, Tert, 
Tle1, Cga, Bmp4, Ebf, Foxa2, Sox17, Sox3 and Zic1) are marked by asterisks. Dppa4 is heterogeneous in 
terms of replication timing within the same population of cells in CM conditions, displaying biphasic (S1 
and S4) peaks. (d) Venn diagram illustrating the 7 common targets (overlap) between loci changing their 
replication timing towards early in CM to CDM
activin
 conditions across H1 (13 earlier loci), H9 (16 earlier 
loci) hES cell lines and hiPS 40 (10 earlier loci) cells. These experiments were performed in collaboration 
with Matias Autio in our laboratory. 
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4.2. Phenotypic and functional characterization of 
distinct populations of undifferentiated hES cells in CM 
and CDM
activin 
growth conditions 
 
4.2.1. CDM
activin
 conditions maintain H1 hES cells in an 
undifferentiated state supporting their self-renewal 
 
Once acclimated, H1 hES cells grown in CDMactivin conditions formed 
homogeneous, tightly clustered colonies that adhered firmly to FBS-coated plates 
(Appendix II, Figure A4 and Figure 4.5a), with low or no sign of spontaneous 
differentiation, as sometimes observed in the edge of H1 cells cultured in CM. The 
undifferentiated state of CDMactivin converted H1 hES cells was further assessed by AP 
activity, IF and FACS analysis. As previously seen in H1 CM cells, H1 CDMactivin cells 
showed strong AP activity across colonies (Figure 4.5b)  
Figure 4.5. Human ES cells transferred from standard CM cell culture conditions to CDM
activin
 conditions retain their undifferentiated characteristics. 
 
  
Figure 4.5. Human ES cells 
transferred from standard CM cell 
culture conditions to CDM
activin
 
conditions retain their 
undifferentiated characteristics. (a) 
Bright field (BF) picture of 
representative undifferentiated H1 hES 
cell colonies and (b) detection of 
alkaline phosphatase (AP) activity 
(pink) in cells grown under CDM
activin
 
conditions. Scale bars, 70 µm. (c) 
Immunofluorescence and/or (d) flow 
cytometry analysis of H1 cells grown 
under CDM
activin
 conditions for the 
differentiation surface SSEA1 (red) 
marker and the pluripotency-associated 
markers Oct4 (green), Nanog (red), 
Sox2 (red, immunofluorescence), 
SSEA4 (green), Tra-1-60 (green) and 
Tra-1-81 (FACS). Nuclei are shown by 
DAPI staining (blue). FACS analysis 
showed that 98.5-99.7% hES cells 
expressed markers of undifferentiation, 
while only 5.7% of the cells were 
positive for SSEA1, as indicated in the 
histograms. The profile of stained cells 
(black) was compared to cells stained 
with the secondary antibody only 
(dotted line). Cells were exposed to 
CDMactivin conditions for ≥ 4 passages 
in all assays. Scale bars, 50 µm. 
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The expression of undifferentiated hES cell markers like Oct4, Nanog, Sox2 and the 
specific surface markers SSEA4, Tra-1-60 and Tra-1-81 was highly and 
homogeneously detected in H1 CDMactivin cells, while SSEA1 (a differentiation marker) 
was absent (Figure 4.5c and d). Quantification by FACS analysis confirmed that 98.5% 
- 99.7% hES cells harboured an undifferentiation phenotype, while only 5.7% cells 
were positive for SSEA1.  
As illustrated in Figure 4.6, H1 hES cells in CDMactivin are actively cycling, 
showing a slight increase in the percentage of cells in S and G2 phases of the cell 
cycle (45.1% and 26.8%, respectively) as compared to CM cells (40.8% and 19.4%, 
respectively). 
 
 
Figure 4.6. Human ES cells in CDM
activin
 conditions show a slight increase in the percentage of cells 
in S and G2 compared to cells grown under standard CM conditions. Bivariate distribution of H1 cells 
grown under CM (left) versus CDM
activin
 (right) conditions, showing incorporation of 5-bromo-2-
deoxyuridine (BrdU) and propidium iodide (PI) staining intensity reflecting the DNA content. Numbers 
indicate percentages of cells in G1/S/G2. These findings are representative of two independent 
experiments. 
 
 
4.2.2. H1 CM and CDM
activin
 form embryoid bodies 
containing tri-germ layer differentiation 
 
 Next, I tested the ability of H1 hES cells in CM and CDMactivin conditions to 
generate derivatives of all three germ layers using an in vitro embryoid body (EB) 
assay of development. EB formation is a simple and widely used method in which 
aggregates of pluripotent cells initiate a differentiation program that is reminiscent of 
early embryonic development (Doetschman et al., 1985; Leahy et al., 1999). In the 
context of the EB, molecular interactions that drive early embryonic development are 
recapitulated and cells differentiate to form ectoderm, endoderm, and mesoderm 
derivatives. Here, in vitro differentiation was achieved by growing hES cell colonies as 
EBs in non-adherent conditions for 7 days, then plating EBs back onto gelatin-coated 
plates and growing them for additional 23 days (Figure 4.7a).  
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Figure 4.7. Human ES cells in CM and CDM
activin
 conditions are able to differentiate in vitro into 
derivatives of the three germ layers. (a) Morphology of EBs formed in non-adherent conditions for 7 
days as well as cell types derived from EBs re-plated onto gelatine-coated surfaces for 23 days. After this 
period of time a wide variety of morphological cell types could be observed in the plates of both H1 CM 
and CDM
activin
: neuronal (A2)-(A6), liver (A3)-(A7) and endothelial-like cells (A4)-(A8). Magnification, 100X. 
(b) Generation of derivatives of the three germ layers was further confirmed by qPCR analysis looking at 
Sox1, P63, β-tubulin (ectoderm), Afp, Pdx1, Gata6 (endoderm), Bmp4, Pecam1 and CD45 (mesoderm) in 
both CM (white bars) and CDM
activin
 (black bars) cells. Expression of the pluripotency-associated markers 
Oct4, Nanog and Cripto is downregulated and almost absent after 30 days of differentiation. Graphs are a 
representative qPCR analysis of three independent experiments. Data was normalized to the expression 
of two housekeeping genes (Gapdh and Hprt). 
 
 
At this stage, a wide variety of morphologically different cell types could be observed in 
the plates of both H1 CM and CDMactivin cells, likely indicating the presence of neuronal 
(Figure 4.7, panels 2 and 6), liver (Figure 4.7, panels 3 and 7) and endothelial-like cells 
(Figure 4.7, panels 4 and 8). Generation of derivatives of the three germ layers after 
long term differentiation (30 days) was further confirmed by qPCR analysis for the 
differentiation markers Sox1, P63, β-tubulin (ectoderm), Afp, Pdx1, Gata6 (endoderm), 
Bmp4, Pecam1 and CD45 (mesoderm); all of these markers were steadily up-regulated  
in both CM and CDMactivin cells (Figure 4.7b). Expression of the pluripotency-associated 
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markers Oct4, Nanog and Cripto was, in contrast, dramatically downregulated or 
absent confirming that both CM and CDMactivin cells had lost their pluripotent status in 
culture conditions favoring differentiation. Altogether, these data demonstrate that both 
CM and CDM populations of hES cells can undergo differentiation into the three germ 
layers upon EBs formation and prolonged cultures. 
 
4.2.3. H1 hES cells in CM and CDM
activin
 conditions have 
different kinetics of in vitro differentiation 
 
 Our replication timing studies above suggest that hES CM and CDMactivin cell 
cultures might represent distinct but interchangeable developmental states, with CM 
cells sharing features of primed (epiblast-like) cells for differentiation, as opposed to 
CDMactivin cells. To further test this hypothesis, I compared the early kinetic of 
differentiation of CM and CDMactivin H1 hES cells upon spontaneous differentiation 
(EBs) and lineage-specific induction (neuroectoderm) using a previous established 
protocol (Chambers et al., 2009). As shown in Figure 4.8 EBs derived from CM and 
CDMactivin cells were collected at four time points: undifferentiated hES cells - day 0 and 
EBs at culture day 3, 6 and 9 and analysed by qPCR.  
 
 
 
Figure 4.8. Human ES cells cultured in CDM
activin
 differentiate more slowly by EBs differentiation 
than hES cells cultured in CM.  Time course analysis of the expression of pluripotency-associated (Oct4, 
Nanog and Cripto), ectoderm (Sox1, Sox3 and P63), endoderm (Afp, Pdx1 and Cdx2) and mesoderm (Ebf, 
Pecam1 and PPAR-γ) markers, during an 9 day course of EB differentiation in H1 CM (H1p63CM; blue 
curves) and CDM
activin
 cells [H1p47(CDM19); red curves]. Graphs show a representative qPCR analysis of 
three independent experiments. Data was normalized to the expression of two housekeeping genes 
(Gapdh and Hprt).  
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The expression of markers associated with the undifferentiated state (Oct4, Nanog and 
Cripto) was similar in both H1 CM and CDMactivin EBs culture. As previously reported 
(Darr et al., 2006), Nanog and Cripto expression was transiently upregulated; Oct4 
expression was steadily downregulated in both cell populations. In contrast, we 
observe clear differences in the onset of ectoderm (Sox1, Sox3 and P63), endoderm 
(Afp, Pdx1 and Cdx2) and mesoderm (Ebf, Pecam1 and PPAR-γ) associated markers, 
with an earlier induction of nearly all genes analysed in CM-derived EBs (Figure 4.8). 
Consistent trends were also observed when culturing CM and CDMactivin H1 hES cells in 
N2B27 media supplemented with 10 µM SB4341542 and 500 ng/ml noggin to induce 
neuroectoderm differentiation, as assessed at days 0, 2, 4 and 6 upon treatment 
(Figure 4.9).  
 
 
 
Figure 4.9. Human ES cells cultured in CDM
activin
 differentiate more slowly into neuroectoderm 
derivatives than hES cells cultured in CM. Time course analysis of the expression of pluripotency-
associated (Oct4, Nanog and Cripto) and neuroectoderm (Sox2, Sox1, β-tubulin, Sox3 and Zic1) markers, 
during a 6 day course of neuroectoderm differentiation as previously published (Chambers et al., 2009) in 
H1 CM (H1p65CM; green curves) and CDM
activin
 cells [H1p58(CDM16); purple curves). Neuroectoderm 
differentiation was performed in N2B27 medium supplemented with 10 µM SB4341542 and 500 ng/ml 
noggin. Mean and standard deviation of three experiments are shown. Data was normalized to the 
expression of two housekeeping genes (Gapdh and Hprt). 
 
 
The kinetic of Oct4, Nanog and Cripto downregulation was remarkably similar in 
induced H1 CM and CDMactivin cells. In contrast, the expression of neuroectoderm-
specific genes, Sox2, Sox1, β-tubulin, Sox3 and Zic1 was enhanced in H1 CM as 
compared to CDMactivin cultures (Figure 4.9). Taken together, these data demonstrate 
that CM and CDMactivin hES cells possess functionally distinct properties, with CM cells 
being more sensitive to the signal inducer of differentiation as tested in these 
experiments. 
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4.2.4 CDM
activin
 conditions tip the balance towards a more 
stable, ICM-like cell phenotype within hES cell cultures 
 
 To further explore the similarities and differences among hES cells grown in CM 
and CDMactivin conditions, we next examined the transcription profiles of undifferentiated 
H1 CM and CDMactivin cultures as assessed at different passage numbers (3, 6, 14 and 
over 25 passages) post transfer (CM to CDMactivin) by qPCR analysis (Figure 4.10). 
 
 
 
Figure 4.10. Differential gene expression profiles in H1 CM and CDM
activin
 hES cell populations. 
Real-time PCR analysis of selected genes in H1 CM (H1p49CM, white bars) and cells transferred and 
cultured for different passage numbers in CDM
activin
 conditions [H1p47(CDM3, 6, 14 and 25), black bars]. 
(a) Pluripotency-associated genes (Oct4 and Sox2) stably expressed in CM and CDM
activin
 cells or showing 
a transient increase (Nanog) or downregulation (Tcf3) in CDM
activin
 cells (b) TGF-β superfamily members 
transiently increased (Cripto, Gdf3 and Nodal) in CDM
activin
 cells. (c) CDM
activin
 strongly induced in H1 hES 
cells in CDM
activin
 conditions the expression of preimplantation-ICM markers (Rex1, Gata2 and Igf2r) and 
downregulation of the postimplantation marker Fgf5, as well as the (d) downregulation of germ layer 
markers (Eomes, Gata6, Sox17 and Foxa2). Mean and standard deviation of three experiments are 
shown. Data was normalized to the expression of two housekeeping genes (Gapdh and Hprt). 
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Here, we found that the expression levels of Oct4 and Sox2 remained constant across 
cell populations analysed (Figure 4.10a). In contrast, Nanog expression was transiently 
increased upon transfer to CDMactivin conditions; a trend also observed for three 
members of the TGF-β superfamily, Cripto (Minchiotti, 2005), Gdf3 (Levine and 
Brivanlou, 2006) and Nodal (Besser, 2004) (Figure 4.10b). Transient increase in Nanog 
expression was further confirmed at the protein level by FACS analysis. As shown in 
Figure 4.11, we observed a clear shift in the mean fluorescence intensity of Nanog 
staining in early CDMactivin cultures as opposed to CM and long-term CDM cultures. 
Note that, Oct4 levels remained steady in all three cell populations. Interestingly, the 
expression of Tcf3 was, in contrast, transiently downregulated and thus showed a 
converse pattern with that of Nanog; an observation consistent with Tcf3 being a 
putative repressor of Nanog as described in mES cells (Pereira et al., 2006; Yi et al., 
2008). 
 
 
 
Figure 4.11. Transient increase in the expression levels of Nanog in H1 CDM
activin
 hES cells. Flow 
cytometry analysis of Oct4 (left panel) and Nanog (right panel) levels in H1 CM (H1p58CM) and CDM
activin
 
early [H1p53(CDM4)] and long term cultures of CDM
activin
 [H1p53(CDM21)]. The red dotted lines indicate 
the mean fluorescence intensity of Oct4 and Nanog in H1p58CM cells. The profile of stained cells (black) 
was compared to cells stained with the secondary antibody only (dotted line). These findings are 
representative of two independent experiments. 
 
 
 Remarkably, CDMactivin conditions strongly and rapidly enhanced the expression 
of Rex1 (Figure 4.10c), a landmark of pluripotency that is specifically expressed in the 
ICM of mouse and human blastocysts, but downregulated in the epiblast stage 
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(Appendix II, Figure A5) (Pelton et al., 2002; Reijo Pera et al., 2009; Rogers et al., 
1991). A strong bias toward an ICM-like phenotype in our CDMactivin cultures was further 
confirmed by the steady induction of two other human ICM-specific markers, Gata2 and 
Igf2r (Reijo Pera et al., 2009) and the extinction of Fgf5 – a marker expressed in mEpiS 
cells but not in mES cells (Appendix II, Figure A5) (Pelton et al., 2002; Tesar et al., 
2007). Similarly, transcripts of Eomes, Gata6, Sox17 and Foxa2 which are upregulated 
in epiblast and early germ layers (Appendix II, Figure A5) (Pelton et al., 2002; Tesar et 
al., 2007), were dramatically downregulated upon transfer to CDMactivin conditions, 
consistent with a global decrease of transcriptional noise. Altogether these data 
strongly suggest that hES cells can transit from a primed epiblast-like to a more naïve 
ICM-like state by changing growth culture conditions (CM to CDMactivin), a level of 
heterogeneity not previously described within normal hES cell cultures. 
 
 
4.3. Generation of inter-species heterokaryons by 
cellular fusion 
 
In normal development, cells transit in a unidirectional process from totipotent 
zygote, pluripotent ICM/epiblast progenitors to fully differentiated somatic cells. 
However, under certain conditions, cell identity can be modified or reversed, leading to 
the establishment of a novel gene expression program defined as a reprogramming 
event. Reprogramming towards pluripotency can be achieved in different ways 
including nuclear transfer, forced expression of one or more transcription factors (iPS 
cells) or by cellular fusion (Egli et al., 2008; Jaenisch and Young, 2008). Spontaneous 
and experimental cell fusion between ES and somatic cells has shown that the 
phenotype of ES cells is dominant, imposing an ES-specific gene expression pattern in 
the nuclei of more differentiated cell types (Tada et al., 2001; Ying et al., 2002). Other 
stem cell populations such as EG and EC cells have also been described to reprogram 
somatic cells (Miller and Ruddle, 1976; Tada et al., 1997) towards their own identity in 
vitro as well as other extraembryonic stem cell populations TS and XEN cells (J. 
Santos and F. Pereira, unpublished data). Here we asked whether hES cells in CM and 
CDMactivin conditions share with mES cells the potential to reprogram the gene 
expression program of somatic nuclei. Also, we further compared the reprogramming 
ability of CDMactivin versus CM hES cell cultures alongside mES and mEpiS cells, using 
a cell fusion based assay (Pereira and Fisher, 2009; Pereira et al., 2008).  
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Figure 4.12. Generation of inter-species heterokaryons by cell fusion. (a) Schematic representation 
(adapted from Pereira et al., 2008) of the experimental strategy used to generate inter-species 
heterokaryons between B-lymphocytes and pluripotent stem cell lines derived from different species 
(human versus mouse and vice versa). Cell partners were fused in the presence of polyethylene glycol 
(PEG) and subsequent cells cultured up to three days under cell culture conditions promoting an 
undifferentiated state. Heterokaryons collected at different time points were analyzed by qPCR using 
primers that specifically amplify human or mouse transcripts. (b) Cell fusion efficiency was determined by 
FACS analysis. B-lymphocytes (hB and mB) were labelled with the cell membrane dye Dil and human 
[H1p70CM and H1p47(CDM30)] and mouse (Oct4Gip mES p31 and Oct4Gip mEpiS p32) stem cell 
populations with DiD. The resulting labelled cell populations were then fused and analyzed by FACS. 
Fusion efficiency evaluated as the percentage of double-labelled cells is indicated in each plot (upper right 
quadrant). These experiments were done in collaboration with Filipe Pereira. 
 
 
As outlined in Figure 4.12a, pluripotent stem cells and B-lymphocytes from 
different species (human versus mouse and vice versa) were mixed in a 1:1 ratio, 
giving rise to inter-species heterokaryons (in which parental nuclei share the same 
cytoplasm but remain separated) by PEG-mediated cell fusion. Fused cells were 
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cultured under conditions promoting the maintenance of undifferentiated stem cells and 
heterokaryons collected at day 0 (no PEG), 1, 2 and 3 prior nuclei fusion, for 
subsequent qPCR analysis, using specific-species primers. Cell fusion efficiency was 
verified by FACS analysis, based on different cell membrane labelling of B-
lymphocytes (Dil) and stem cells (DiD) prior to fusion. Figure 4.12b shows the FACS 
profiles obtained and the percentage of double-labelled cells (fusion efficiency) from 
mES x hB (upper left panel; 9.3%), mEpiS x hB (upper right panel; 10.2%), hES 
CDMactivin x mB (lower left panel; 8.5%) and hES CM x mB (lower right panel; 9.7%) 
fusions. These results indicate that all the population of cells analyzed (mouse and 
human) are able to be successfully fused with B-lymphocytes at similar efficiency rates. 
 
4.3.1. Mouse EpiS cells are not able to reprogram human 
B-lymphocytes for pluripotency in contrast to mES cells 
 
A panel of hES-associated genes (Oct4, Nanog, Rex1, Cripto, Tert, Tle1 and 
Dnmt3b) was selected for this analysis. The kinetics of gene re-activation potentially 
induced at these loci upon heterokaryon formation was assessed at day 0 (before 
fusion), 1, 2 and 3 by qPCR using species-specific primers. Human Hprt housekeeping 
gene was also included in these experiments as internal control, showing consistent 
and robust expression levels in both mES x hB and mEpiS x hB fusion experiments 
(Figure 4.13a). As previously published, mES cells were able to reprogram hB 
lymphocytes for pluripotency as indicated by the rapid re-activation of human Oct4, 
Nanog, Cripto, Tle1 and Dnmt3b in hB cell nuclei 2 days after heterokaryon formation 
and subsequent induction of hRex1 and hTert one day later. Conversely, we observed 
a rapid extinction of hCD19 expression – a specific lymphocyte marker, further 
indicating a loss of hB cell identity in fused somatic cells and the acquisition of a hES 
cell-like phenotype upon heterokaryon formation.  
Surprisingly and in contrast to mES cells, when pluripotent mEpiS cells were 
used as fusion partners, hOct4 and hNanog expression was not induced in hB cell 
nuclei as well as other hES-associated markers analysed. A modest induction of hTle1 
and hDnmt3b was seen at day 2 yet disappeared by day 3 (Figure 4.13a). Note that 
Fgf5, a putative human epiblast marker was neither induced in our mEpiS x hB (or 
mES x hB) fusion experiments (data not included in Figure 4.13). Notably, CD19 
expression remained relatively steady in mEpiS x hB as compared to mES x hB 
heterokaryons, further indicating that reprogramming may have failed to occur in hB 
cell nuclei fused with mEpiS cells. 
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Figure 4.13. Mouse EpiS cells are not able to reprogram human B-lymphocytes for pluripotency by 
cellular fusion in contrast to mES cells. (a) Oct4Gip mES p31 (black bars) and Oct4Gip mEpiS p32 
(grey bars) cell lines were fused to human B-lymphocytes (hB). The expression of hES-specific genes 
(hOct4, hNanog, hRex1, hCripto, hTert, hTle1 and hDnmt3b) was assessed by qPCR analysis between 
day 0 and day 3 after cell fusion using human-specific primers. Human B-lymphocytes were included as a 
negative control for this analysis. The constitutively expressed gene hHprt remains detectable at similar 
levels at all time points in both mES and mEpiS fusions. Activation of embryonic genes in mES x hB 
fusions is accompanied by silencing of the lymphocyte-specific gene (hCD19). Data were normalised to 
hGapdh expression. Error bars indicate the standard deviation of three independent experiments. (b) Real-
time PCR analysis of gene expression levels of reprogramming factors (Oct4, Nanog, Sox2, c-Myc, Klf4, 
Esrrb and Lin28) in Oct4Gip mES (black bars) and Oct4Gip mEpiS (grey bars) cells. Mean and standard 
deviation of three independent experiments are shown. Data was normalized to the expression of two 
housekeeping genes (Gapdh and Hprt). These experiments were performed in collaboration with Filipe 
Pereira. 
 
 
In an attempt to explain the differences observed between mES and mEpiS 
cells in terms of reprogramming potential, we compared the expression levels of known 
reprogramming factors - Oct4, Sox2, c-Myc, Klf4 (Takahashi and Yamanaka, 2006), 
Esrrb (Feng et al., 2009a) Nanog and Lin28 (Yu et al., 2007) as assessed in both cell 
populations by qPCR (Figure 4.13b). As anticipated, Oct4 was expressed at similar 
levels in mES and mEpiS cells, while Nanog and Sox2 showed a reduced mRNA levels 
in mEpiS cells as compared to mES cells, consistent with previous reports (Brons et 
al., 2007; Tesar et al., 2007). Interestingly, mEpiS cells displayed a drastic reduction in 
the expression of c-Myc, Klf4 and Essrb (more than 2, 15 and 100-fold, respectively) 
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compared to mES cells (Figure 4.13b). No significant change in Lin28 expression 
patterns was noticed in these experiments. Altogether these data demonstrate 
fundamental differences between pluripotent mouse stem cells derived from the early 
embryo. In contrast to mES cells, we found that mEpiS cells derived from gastrulating 
embryos were unable to reprogram the fate of hB-lymphocytes upon cell fusion, 
possibly reflecting the loss of key reprogramming factors expression in this cell type. 
 
4.3.2. Both H1 CM and CDM
activin
 hES cells are able to 
reprogram mouse B-lymphocytes for pluripotency 
 
The same methodology was used to generate heterokaryons between H1 hES 
cells grown in either CM or CDMactivin conditions and mouse B-lymphocytes. 
Reprogramming events were assessed by qPCR analysis of the mES-associated 
genes, Oct4, Nanog, Sox2, Rex1, Cripto, Tert and Dnmt3b. Mouse Hprt was also 
included in these experiments as internal control (Figure 4.14a). Here we found that 
both hES cell populations analysed were able to induce the reactivation of mOct4 in B-
lymphocyte nuclei upon cell fusion (Figure 4.14a). However, a more detailed 
comparison between hES CM and hES CDMactivin x mB fusions revealed clear 
differences in terms of genes being reactivated in each cell fusion type. Strikingly, 
mNanog was not reactivated in CM-type fusion in contrast to CDMactivin-type fusion. 
mSox2 and mRex1 showed a converse pattern, being strongly enhanced in B-cell 
nuclei fused with CM cells but not with CDMactivin cells. The expression of mouse Oct4, 
Cripto, Tert and Dnmt3b was detected at similar levels by day 3, although differences 
in the kinetic of gene reactivation were observed. Such differences could not be simply 
explained by differential Nanog or Sox2 mRNA levels in the two hES cell populations 
analysed (Figure 4.14b). Note that long-term CDMactivin hES cell cultures were solely 
used for these fusion experiments. Similarly, we did not notice any significant 
difference in the expression patterns of other key reprogramming factors (c-Myc, Klf4, 
Esrrb and Lin28) between CM and CDMactivin hES cell cultures (Figure 4.14b). Note that 
we were not able to accurately verify whether the expression of the mB-lymphocyte-
associated CD19 gene was shutdown upon reprogramming, as anticipated, in the 
absence of selective drugs to eliminate unfused mB-lymphocytes in these experiments 
(see section 2.2.11). 
Collectively, these results suggest that hES cells share with mES cells the 
potential to reprogram somatic cells for pluripotency upon heterokaryon formation. This 
contrast with mEpiS cells that were found unable to reprogram hB cell nuclei within 3 
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days post cell fusion as tested in our experiments. Interestingly, we noticed clear 
differences in the set of pluripotency-associated genes reactivated in mB cell nuclei 
when fused with either CM or CDMactivin hES cells, further highlighting distinct properties 
between these two hES cell populations. 
 
 
 
Figure 4.14. Both H1 CM and CDM
activin
 hES cells are able to reprogram mouse B-lymphocytes for 
pluripotency by cellular fusion. (a) H1p70CM (white bars) and H1p47(CDM30) (green bars) hES cells 
were fused to mouse B-lymphocytes (mB). The expression of mES-specific genes (mOct4, mNanog, 
mSox2, mRex1, mCripto, mTert and mDnmt3b) was assessed by qPCR analysis between day 0 and day 3 
after cell fusion, using mouse-specific primers. Mouse B-lymphocytes were included as a negative control 
for this analysis. The constitutively expressed mHprt gene remains detectable at similar levels at all time 
points in both hES CM and hES CDM
activin
 fusions. Data were normalized to mGapdh expression. Error 
bars indicate the standard deviation of at least two independent experiments. (b) Real-time PCR analysis 
of gene expression levels of reprogramming factors (Oct4, Nanog, Sox2, c-Myc, Klf4, Esrrb and Lin28) in 
H1p70CM (white bars) and H1p47(CDM30) (green bars) hES cells. Mean and standard deviation of three 
independent experiments are shown. Data was normalized to the expression of two housekeeping genes 
(Gapdh and Hprt). 
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CHAPTER 5. EPIGENETIC AND MOLECULAR 
MECHANISMS UNDERLYING DISTINCT PLURIPOTENT 
STATES WITHIN HUMAN ES CELLS 
 
 
5.1. A possible role for TGF-β/Activin signalling in 
defining a hES cell naive versus primed state in culture 
 
The mechanisms controlling self-renewal versus lineage commitment in hES 
cells remain poorly understood. Nonetheless, several studies suggest that TGF- 
superfamily ligands are involved in sustaining an undifferentiated and self-renewing 
hES cell state. In particular, the TGF-β/Activin signaling through its signal inducer 
Smad2/3 was proven to be essential for maintaining pluripotency in hES cells; while its 
inhibition leads to the upregulation of differentiation markers (James et al., 2005; Vallier 
et al., 2005; Xiao et al., 2006; Xu et al., 2008). Interestingly, we found that the 
acquisition of a more stable early-replicating epigenetic state in pluripotent CDMactivin 
hES cell cultures was accompanied by a transient upregulation of three key TGF-β-
associated members, Cripto, Gdf3 and Nodal, alongside Nanog (Figure 4.10). 
To further explore whether differential levels of TGF-β/Activin signaling 
activation might directly influence the balance between a more naive and primed state 
for differentiation in hES cells, we compared the relative levels of phosphorylated 
Smad2/3 (P-Smad2/3) in CM and CDMactivin H1 cultures from different passage 
numbers (3, 5, 14 and over 25), by western blot analysis. As shown in Figure 5.1, clear 
differences in the levels of P-Smad2/3 detected in CM and CDMactivin cell cultures were 
observed. Active P-Smad2/3 levels become consistently higher in hES cells when 
transferred from CM to CDMactivin conditions. This increase is also mirrored by an 
increase in Nanog induction in CDMactivin cell cultures. This is consistent with a direct 
role for Smad2/3 in regulating Nanog expression in hES cells (Xu et al., 2008). While 
Nanog was only transiently upregulated, P-Smad2/3 levels remained steady in 
CDMactivin cultures, regardless of passage numbers. Note that Oct4 levels were kept 
constant across CM and CDMactivin cultures, indicating that both CM and CDMactivin hES 
cell populations retain an undifferentiated state, as previously verified (Figure 4.5 and 
5.1). Interestingly, Nanog was also recently shown to interact directly with the Smad2/3 
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proteins, thus modulating the activity of TGF-β/Activin signaling pathway (Vallier et al., 
2009a). This negative feedback loop, may in turn, regulate and perhaps reduce the 
levels of Nanog expression in our long-term CDMactivin cultures to levels seen in CM 
cultures. Unfortunately, our attempt to quantify the levels of Smad2/3 occupancy at the 
Nanog promoter in CM and early and late CDMactivin cultures by ChiP assay were 
unsuccessful and did not allowed verifying this hypothesis.  
Altogether these results indicate that the activity of TGF-β/Activin signaling 
pathway can be dynamically altered in response to CDMactivin growth conditions, 
highlighting a possible role in modulating a self-renewing versus primed state within 
hES cell cultures. 
 
 
 
Figure 5.1. H1 CDM
activin
 hES cells are characterized by 
higher levels of activated Smad2/3 complexes in 
comparison to H1 CM cell cultures. Western blot analysis 
of H1 hES cells cultured in CM (H1p49CM) and CDM
activin
 for 
different passage numbers [H1p47(CDM3, 5, 14 and 25). 
Membranes were probed with antibodies specific for 
phosphorylated (P) Smad2/3, Smad2/3, Nanog, Oct4 and β-
actin (as a control for protein loading).  
 
 
 
 
 
 
5.2. Shift from early to late replication is 
accompanied by an increased recruitment of active 
p300 at the promoter of target genes in CDM
activin
 cells 
 
5.2.1. Global increase of p300-mediated histone H3 
acetylation in CDM
activin
 hES cell cultures 
 
Activated Smad complexes (in particular Smad2/3) are thought to alter the 
chromatin states of target loci by recruitment of various histone acetyltransferases 
(HATs), including p300/CBP (Ross et al., 2006; Ross and Hill, 2008), Pcaf (Itoh et al., 
2000; Kahata et al., 2004) and Gcn5 (Kahata et al., 2004) as well as the chromatin 
remodeler SWI/SNF ATPase, Brg1 (Ross et al., 2006) in a TGF-β dependent manner. 
To further investigate a possible link between Smad2/3-associated chromatin 
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remodeling activity and the establishment of early-replicating domains in hES cells 
grown in CDMactivin conditions, we initially surveyed dynamic changes in gene 
expression levels of different HATs (p300, CBP, Pcaf, Gcn5) and Brg1 that are 
potentially recruited by activated Smad2/3 complexes in H1 CM and CDMactivin hES 
cells from different passage numbers (Figure 5.2a). Interestingly, p300 showed a 
robust increase of more than 3-fold in CDMactivin as compared to CM cells; a level of 
induction maintained in CDMactivin cultures upon serial passages (Figure 5.2a). This was 
accompanied by a transient induction of both CBP and Brg1, two co-factors commonly 
associated with p300. In contrast, Pcaf was expressed at very low levels in all cell 
populations analysed while Gcn5 mRNA levels remained unchanged in both CM and 
CDMactivin culture conditions.  
 
 
 
Figure 5.2. The histone acetyltransferase p300 is highly expressed in H1 CDM
activin
 hES cells in 
contrast to H1 CM cells. (a) Real-time PCR analysis of HATs recruited by activated Smad complexes, 
(p300, CBP, Pcaf, Gcn5) and Brg1 in H1 CM (H1p49CM, white bars) and CDM
activin
 hES cells 
[H1p47(CDM3, 6, 14 and 25), black bars]. Mean and standard deviation of three experiments are shown. 
Data was normalized to the expression of two housekeeping genes (Gapdh and Hprt). (b) Western blot 
analysis of H1 hES cells cultured in CM (H1p49CM) and CDM
activin
 for different passage numbers 
[H1p47(CDM3, 5, 14 and 25). Membranes were probed with antibodies specific for p300 and β-actin (as a 
control for protein loading) or (c) with antibodies specific for p300 preferentially acetylated histone H3 
targets (H3K9ac, H3K18ac and H3K56ac). Antibodies against two histone modifications independent of 
p300 activity - H3K4me2 and H3K27me3 were also used as controls. Equivalent protein loading is shown 
by the total H3 and β-actin detection. 
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 The induction of p300 was further confirmed at the protein level by western blot 
analysis (Figure 5.2b) and shown to be accompanied by a global increase of its HAT 
activity (Figure 5.2c). Here we focused on p300 preferentially acetylated nucleosomal 
histone H3 (H3K9ac, H3K18ac and H3K56ac) (Das et al., 2009; Ross et al., 2006), 
showing a steady and gradual increase in histone acetylation levels in continued 
CDMactivin cultures as compared to H1 CM cells. In contrast, H3K4me2 and 
H3K27me3 levels, two histone modifications independent of p300 activity, remained 
constant between CM and CDMactivin cells. These results indicate that hES cells grown 
under CDMactivin conditions display high and steady levels of active Smad2/3 and the 
HAT p300, likely responsible for the global increase of histone H3 acetylation observed 
within these cultures. 
 
5.2.2. Recruitment of active p300 complexes at target loci 
is enhanced in response to CDM
activin
 growth conditions 
 
 Histone acetylation has been shown to positively correlate with early replication 
timing (Mendez, 2009). To investigate whether p300 is directly recruited to loci 
changing replication timing, from late to early, CDMactivin hES cells as compared to CM 
cells, we examined by ChiP assay and qPCR analysis the levels of p300 occupancy at 
selected promoters as well as the levels of enrichment for associated acetylated 
histone H3 (H3K9ac, H3K18ac and H3K56ac) in H1 CM and CDMactivin hES cell 
cultures. As summarised in Figure 5.3a, Cga, Foxa2, Gata6, Rex1, Sox17 and Tert are 
all targets for replication timing alterations (from late to early S-phase) in response to 
CDMactivin conditions. Nanog is here shown as an early-replicating control in both CM 
and CDMActivin populations. Strikingly, and as seen in Figure 5.3b, p300 was 
consistently detected at higher levels in the promoter regions of these loci in CDMactivin 
hES cells, where they replicate in early S-phase as compared to CM cells. In contrast, 
no significant change in the levels of enrichment for p300 at Nanog promoter was 
noticed between the two cell populations. As anticipated from the presence of p300, 
the relative enrichment for acetylated H3K9, K18 and 56 at the promoter regions of 
Cga, Foxa2, Gata6, Rex1 and Sox17 was also found generally higher in H1 CDMactivin 
cells than in CM (Figure 5.3c). Tert did not however, show the same trend, yet 
replication timing was found to be highly variable (from middle and middle-early) across 
CM cultures of the same line, highlighting Tert as a complex exception. These studies 
clearly suggest a direct correlation between the establishment of early-replication 
profiling and p300 HAT recruitment and activity in hES cells regardless of the 
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transcriptional states of target loci – note that Rex1 and Tert are expressed in hES cells 
while all other candidate loci analysed are silent. These results are in accordance with 
recent observations from Cedar and colleagues that HATs recruitment to the human β-
globin locus in a non-erythroid cell line is sufficient to trigger a change of replication 
timing, from late to early. Conversely, tethering a histone deacetylase (HDAC) to this 
locus in an erythroid cell line (where its normally expressed) was sufficient to change 
its replication timing from early to late (Goren et al., 2008). 
 
 
 
Figure 5.3. Loci changing replication timing from late in CM to early in CDM
activin
 hES cells have 
higher levels of p300 and histones acetylation at their promoter regions in CDM
activin
 hES cells. (a) 
Replication timing status of Cga, Foxa2, Gata6, Rex1, Sox17, Tert and Nanog was assessed in hES cells 
in CM and CDM
activin
 conditions. The replication timing of each locus is indicated in a colour coded way as 
previously designated. Relative enrichments for (b) p300 and (c) acetylated histone H3 (H3K9ac, 
H3K18ac and H3K56ac) was assessed in H1p67CM and H1p47(CDM23) hES cells using ChiP assay and 
qPCR analysis (black bars). Grey bars indicate background levels (control IgG). p300 enrichments is 
expressed relative to input and histones data normalised to total histone H3. Error bars indicate standard 
deviations of at least two independent experiments. 
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5.3. Inhibition of p300 acetyltransferase activity 
leads to early to late replication timing alterations in H1 
CDM
activin
 hES cells 
 
 To further decipher the relationship between p300-mediated histone acetylation 
and maintenance of stable, early-replicating profiles in hES cell cultures, we examined 
whether inhibiting p300 activity would be sufficient to change the replication timing 
status (from early to late) of loci directly targeted by this enzyme. Here, the replication 
profile of H1 CDMactivin hES cells treated with curcumin (also known as 
diferuloylmethane), a specific inhibitor of p300/CBP HAT activity (Balasubramanyam et 
al., 2004) was compared to that of untreated CDMactivin and CM hES cells.  
 Initially it was tested by western blot a range of curcumin concentrations (10, 25 
and 50 µM) in H1 CDMactivin cells to assess the impact of the drug on global histone 
acetylation levels. As shown in Figure 5.4a, the acetylation of histone H3 (H3K9ac, 
H3K56ac and H3K18ac) by p300 was strongly inhibited after 24 hours treatment with 
10 and 25 µM curcumin. Higher concentration of curcumin (50 µM) induced a high 
incidence of cell death, as previously reported (Balasubramanyam et al., 2004). H3K9 
and H3K56 acetylation was completely abolished after treatment with 10 µM curcumin 
and H3K18ac levels reduced yet still detected at both 10 and 25 µM concentrations. In 
contrast, the presence of curcumin did not induce any change in H3K27me3 levels, 
confirming the specificity of this treatment (Figure 5.4a). In these experiments 
asynchronously dividing H1 hES cell cultures grown in CDMactivin, were treated for 4 
days with the lowest concentration of curcumin able to produce an effect on histone 
acetylation levels (10 µM). Culture media supplemented with curcumin was changed 
daily. In order to exclude the influence of spontaneous differentiation in these 
curcumin-treated cultures, the expression of undifferentiated ES-associated genes 
(Oct4, Nanog and Rex1) was verified by RT-PCR analysis at day 4 of treatment, 
showing similar levels in both H1 CDMactivin untreated and treated cells (DMSO and 
curcumin). Differentiated-associated markers (Foxa2, Gata6, Eomes and Cdx2) were 
also included and found absent or residual in all three conditions (Figure 5.4b). 
Homogeneous staining for Oct4 and Nanog were further observed by IF analysis, while 
the differentiated surface marker SSEA1 was absent in cell populations tested (Figure 
5.4c). 
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Figure 5.4. Inhibition of p300 activity in H1 CDM
activin
 hES cells by curcumin leads to a reduction in 
the levels of histone acetylation without inducing cell differentiation. (a) Western blot analysis of H1 
CDM
activin
 hES cells treated during 24 hours with DMSO (solvent control), 10 and 25 µM of p300 inhibitor 
curcumin. Membranes were probed with antibodies specific for p300-mediated acetylated histone H3 
(H3K9ac, H3K56ac and H3K18ac). Antibody against H3K27me3 was also used as a control for the 
specificity of curcumin p300 inhibition. Equivalent protein loading is shown by the total H3 and β-actin 
detection. (b) RT-PCR analysis of the expression of undifferentiated ES-associated (Oct4, Nanog and 
Rex1) and differentiated-associated (Foxa2, Gata6, Eomes and Cdx2) genes in H1 CDM
activin
 hES cells 
treated during 4 days with DMSO and 10 µM of curcumin. (c) Immunofluorescence analysis of H1 
CDM
activin
 hES cells treated during 4 days with DMSO and 10 µM of curcumin for Oct4 (green), Nanog 
(green) and SSEA1 (red). Nuclei are shown by DAPI staining (blue). Scale bars, 70 µm. These 
experiments were performed in collaboration with Matias Autio in our laboratory. 
 
 
 Interestingly, we found that inhibiting p300 activity was sufficient to convert the 
replication timing profile of H1 CDMactivin cells into a CM-like profile when treated with 
curcumin. In particular, 12 out of 13 loci previously identified as targets for replication 
timing changes, from late to early in response to CDMactivin conditions (Bmp4, Cga, Ebf, 
Foxa2, Gata6, Neurog1, Rex1, Sox1, Sox17, Sox3, Sycp1 and Tle1), replicated in the 
second half of S-phase upon p300 activity inhibition in H1 CDMactivin cell cultures 
(Figure 5.5). Most of the shifting loci started to display a replication timing similar to that 
previously observed in H1 CM cells, as for example Foxa2: middle-late in CM, middle-
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early in CDMactivin and back to middle-late upon curcumin treatment. Importantly, loci 
that were consistently early (Dppa4, Gata4, Gbx2, Hoxb1, Nanog, Oct4, Wnt3 and 
Zic1), middle (Sox7) or late (Ikaros and Mash1) replicating in both CM and CDMactivin 
cells were not affected by the global inhibition of p300 activity (Figure 5.5), highlighting 
the target specificity of p300 action. Altogether these results suggest a pivotal role for 
p300-mediated histone acetylation in defining the balance between hES cell naive 
versus primed states for differentiation as reflected at the DNA replication timing level. 
 
 
 
Figure 5.5. Inhibition of p300 
acetyltransferase activity in curcumin-treated 
H1 CDM
activin
 hES cells induces replication 
timing changes towards a CM-like profile. (a) 
The replication timing of individual loci was 
compared between untreated H1 CM, CDM
activin
 
and CDM
activin
 hES cells treated during 4 days 
with 10 µM curcumin. Loci that changed 
replication timing from late to early in response to 
CDM
activin
 conditions (Bmp4, Cga, Ebf, Foxa2, 
Gata6, Neurog1, Rex1, Sox1, Sox17, Sox3, 
Sycp1, Tert and Tle1) delayed their replication 
timing towards late in curcumin-treated CDM
activin
 
cultures, with the exception of Tert. Other loci 
consistently replicated early (Dppa4, Gata4, 
Gbx2, Hoxb1, Nanog, Oct4, Wnt3 and Zic1), 
middle (Sox7) and late (Ikaros, Mash1 and Neuro 
D) in untreated CM and CDM
activin
 cells as well as 
in CDM
activin
 cells treated during 4 days with 10 
M curcumin.  
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CHAPTER 6. DISCUSSION 
 
 Pluripotent ES cells provide a unique opportunity for studying mammalian 
development and differentiation in vitro. A growing panel of mouse and human 
pluripotent stem cell lines has been derived from the early embryo at different 
developmental stages, as well as from adult cells reprogrammed by a variety of 
approaches. These cell lines share the expression of key pluripotency markers and are 
able to self-renew and to generate differentiated progenies when induced (Jaenisch 
and Young, 2008; Rossant, 2008). However, their relationship to each other and 
whether they correspond to different pluripotent states with distinct developmental 
potencies and affiliations in vivo is not clear. For example, hES cells, in contrast to 
mES cells, can spontaneously differentiate into extra-embryonic cell types despite 
being derived from the ICM of pre-implantation embryos. One possible explanation is 
that hES cells originate from a less committed (possibly pre-epiblast) stage while mES 
cells represent the lineage-restricted epiblast progenitors in the ICM. Yet such an 
explanation is hard to reconcile with most recent reports suggesting that hES cells 
closely resemble mEpiS cells - a pluripotent stem cell population derived from post-
implantation embryos (Brons et al., 2007; Tesar et al., 2007). In this study, I have 
investigated whether distinct pluripotent states could be reliably delineated at the 
chromatin level by comparing the replication timing profiles of hES, mES and mEpiS 
cell populations. Importantly I showed that hES cells can transit from a primed epiblast-
like to a naive ICM-like state by changing growth culture conditions, a level of 
heterogeneity not previously described within hES cell cultures. Early and steady 
replication timing profiles are shown to be a unique feature of the naive state while late 
and variable replication profiles characterize a more primed hES cell state. In addition, 
our findings strongly suggest a pivotal role for TGF-β/Activin signalling through 
Smad2/3 action and its downstream target p300, in modulating the balance between 
distinct hES cell states in culture (Figure 6.1). 
 
6.1. Human and mouse ES cells have distinct 
replication timing profiles 
 
 In this study, I have compared the DNA replication timing status of a large panel 
of key developmental genes in several hES cell lines alongside mES and mEpiS cells 
to investigate whteher we can reliably discriminate these distinct but closely related 
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developmental states using a chromatin-based approach. The candidate genes 
selected for this analysis mainly encode human and mouse homologs selectively 
expressed in embryonic and extraembryonic tissues of the early embryo or involved in 
somatic and germ-line lineages specification. 
 Here, I showed that the replication timing profile of independently derived mES 
cell lines from different genetic backgrounds is remarkably steady and consistent 
across cell lines. This contrasts with the recent demonstration that mES cells display 
considerable cell to cell heterogeneity in the expression levels of certain pluripotency-
associated genes such as Nanog, Rex1 and Stella (Chambers et al., 2007; Hayashi et 
al., 2008; Toyooka et al., 2008) suggesting that replication-timing profiles might be a 
more robust indicator of a pluripotent mES cell identity than transcriptional profiles. In 
addition, and in agreement with previous studies (Azuara et al., 2006; Hiratani et al., 
2008), I confirmed that many genes in mES cells replicate early during S-phase, 
regardless of their transcriptional status, thus reflecting a broadly accessible chromatin 
structure. In fact, replication timing as an indicator of chromatin accessibility has been 
previously used to study epigenetic events underlying lineage commitment and 
pluripotency (Azuara et al., 2006; Hiratani and Gilbert, 2009; Kitsberg et al., 1993; Wutz 
and Jaenisch, 2000). In particular, replication timing profiling was capable of 
discriminating pluripotent mES cells from cells with a more restricted differentiation 
capacity, with many lineage-specifying genes becoming late replicating in unrelated cell 
types (i.e. neural genes in fully differentiated lymphocytes) (Azuara et al., 2006; 
Hiratani et al., 2008; Perry et al., 2004). These features, made of replication timing an 
attractive approach to characterize hES cells, where lineage affiliation and functional 
verification of embryonic potential in vivo is not possible, due to obvious ethical 
reasons.  
Surprisingly, I observed that human ES cells have a significantly distinct 
chromatin profile from that of mES cells. A profound difference was the increased 
proportion of genes replicating later during S-phase as seen in H1, H7 and H9 hES cell 
lines; a feature that is normally found in differentiated cells (Azuara et al., 2006; Perry 
et al., 2004). Yet these hES cell cultures displayed high and homogeneous expression 
levels of undifferentiated markers (like Oct4 and Nanog), excluding spontaneous 
differentiation as the primary cause of late replication. Moreover, hES cell replication 
profiles could still be discriminated from that of cells with a more restricted 
developmental competence like hES-derived neuronal progenitor (NP) cells, as 
previously seen for mES cells (Hiratani et al., 2008; Perry et al., 2004). In particular, I 
found that many neural-specific genes (such as NeuroD, Sox3 and Sox1) advanced 
their replication timing toward early S-phase upon neural induction in differentiating 
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hES cells, consistent with an increase of chromatin accessibility at these loci. In 
contrast, many non-neural genes, including ES-specific (Cripto and Tle1) and other 
somatic lineage-associated markers (such as Bmp4, Foxa2, Sox17 and Eomes), 
shifted to their replication timing toward late S-phase in NP cells as compared to hES 
cells, suggesting that epigenetic changes associated with neural lineage commitment 
and loss of pluripotency have indeed taken place. 
 
6.2. Replication timing variability is a hallmark of 
hES cells in CM conditions and mEpiS cells 
 
 Intriguingly, hES cell replication profiles were also found to significantly vary 
between cell lines and cultures; a level of variability not observed among mES cells 
that harbour a steady and mostly early-replicating profile. This variability could not be 
simply explained by distinct derivation histories since H1, H7 and H9 were all derived 
simultaneously in the same laboratory (Thomson et al., 1998) and expanded in the 
same culture conditions (CM) (Xu et al., 2001). Moreover, variability was observed at 
specific loci (Dppa4, Tert, Tle1, Sycp1, Bmp4, Ebf, Foxa2, Gata6, Sox17, Sox3 and 
Zic1) and it is likely that this is a lower-limit estimate as inclusion of additional hES cell 
lines and genes could substantially increase the spectrum of observed replication 
timing variability. One possibility would be that such level of epigenetic variability solely 
reflects the considerable genetic variation that exists within the human population (in 
contrast to inbred mouse laboratory strains). In accordance, several reports have 
similarly revealed variability between hES cells at the transcriptional level (Abeyta et 
al., 2004; Adewumi et al., 2007; Skottman et al., 2006; Wei et al., 2005). This possibility 
was, however, ruled out by analysing the replication timing status of variable replicating 
loci (as defined in hES cells) in human CD34+ haematopoietic stem cells isolated from 
blood samples of three unrelated volunteers; these profiles were shown to be 
remarkably similar across samples, with no or little evidence of epigenetic variability. 
Moreover, a recent study comparing the replication timing of human and mouse 
homolog genes in lymphocytes showed a high conservation across species in terms of 
replication timing (Farkash-Amar et al., 2008). This study together with our 
observations, suggest that replication timing variability might be a unique feature of 
hES cell cultures and/or their in vivo equivalent in the human embryo.  
 
 Changes in DNA replication timing profiles are generally thought to reflect 
variations in chromatin accessibility and transcriptional permissiveness (Donaldson, 
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2005). ChIP data generated for different histone acetylation marks (H3K9ac, H3K14ac, 
H3ac and H4ac) were compared with the replication timing and expression status of 
selected genes across hES cell lines grown under the same culture conditions. Highly 
expressed and early replicating genes across H1, H7 and H9 hES cells (such as Oct4, 
Nanog and Sox2) showed a positive correlation with higher levels of histone 
acetylation, as previously described for mES cells (Azuara et al., 2006; Jorgensen et 
al., 2007; Perry et al., 2004). Accordingly, silent and late replicating genes (as for 
example Myf5) showed background levels for histone acetylation as seen at satellite 
repeats (a constitutive heterochromatic control region used in these experiments). In 
contrast, no straightforward correlation between replication timing variability, histone 
acetylation patterns and/or expression could be drawn when analysing variable 
replicating genes across H1, H7 and H9 cells. Complementary DNA methylation 
analysis did not reveal any correlation between DNA methylation and replication timing 
variability at specific loci in hES cells neither. This is in agreement with previous studies 
showing that the replication timing status of individual loci did not change in DNA 
methyltransferase-deficient mES cells (Gribnau et al., 2003; Jorgensen et al., 2007). 
No direct correlation was observed neither between chromosomal location or genomic 
features (such as GC content and LINE density) and replication timing variable targets, 
in contrast to previous studies (Hiratani et al., 2004). Interestingly, all variable genes 
(apart from Tert) were located in gene poor genomic regions. Although this is not a 
unique feature of variable loci in hES cells, it implies that the changes in replication 
timing of those genes are not influenced by the transcriptional status of neighbouring 
genes.  
 
 What is then the functional significance of replication timing variability? Such a 
level of plasticity within hES cell cultures could indicate an unstable or transitional 
state: primed on the verge of differentiation. This interpretation would be consistent 
with hES cells resembling most closely to mEpiS cells than mES cells, as previously 
suggested (Brons et al., 2007; Tesar et al., 2007). In this study, we observed that 
mEpiS and hES cells share similar cell cycle profiles, most likely reflecting their 
common growth requirements (Brons et al., 2007; Tesar et al., 2007). Similarly, we 
found that Rex1 – an ICM-specific marker that is shutdown in the epiblast - replicates 
early during S-phase in mES cells but consistently late in all mEpiS and hES cell lines 
analysed. In contrast, the replication timing of Fgf5, an epiblast-specific marker, shifts 
from late in mES cells to early in mEpiS cells, underlying gene de-repression 
mechanisms yet remains late replicating in hES cells Thus, establishing the replication 
status of ICM/epiblast-specific markers was not sufficient to clarify the developmental 
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status of hES cells.It should, however, be noted that the regulation of Rex1 and Fgf5 
expression might be different between species. In fact, the selection of these markers 
was based on gene expression analysis in mouse embryos, in the absence of 
equivalent information in human embryos. Our replication timing analysis was further 
extended to other target loci previously analysed in mES and hES cells, i.e. 
differentiation-associated markers such as Ebf, Ikaros, Foxa2, Sox17, Sox3 and Zic1 
that are subjected to variable replication timing profile in hES cells. Remarkably, hES 
cells (grown under MEF-CM conditions) and mEpiS cells were revealed to share a 
common ‘unstable’ state, as indicated by a a high level of replication timing variability 
across a common set of loci, as opposed to mES cells. This observation is in 
agreement with previous suggestions that hES cells harbour an epiblast-like phenotype 
in culture, suggesting a pre-gastrulating developmental stage affiliation in vivo. 
 
6.3. Identification and characterization of distinct 
pluripotent states within hES cell cultures: naive vs 
primed 
 
 One of the most surprising results arising from this work is the demonstration 
that hES cell replication timing profile can be prone to extensive changes under 
different culture conditions. We found that H1 and H9 hES cells grown under standard 
MEF-CM conditions undergo dramatic epigenetic alterations when transferred into 
CDMactivin conditions, with many genes stably and consistently shifting their replication 
timing towards early S-phase in both cell lines. Moreover, the modulation of hES cell 
replication profiles was here demonstrated to be a reversible process as returning cells 
from CDMactivin to CM conditions was sufficient to revert to an unstable and late profile. 
A significant overlap between genes advancing their replication timing in H1 and H9 
hES cells was observed, suggesting that a conserved mechanism is driving hES cell 
cultures towards a more stable state. Importantly, these results further challenge the 
view that hES cells closely resemble mEpiS cells, and suggest that distinct but 
interchangeable subpopulations may exist within hES cell cultures, as delineated by a 
stable, early-replicating (naïve) versus unstable, late-replicating (primed) profile (Figure 
6.1). These results are reminiscent of recent studies showing that undifferentiation 
mES cell cultures contain distinct subpopulations that either correspond to a ICM-like 
or epiblast-like identity, that can vary in response to different culture conditions (Bao et 
al., 2009; Chou et al., 2008; Hanna et al., 2009; Nichols and Smith, 2009). Importantly, 
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we showed for the first time that hES cell cultures are equally metastable and can 
alternate between different pluripotent states when grown in CM and CDMactivin 
conditions. Our observations were further extended and confirmed in human iPS cells, 
providing additional evidence that induced (iPS) and natural (hES) pluripotent cells 
share common properties (Colman and Dreesen, 2009) and reiterating the impact of 
culture conditions in modulating or supporting different epigenetic states within 
pluripotent cell cultures. This is an important consideration as responses to 
differentiation protocols are likely to vary depending on where the cells stand in a 
developmental hierarchy. Interestingly, a recent study shows that reprogramming using 
a commercial CDM media supplemented with FGF2 and TGF-β, favors the formation of 
fully reprogrammed over partially reprogrammed colonies (Chan et al., 2009). It would 
be interesting to compare the replication profiles of different iPS cell lines derived from 
distinct methodologies.  
 
 
 
Figure 6.1. Proposed model for the maintenance of distinct pluripotent states within hES cell 
cultures. Human ES cell cultures contain distinct subpopulations of pluripotent cells that can transit from a 
naive ICM-like to a primed for differentiation epiblast-like state or vice versa. Oscillations between these 
subpopulations (indicated by the broken arrow) are induced by changing hES cell culture conditions. 
Human ES cells grown under standard MEF-CM share characteristics with primed cells for differentiation, 
and are notably specified by low expression levels for the ICM marker Rex1. In contrast, cells transferred 
to CDM
activin
 show characteristics of a naive state, with high levels of Rex1 expression. Changes in culture 
conditions (from CM to CDM
activin
) are here accompanied by increased levels of the TGF-β/Activin signal 
inducer P-Smad2/3. Activated Smad2/3 act through the HAT p300, that is also present at higher levels in 
CDM
activin
 cells, promoting an increase in histone acetylation levels at the promoters of target loci, shifting 
from late to early replication timing (in CDM
activin
) and thus a general increase in chromatin accessibility 
across many lineage-specifying genes in hES cells. 
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The fact that hES cell replication profiles can be very rapidly and dynamically 
shifted upon culture condition changes (from CM to CDMactivin conditions and vice 
versa) excludes “cell culture adaptation” as a unique cause for these alterations. Cell 
adaptation is a common phenomenon observed in undifferentiated hES cell cultures, 
especially long-term cultures, often associated with karyotypic changes that provide 
some advantages in terms of clonogenic capacity and self-renewal properties of these 
cells (Baker et al., 2007; Draper et al., 2004; Enver et al., 2005). However, this 
phenomenon did not seem to influence on hES cell replication properties as verified by 
directly comparing the profiles of normal diploid H1-BH1 cells and adapted, long-term 
H1-BH1 cultures that were confirmed to be karyotypically abnormal; these cells were 
kindly provided by Professor Peter Andrews in Sheffield (Appendix II, Figure A6). 
 
Phenotypically, hES cells grown in both CM and CDMactivin conditions display 
characteristics of undifferentiated and self-renewing cells, similarly showing strong 
staining for alkaline phosphatase, and high expression levels for the key pluripotency 
transcription factors, Oct4, Nanog and Sox2, and cell surface markers,Tra-1-60, Tra-1-
81 and SSEA4. Moreover, both hES cell populations can undergo differentiation into 
derivatives of the three germ layers upon EBs formation and prolonged cultures. Yet 
CM and CDMactivin hES cells were demonstrated to possess functionally distinct 
properties, with CM cells being more responsive to differentiation signals than CDMactivin 
cells. This corroborates the view that CM cells might be already in a pre-gastrulating 
stage, while CDMactivin cells preferentially adopt an ICM-like phenotype. Such bias 
towards an ICM-like phenotype in cultures transferred to CDMactivin conditions was 
further confirmed by a rapid and dramatic increase in Rex1 expression levels, as well 
as the up-regulation of Gata2 and Igf2r - a set of markers recently found to be 
specifically expressed in ICM cells of the early human embryo (Reijo Pera et al., 2009). 
Conversely, many early germ layer markers such as Eomes, Gata6, Sox17 and Foxa2 
that are commonly expressed at low levels in mEpiS but not in mES cells, were 
drastically downregulated in CDMactivin hES cell cultures, indicating a loss of 
transcriptional noise. These results suggest that CM conditions might either contain 
extrinsic differentiation stimuli, possibly secreted by the MEFs that prime cells for 
lineage commitment or on the contrary be deprived of adequate concentrations of 
signalling factors essential for the maintenance of a true embryonic ground state, as 
recently suggested for mES cells (Ying et al., 2008). 
 
 Several studies have previously shown that somatic (i,e, lymphocyte) nuclei can 
be reprogrammed to a pluripotent state when injected into Xenopus oocytes (Byrne et 
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al., 2003), upon nuclear transfer into mouse oocytes (Hochedlinger and Jaenisch, 
2002), or through the generation of cell hybrids with pluripotent ES (Tada et al., 2001) 
and EG cells (Tada et al., 1997). Here, I investigated the potential of hES cells grown 
either in CM or CDMactivin conditions, alongside mEpiS and mES cells to reprogram the 
gene expression program of lymphocyte nuclei, using inter-species cell fusion assays 
(Pereira and Fisher, 2009). While mES cells were able to reprogram hB lymphocytes 
for pluripotency, as expected, re-activation of human pluripotency-associated genes, 
including hOct4 and hNanog and extinction of hCD19 – a lymphocyte-specific marker 
were not observed in our mEpiS x hB fusions, indicating that mEpiS cells might lack the 
potential to reprogram hB lymphocytes, at least in the conditions tested in our 
experiments. This result was surprising and could not be simply explained by 
differential fusion efficiencies between mES or mEpiS and hB cells. Moreover, other 
specialised cell types like fibroblasts (Massa et al., 2000) or extraembryonic stem cells 
(J. Santos and F. Pereira, personal communication) were previously found capable of 
reprogramming lymphocytes towards their own identity. This may relate to the limiting 
amounts of c-Myc, Esrrb and Klf4, three key reprogramming factors (Feng et al., 
2009a; Takahashi and Yamanaka, 2006), present in mEpiS cells as compared to mES 
cells. Accordingly, a recent study showed that the forced expression of Klf4 in mEpiS 
cells was sufficient to induce the formation of cells with characteristics of mES cells 
(Guo et al., 2009). Another possibility is that reprogramming inhibitor trans-acting 
factors present in mEpiS and lacking in mES cells may constrain gene activation in hB 
lymphocytes. Although the precise mechanisms controlling reprogramming are still not 
full understood, recent evidences suggest a central inhibitory role for senescence 
factors in reprogramming efficiency (Banito et al., 2009; Hong et al., 2009; Kawamura 
et al., 2009; Li et al., 2009a; Marion et al., 2009; Utikal et al., 2009). Further studies 
comparing the regulation of senescence pathways in mES and mEpiS cells would bring 
more insights into this subject. A third possibility for the lack of reprogramming potential 
in mEpiS cells might correlate with cell cycle differences between mES and mEpiS 
cells. It was shown that in cell-hybrids, cells were most effective at reprogramming 
when they contained a high proportion of cells in the S- and G2/M- phases of the cell 
cycle. Accordingly, we showed that mES cells have a higher proportion of cells in S-
phase than mEpiS cells.  
 Human ES cells in CM and CDMactivin share with mES cells the potential to 
reprogram somatic cells for pluripotency upon heterokaryon formation, as previously 
described (Cowan et al., 2005; Yu et al., 2006). This contrast with mEpiS cells that 
were unable to reprogram hB cell nuclei within three days after fusion. Importantly, 
these results demonstrate that hES cells, independently of their culture conditions are 
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clearly different from mEpiS cells. Interestingly, the set of pluripotency-associated 
genes reactivated in the mB cell nuclei when fused with either CM or CDMactivin hES 
cells was different. In particular, mNanog was not reactivated in CM in contrast to 
CDMactivin fusions while mSox2 and mRex1 were strongly enhanced in CM fusions but 
not CDMactivin, further highlighting distinct properties between these hES cell 
populations. 
 
6.4. Investigating the mechanisms that specify 
distinct pluripotent states within human ES cell 
cultures: a pivotal role for TGF-/Activin signalling and 
the histone acetyltransferase p300  
 
 Although the mechanisms controlling self-renewal versus lineage commitment 
remain poorly understood in hES cells, several studies demonstrated that TGF-
/Activin signaling acting through the signal inducer Smad2/3 is essential for 
maintaining pluripotency in human cell lines (James et al., 2005; Vallier et al., 2005; 
Xiao et al., 2006; Xu et al., 2008). In this study, we showed that increased levels of the 
active P-Smad2/3 forms underlie the acquisition of an ICM-like phenotype in pluripotent 
hES cell cultures when transferred from CM to CDMactivin conditions. Although both 
culture conditions similarly rely on the presence of the TGF- β member Activin A to 
sustain an undifferentiated hES cell state (note that FGF2 directly induces the secretion 
of activin A by MEFs used to prepare CM media (Beattie et al., 2005), this essential 
signaling pathway was found to be differentially activated in CM and CDMactivin 
conditions - two commonly used protocols to maintain hES cells in vitro. This is of 
major importance, considering that many different members of the TGF- family, 
including Activin A, are known to either favor self-renewal or differentiation depending 
on their respective concentrations; the concentrations of these pleitrophic factors are 
indeed very likely to vary between CM and CDMactivin conditions (Sulzbacher et al., 
2009). In agreement, follistatin, a known inhibitor of activin A activity (Nakamura et al., 
1990) was shown to be highly abundant in MEF-CM media (Bendall et al., 2007).  
 Interestingly, the acquisition of a more stable, early-replicating pluripotent state 
in CDMactivin hES cells is also accompanied by a transient yet significant upregulation of 
Nanog levels. This is consistent with a direct role for Smad2/3 in regulating Nanog 
expression in hES cells (Vallier et al., 2009a; Xu et al., 2008). Note that Nanog was 
shown to directly regulate the expression of Rex1 in mES cells (Shi et al., 2006). If 
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similar mechanisms are conserved in human cells, this could explain the rapid and 
steady increase in Rex1 levels observed in hES cell cultures upon transfer from CM to 
CDMactivin conditions. Further ChIP studies to assess the levels of Nanog occupancy at 
the human Rex1 promoter in both CM and CDMactivin cultures would be required to test 
this possibility. Moreover, our results suggest a possible role for Nanog in the 
establishment of an ICM-like state as defined in this study by a stable, early-replicating 
profile in CDMactivin hES cells. These results are in agreement with Nanog’s role in 
stabilizing mES cells in culture, as well as during epigenetic reprogramming of  
pluripotent and germ cells in vivo (Chambers et al., 2007) or upon cell fusion in vitro 
(Silva et al., 2006). Once established, this new pluripotent state is thought to be stably 
propagated throughout cell divisions while negative feedback mechanisms are likely to 
regulate Nanog expression levels. In agreement, Tcf3, a putative repressor of Nanog in 
mES cells (Pereira et al., 2006; Yi et al., 2008) showed a converse pattern of gene 
expression with that of Nanog in hES cell cultures when transferred from CM to 
CDMactivin conditions. Of note, several members of the TGF-β family, including Nodal 
were also found first up-regulated yet down-regulated alongside Nanog, also 
suggesting the occurrence of negative feedback mechanisms that modulate their 
expression levels in hES cells. Accordingly, Nodal expression in undifferentiated hES 
cells was previously shown to require activation of Smad2/3 and is regulated by a 
negative feedback mechanism, involving the expression of the antagonists Lefty-A and 
B. (Besser, 2004).  
 
 The transition from early to late replication in CDMactivin hES cells was also 
accompanied by an increase in the expression and activity of a known Smad2/3 co-
activator, the HAT p300 (Schmierer and Hill, 2007). Importantly, we showed that p300 
is recruited at specific target loci shifting replication timing from late to early in CDMactivin 
cells, where it mediates high levels of histone H3 acetylation. Such increase of 
chromatin accessibility through p300 recruitment was shown to occur at both active 
(i.e. Rex1) and inactive genes (i.e. Cga and Foxa2) that commonly replicate in early S-
phase, in accordance with a strong positive correlation between histone acetylation and 
early replication timing, as previously reported (Mendez, 2009). In particular, a recent 
study showed that the recruitment of HATs to the silent human β-globin locus in a non-
erythroid cell line changed its replication timing from late to early. Conversely, tethering 
a HDAC to this locus in an erythroid cell line (where β-globin is expressed) was 
sufficient to change its replication timing from early to late (Goren et al., 2008). 
Similarly and most importantly, we demonstrated that inhibiting p300 activity by a 
specific inhibitor (curcumin) was sufficient to convert the replication timing profiles of 
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early CDMactivin cells into a late CM-like profile. Altogether our results strongly suggest a 
key role for the HAT p300 in regulating the balance between naïve versus primed 
states in hES cell cultures (Figure 6.1). Interestingly, this mirrors recent findings 
showing that the use of trichostatin A, an HDAC inhibitor was sufficient to bias mES cell 
cultures towards a Stella-positive, ICM-like state (Hayashi et al., 2008).On the same 
note, sodium butyrate, another HDAC inhibitor, was found capable of promoting both 
mouse and human ES cells self-renewal in minimum culture conditions; interestingly, 
both pluripotent cell types displayed a more closely related, ICM-like phenotype in 
these culture conditions (Ware et al., 2009).It would be of high interest to further 
explore how different HDACs and HATs may act together to regulate and balance 
distinct pluripotent states in hES cell cultures.  
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APPENDIX I – PRIMER SEQUENCES 
 
Table A1. Primers for the amplification of human or mouse transcripts by real 
time quantitative PCR 
 
Human primers  
Species/Gene  Sequence 5’-3’ 
hβ-tubulin 
s CAGATGTTCGATGCCAAGAA 
as TGCTGTTCTTGCTCTGGATG 
hAfp 
s AAATGCGTTTCTCGTTGCTT 
as GCCACAGGCCAATAGTTTGT 
hBmp4 
s TGGTCTTGAGTATCCTGAGCG 
as GCTGAGGTTAAAGAGGAAACGA 
hBrg1 
s TGGACTACAGCGACTCACTGA 
as TCGATGGCCTTTGACGCAC 
hCBP 
s GACAAGCGAAACCAACAAACC 
as TGGGGTCTATGGGATTTGGGT 
hCD19 
s GCTCAAGACGCTGGAAAGTATTATT 
as GATAAGCCAAAGTCACAGCTGAGA 
hCD45 
s CCCCATGAACGTTACCATTTG 
as GATAGTCTCCATTGTGAAAATAGGCC 
hCdx2 
s CAGGACGAAAGACAAATATCGAGTG 
as CCAGATTTTAACCTGCCTCTCAGA 
hc-Myc 
s TTGTACCTG CAGGATCTGAG 
as CTTGTTCCTCCTCAGAGTCG 
hCripto 
s AGAAGTGTTCCCTGTGTAAATGCTG 
as CACGAGGTGCTCATCCATCA 
hDnmt3b 
s GTCAAGCTACACACAGGACTTGACAG 
as AGTTCGGACAGCTGGGCTTT 
hEbf 
s GGAGATCGAGAGGACAGCGT 
as GTCAATGAGGCGCACGTAGA 
hEomes 
s CAAAGGCGCAAATAACAACAAC 
as CCACGCCATCCTCTGTAACTTC 
hEsrrb 
s TGAGGCCAGAGGTGATCCAG 
as TCTTGATGAAGGAGCCGCAG 
hFgf5 
s CAGCACCAAAGGCTCAGCTT 
as CCTTGCTTCTAACCCATCATATCC 
hFoxa2 
s GGGAGCGGTGAAGATGGA 
as TCATGTTGCTCACGGAGGAGTA 
hGapdh 
s TCTGCTCCTCCTGTTCGACA 
as AAAAGCAGCCCTGGTGACC 
hGata6 
s ACCACCTTATGGCGCAGAAAC 
as TTTTTCATAGCAAGTGGTCTGGG 
 152 
hGcn5 
s GCTACATCAAGGACTACGAG 
as GCTTCTTGATGATCTCTTTCTG 
hGdf3 
s GTACTTCGCTTTCTCCCAGAC 
as GCCAATGTCAACTGTTCCCTT 
hHprt 
s TCCTTGGTCAGGCAGTATAATCC 
as GTCAAGGGCATATCCTACAACAAA 
hKlf4 
s CACATTAATGAGGCAGCCACC 
as AAGTCGCTTCATGTGGGAGAG 
hLin28 
s TGCGGGCATCTGTAAGTGG 
as GGAACCCTTCCATGTGCAG 
hNanog 
s CCAACATCCTGAACCTCAGCTAC 
as GCCTTCTGCGTCACACCATT 
hNodal 
s AGAAGCAGATGTCCAGGGTAGCT 
as GAGAGGTTGGAGTAGAGCATAAGGA 
hOct4 
s TCGAGAACCGAGTGAGAGGC 
as CACACTCGGACCACATCCTTC 
hp300 
s TCAGCCAAGCGGCCTAAAC 
as TCACCACCATTGGTTAGTCCC 
hP63 
s TTTCAGAGGCAATCCACACA 
as ATGCATGCAAATGAGCTCTG 
hPcaf 
s CGAATCGCCGTGAAGAAAGC 
as GAGGGGTTAGGGTTTTTCCAG 
hPdx1 
s CCTTTCCCATGGATGAAGTC 
as GGAACTCCTTCTCCAGCTCTA 
hPecam1 
s AACAGTGTTGACATGAAGAGCC 
as TGTAAAACAGCACGTCATCCTT 
hPPAR-γ 
s GCTGGCCTCCTTGATGAATA 
as TTGGGCTCCATAAAGTCACC 
hRex1 
s GCGTACGCAAATTAAAGTCCAGA 
as CAGCATCCTAAACAGCTCGCAGAAT 
hSox1 
s AACACTTGAAGCCCAGATGGA 
as GCAGGCTGAATTCGGTTCTC 
hSox17 
s GGCGCAGCAGAATCCAGA 
as CCACGACTTGCCCAGCAT 
hSox2 
s CACACTGCCCCTCTCACACAT 
as CATTTCCCTCGTTTTTCTTTGAA 
hSox3 
s TTTGATAAGCCTACCCTTCC 
as GTTCTTGAGTTCAGTCTCCA 
hTcf3 
s GCCTCCCGACTCCTACAGT 
as CGCTGACGTGTTCTCCTCG 
hTert 
s GCCAGCATCATCAAACCCC 
as CTGTCAAGGTAGAGACGTGGCTC 
hTle1 
s TGTCTCCCAGCTCGACTGTCT 
as AAGTACTGGCTTCCCCTCCC 
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hZic1 
s CTGGCTGTGGCAAGGTCTTC 
as CAGCCCTCAAACTCGCACTT 
Mouse primers  
Species/Gene  Sequence 5’-3’ 
mActin 
s CGAGGCCCAGAGCAAGAG 
as CGTCCCAGTTGGTAACAATGC 
mCD19 
s GGAGAGCACCCGGTCAGA 
as CCACACTGCTGACCTTGCAA 
mc-Myc 
s TTCATCTGCGATCCTGACGAC 
as AGGGGTCAATGCACTCGGA 
mCripto 
s CACCAACCCAGGGTATCAGTT 
as AGAGTTCTGTCCAGTGTCGTC 
mDnmt3b 
s ACTGCCTGGAGTTCAGTAGGA 
as CCCTGTCTGATGGAGTTCGAC 
mEomes 
s CCTGGTGGTGTTTTGTTGTG 
as TTTAATAGCACCGGGCACTC 
mEsrrb 
s GCACCTGGGCTCTAGTTGC 
as TACAGTCCTCGTAGCTCTTGC 
mFgf5 
s TGTGTCTCAGGGGATTGTAGG 
as AGCTGTTTTCTTGGAATCTCTC 
mFoxa2 
s TAGCGGAGGCAAGAAGACC 
as CTTAGGCCACCTCGCTTGT 
mGapdh 
s TGCACCACCAACTGCTTAGC 
as GGCATGGACTGTGGTCATGAG 
mGata6 
s GACTCCTACTTCCTCTTCTTCTAATTCAGA 
as ACCTGAATACTTGAGGTCACTGTTCTC 
mGdf3 
s GGCCTCGCAGGACTTATGC 
as TGGTCGCAGGTTATAGTAGGAC 
mHprt 
s TTGAAATTCCAGACAAGTTTGTTGTTGG 
as CCTGCTAATTTTACTGGCAACATCAACA 
mKlf4 
s TCCTTTCCAACTCGCTAACCC 
as CGGATCGGATAGCTGAAGCTG 
ml-19 
s TGATCTGCTGACGGAGTTG 
as GGAAAAGAAGGTCTGGTTGGA 
mLin28 
s TCACTGGCCCTGGTGGTGTGTT 
as TGGACACGAGGCCACCATATGG 
mNanog 
s CTTACAAGGGTCTGCTACTGA 
as TCTGCTTCCTGGCAAGGACC 
mNodal 
s ACCATGCCTACATCCAGAGC 
as ATCAGCATTGTGGAATGCAA 
mOct4 
s CGTGGAGACTTTGCAGCCTG 
as GCTTGGCAAACTGTTCTAGCTCCT 
mRex1 
s CTCCTAGCCGCCTAGATTTCCA 
as CGTGTCCCAGCTCTTAGTCCATT 
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mSox17 
s TTTAAATGGGAGGGAGGGTC 
as TCAGATGTCTGGAGGTGCTG 
mSox2 
s GAGTGGAAACTTTTGTCCGAGA 
as GAAGCGTGTACTTATCCTTCTTCAT 
mTcf3 
s TTTTAAGGGAGGTGCGTATCCT 
as GGGGCCATTTCATCTGTAGGTA 
mTert 
s TCAAGAGCAGTAGTCGCCAG 
as TCTCGGGACAGGATAGCATCT 
mTle1 
s TCTGAGTGGGCAGTCTCACTT 
as GAAGAAGGGTCCTCGTTAGACA 
s indicates the sense and as the anti-sense primer. 
 
 
 
Table A2. Primers used for the amplification of human transcripts by semi-
quantitative RT-PCR 
 
 
Human primers  
Species/Gene Tm n  Sequence 5’-3’ 
hβ-actin 60ºC 25 
s TCACCACCACGGCCGAGCG 
as TCTCCTTCTGCATCCTGTCG 
hGata6 60ºC 25 
s CCATGACTCCAACTTCCACC 
as ACGGAGGACGTGACTTCGGC 
hNanog 60ºC 25 
s AGCCTCTACTCTTCCTACCACC 
as TCCAAAGCAGCCTCCAAGTC 
hNestin 65ºC 25 
s CAGCTGGCGCACCTCAAGATG 
as AGGGAAGTTGGGCTCAGGACTG 
hOct4 60ºC 25 
s CTTGCTGCAGAAGTGGGTGGAGGAA 
as CTGCAGTGTGGGTTTCGGGCA 
hPax6 60ºC 25 
s AACAGACACAGCCCTCACAAACA 
as CGGGAACTTGAACTGGAACTGAC 
hSox1 60ºC 25 
s CAATGCGGGGAGGAGAAGTC 
as CTCTGGACCAAACTGTGGCG 
hSox2 60 ºC 25 
s CCCCCGGCGGCAATAGCA 
as TCGGCGCCGGGGAGATACAT 
hT 63ºC 30 
s GTGACCAAGAACGGCAGGAGG 
as TGTTCCGATGAGCATAGGGGC 
Tm indicates the annealing temperature of the primers and n the number of cycles of amplification used in 
PCR reactions. s indicates the sense and as the anti-sense primer. 
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Table A3. Primers for the selective amplification of human or mouse genomic 
regions by real time quantitative PCR 
 
Human specific primers for replication timing, ChIP and MeDIP analysis 
Species/Gene  Sequence 5’-3’ 
h-globin promoter  
s TTTGTCCCCGGACCTGCTGCC 
as CCCCACGGTCGGCTGACAC 
hAmylase promoter 
s GGTGAGTCTGTGTGGTCAGCAGTCTCT 
as CCACGGTGCTCTGGTAGATAACGTAAG 
hBmp4 promoter 
s CAGCTCCTTTCTCCATAACCTGA 
as GGTACTAGAAAGCATGCACCGAC 
hCdx2 promoter 
s AACAACCACTGCTCCTGTCTCC 
as CGACCTGACACAGCTAAATATTCAA 
hCga promoter 
s ATGGCTCCAAACAAAAATGACC 
as TCCTCACCTGCTTTTATACCAGC 
hCripto promoter 
s ACTTCAAGTCTGGAGCCCCC 
as GCCTGAGGAGCTAGGTGTGTGT 
hCxcr4 promoter 
s GAAGTCACTATGGGAAAAGATGGG 
as GCTTGCTTTCTTCAGGAAATTCTG 
hDazl promoter 
s TCCTGAATGTCAAACTGGCATT 
as CGCCATCACTTTTAGCTTCACA 
hDnmt3b promoter 
s TGTGTGTCTCCGTTCGGGTT 
as ATCAGAAGCCCTAAGCGGGA 
hDppa4 promoter 
s AAATAGCTTTCTTCAAGCCGCC 
as CGGAGACATTGGGAGATTGAG 
hEbf promoter 
s ACTTGAAGTAGCAAAGCCGGCA 
as TGTAATGATCACAGGCCGGTGG 
hEomes promoter 
s AGGAAAAGAAAGTCACAGGCGA 
as CATCGGTCAAGTTGACCACTTG 
hEsxl1 promoter 
s AGCATGTTCACTACCTGCACCA 
as TATAGCGGTACGGTGCCTTCC 
hFgf5 promoter 
s AAAAACAGCCTTCTCCCCGAAC 
as CACTGCTTCTACGTCTTTCGGC 
hFoxa2 promoter 
s CCCTTACTCAAGCTTCAATGCG 
as TTCTTGGTTCTGAAAACCTGGC 
hGata4 promoter 
s CGGTAGCACTTGGGCATTTT 
as AGCAGGCAAAGTCCAGGCT 
hGata6 promoter 
s ACGACCTGAGCCGTAGCAT 
as CCTAGCCCCTTCACAGCAAA 
hGbx2 promoter 
s GGCAGGCAAAATGTGAATGAG 
as GAAGCCGGCGTACTTATCTCC 
hGdf3 promoter 
s AAAGCCATCGTGAGCCTCAT 
as GACAGAGTGAAAAGGAGACATGCA 
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hHoxb1 promoter 
s CTAGCCCACCACCCTAAGACAA 
as GGCTCCTGGGTTATTAGATTTGG 
hIgf2/hH19 ICR 
s ACATTCACACGAGCATCCAGG 
as GCTCTTTAGGTTTGGCGCAAT 
hIkaros promoter 
s GAACAATGCGAGTGAGCAACTTCAGG 
as GGCCGAGCGTCCCGCCCAGGCTG 
hMash1 promoter 
s CAATTTCTAGGGTCACCGAGGA 
as GAACGGTGTGGAGGTGAGGA 
hMixl1 promoter 
s GTTTGACCAACCTGGTACAGGG 
as GCAGGCGACAGAACTCTCTTCT 
hMyf5 promoter 
s TGTCTGTAGAGGAAAGGCGGA 
as ATATTCTTTCGGGAGGGAGGC 
hNanog promoter 
s ACGGCCTCCCAATTTACTGG 
as GGTTCAACAGGAATGGGATAAAAC 
hNestin promoter 
s TTTCCAGGCAGCGTCTCTCTAG 
as GGATGTGGCCAGGTTTTTGTT 
hNeuroD promoter 
s CTTCACTGCGTGCCTCAGTCT 
as GAGAGATTAACCCTTTCAGGCG 
hNeurog1 promoter 
s TTGTTGCGCCGGGTACTTAAG 
as GCCGGTCTCCTGAGTGATGT 
hOct4/Pou5f1 promoter  
s TTGGGAGTTGAAAGTTGGGTGT 
as AGGCTGGTCTTGAATTCCTGTC 
hPax6 promoter 
s AAAGGACAGCACAGAAACTTGC 
as TCAAGTGAAGGTTTCTGGGTTG 
hPdx1 promoter 
s GAATGCCAGAGTTTCGTGTGTTT 
as CCCAGCTCTCTAGGTCAGAAGC 
hPsc1/Rbm27 promoter 
s GTGAACGTATTGCACGTTGTGTTGC 
as TCAGCCTGGTTCCTTCCTCTCGTTT 
hPrce/Espl1 promoter 
s AGGAAGGAAGAGCGGAATCGT 
as GGAAGGAGGCAAAGAATCACAT 
hRex1/Zfp42 promoter  
s CTCATGTGATCCCCCCGTCT 
as TACGCGTGGGTGTAATCACATT 
hSatellite repeats 
s ATCGAATGGAAATGAAAGGAGTCA 
as GACCATTGGATGATTGCAGTCA 
hSox1 promoter 
s TCTTTGGCAAGTGGTTTGTGC 
as GGAGGCAACGACAACAAAAAAA 
hSox17 promoter 
s TATCAACGGTGTCTTTCGCATT 
as AAGCCGAGGGTGTTTCAGTG 
hSox2 promoter  
s CGTGAGAGAGTGTTGGCACCT 
as TTGTTCTCCCGCTCATCCAC 
hSox3 promoter 
s AATGGCCACAGAGCAGAGACA 
as TGTGGAAAGTATGTGTGGGACG 
hSox7 promoter 
s TGGCAGTCGGAGTATTAAGAACG 
as TCAGAAAATCAACCCAACCAGG 
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hSycp1 promoter 
s GAGCCTGACAGTTTCCCTAGCA 
as CTGGCAGTTCAACGGCTAAATA 
hTekt1 promoter 
s GAGTGACTTCTGGAGTGTTTGCC 
as GAGGGTTAAAAATCAGGAAGCCA 
hTert promoter 
s TCACGTCCGGCATTCGTGGT 
as TCGAATCGGCCTAGGCTGTG 
hTle1 promoter 
s CTGTTTTCCCCACCATCTCGT 
as TCCTTCACCTTCGTGTGCTTCT 
hWnt3 promoter 
s CGCGTGATTGACAGGCTG 
as CAGCCGGGTTTGAGGATGT 
hZic1 promoter 
s CTGTGTTTACTAGCCCCATCCC 
as ATTCCTCTTCCTCCTTTGCCC 
   
D. melanogaster EMC  
s GGTTTCAAGTTGTGGTCCAAGTTCC 
as GTTCGTTCGGCTGGAGAGAGAT 
Mouse specific primers for replication timing, ChIP and MeDIP analysis 
Species/Gene  Sequence 5’-3’ 
m-globin promoter  
s CCACAAGCTGCGTGTGGAT 
as ATGCCGCCTGCCAGGT 
mAmylase promoter 
s CAAAGCAAAATGAAGTTCGTTCTGCTGC 
as GAAGTTATCTTACCTGCACCCCTCCAAATC 
mBmp4 promoter 
s TTGAAGAGGTATCTCCTTCGGG 
as GATTGGTTTAAAGGGTGGCCT 
mCdx2 promoter 
s ACCACCTTCTGCCTGAGAATGTAC 
as CCTCCAATCACAGGTTCAAAGACT 
mCga promoter 
s GCCATCCAATCACTGGGTAGA 
as TCCCACTGTCTTTTATACCAGC 
mCripto promoter 
s CTGTATAGGGTCAGCACTTCCAGCC 
as CCCCGGAGGCACCCTTTACT 
mCxcr4 promoter 
s CCTTCCTCCTTTGGCTAATCCT 
as TCACTCTCAAAACTGTGTGCGG 
mDazl promoter 
s TGCCGCCCGTTATTAATTTC 
as CAAAAATGGCACCTCGAAGG 
mDnmt3b promoter 
s CGAAAAGCCAATGCAGGGTTGCTGT 
as GCACACACGCACATACAAGCACATTCAC 
mDppa4 promoter 
s TCCCAGATCTACAGTTGCCAGG 
as GGCCAGAAATGCGCTTTGT 
mEbf promoter 
s ATTGGCTGTGATAAGGCGGAAGGATGACG 
as CCCCAGAGCTAAACACAGGCACACTAA 
mEomes promoter 
s CCTCCTCTCACCCCAACAGAGCGAA 
as AACCGATGTCTAGCTTGTTGGTCACAGG 
mEsx1 promoter 
s GCGAACTCGGAGCTGCTAAA 
as TCCACGTGCTGTTAACTGACTTTT 
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mFgf5 promoter 
s CATGTGTCCCAGCCAACTCACT 
as TTCCCAGGCTCCAGATGGC 
mFoxa2 promoter 
s CAGCCTAGACTTCTCTGAGATCCTCC 
as TCAATAATGGGCCTTGTGGGA 
mGata4 promoter 
s GATCTGAGGCTAGCAAGGCAT 
as TTTGCTGCTCTGCCAAGGA 
mGata6 promoter 
s AGCTCTTATTGTCCGCTAGGGC 
as TGAAGAGAAGGAGGAGGGATCC 
mGbx2 promoter 
s CGAACAGCTGCTGGAGCTGGAGAAAG 
as GCACCTCGCTGAGTTTGAGGGCG 
mGdf3 promoter 
s GCTCCCAGAAGTTATCTTATTGCC 
as TCAGCAGTGTACAGCGTGAGTG 
mHoxb1 promoter 
s CTTCCTAGTCATCCTTTTGTCCCA 
as CTTATCCCAGAACCCCCATTC 
mIkaros promoter 
s CCAGTTTCAGGGACTCGGCT 
as TCGGGGAACACGGGACAC 
mMash1 promoter 
s CCAGGCTGGAGCAAGGGA 
as CGGTTGGCTTCGGGAGC 
mMixl1 promoter 
s CACAGATACTCTAGGCAGGAGCAGC 
as CCTGTCACCATCAAAGGCGC 
hMyf5 promoter 
s GGAGATCCGTGCGTTAAGAATCC 
as CGGTAGCAAGACATTAAAGTTCCGTA 
mNanog promoter 
s CCCTCTGAGTTTGACCGGTGA 
as CAAGCTAGGATGTTAGGTCTCCCTG 
mNestin promoter 
s GGAGCACTGGCAGACTTCCCT 
as GGTGTTGGAAACCTCGTGAACTG 
mNeuroD promoter 
s TTCAGGCTAGGACATAGACTCAGTGA 
as CCCTTTGTGGCAGCAGAAGA 
mNeurog1 promoter 
s TTGTTGCGCGCCGTACTTAAGG 
as TGGTCTCCTGAGTGATGTCGCC 
mOct4/Pou5f1 promoter  
s GGCTCTCCAGAGGATGGCTGAG 
as TCGGATGCCCCATCGCA 
mPax6 promoter 
s GGTCAGAGGTAATTATGTCACCGCG 
as TTATTCCAGAGTTGAGCCGTGAGCA 
mPdx1 promoter 
s GGACTACATCTTGAGTTGCAGGC 
as CCCCCTCGCTATGTTTTTTGT 
mPsc1/Rbm27 promoter 
s ACATAAACGCACCGCACGTTGT 
as CCTGGTTACTTCCGCTGGTTTTT 
mPrce/Espl1 promoter 
s GACAGCGCGGCAGATAAACTAC 
as GCACCTCCTTTCAAATATCCCTAG 
mRex1/Zfp42 promoter  
s TTTGCGGGAATCCAGCAGT 
as CGTCCCATCGCCACTCTAGAC 
mSox1 promoter 
s ACAAGAGGAGGCAGCGAACC 
as TCGCAGGTGGAAAGTTTCTCC 
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mSox17 promoter 
s TGAGGCTCGCTGTAGAAGAGTG 
as AGCTGTGCCCGTAACCATTT 
mSox2 promoter  
s CCATCCACCCTTATGTATCCAAG 
as CGAAGGAAGTGGGTAAACAGCAC 
mSox3 promoter 
s AGGAGGAAGCGGGAATCCAG 
as AAACCTCCGCTGCCCG 
mSox7 promoter 
s TCCACAGTGCCAGTTTAGGGAA 
as CAGTAAACGTGGGCAGCCAC 
mSycp1 promoter 
s AAGCCATCTTTAGCACCCAGC 
as TGGTTGTTAGTTGCCTGGTGG 
mTekt1 promoter 
s GATAAGCAGATACACCCAGCTCATC 
as CCTTCTGGTGTGCATGAAAACA 
mTert promoter 
s GTCGCACCACAATAAAGCCTTAAC 
as GCTGTGGTTGACACAGACAGTGA 
mTle1 promoter 
s ATCCCTCCCCCAACAAGAAA 
as TTGAAGTTTGCAGAAGCCTGTG 
mWnt3 promoter 
s CATTTTCCTAGCCCCTGATCC 
as TTTCTGTGATCCCTTGGCACTT 
mZic1 promoter 
s AGGGAAAAGAAATCGTGGCATT 
as CGCTTGACATCCCCTTTTGA 
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Figure A1. Comparison of replication timing profiles between mES (E14tg2A, B6 and Dc7), mEpiS 
(129, B6/CBA and NOD) and hES (H1, H7 and H9) cell lines. (a) The proportion of genes that replicate 
early (E), middle-early (ME), middle (M), middle-late (ML) or late (L) in S-phase are represented as a pie-
chart. The late replicating set (from yellow to red) is separated from the early set (dark and light green) in 
mouse and human cells. (b) Proportion of candidate loci that replicate in each S-phase fraction, expressed 
as a percentage of the total for mES (E14tg2A, B6 and Dc7), mEpiS (129, B6/CBA and NOD) and hES 
(H1, H7 and H9) cell lines. 
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Figure A2. Comparative replication timing analysis of mES (E14tg2A, B6 and Dc7), mEpiS (129, 
B6/CBA and NOD) and hES (H1, H7 and H9) cell lines. The replication timing of each gene was defined 
as early (E), middle-early (ME), middle (M), middle-late (ML) or late (L) and shown as a gradation of 
colours from green (earliest) to red (latest). 
 
 
 
 
 
 
 
 162 
 
 
Figure A3. Replication timing analysis of H1 hES cells re-swapped to CM conditions after growing 
in CDM
activin
 . (a) The proportion of genes that replicate early (E), middle-early (ME), middle (M), middle-
late (ML) or late (L) in S-phase is represented as a pie-chart for H1 hES cells grown for 14 passages in 
CDM
activin
 and re-swapped back to CM conditions for 6 additional passages [H1p47(CDM14;RS6)]. (b) 
Proportion of candidate loci that replicate in each S-phase fraction, expressed as a percentage of the total 
for H1p47(CDM14;RS6). 
 
 
 
 
 
 
 
 
 
 
 
Figure A4. Human ES cell populations grown under CDM
activin
 conditions are more homogeneous 
than cells grown under standard CM conditions. Flow cytometry correlated measurements of cells size 
(forward scatter) and internal complexity (side scatter) of hES cells grown under standard CM (H1p58CM), 
transferred to CDM
activin
 conditions [H1p53(CDM21)] and backwards to CM conditions 
[H1p47(CDM14;RS9)]. When hES cells are transferred from CM to CDM
activin
 conditions the population of 
cells become more homogeneous as highlighted by the differential position of region 1 (R1) in red. This 
can be reverted by transferring cells back to CM growth conditions. These findings are representative of 
three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 163 
 
Figure A5. Differential gene expression of mES and mEpiS cell populations. Real-time PCR analysis 
of transcription profiles of key early developmental genes in mES (average of three mES cell lines – 
E14tg2A, B6 and Dc7; green bars) and mEpiS cells (average of three mEpiS cell lines – 129, B6/CBA and 
NOD; orange bars). (a) Stably expressed genes (Oct4, Sox2, Cripto and Nodal) across mES and mEpiS 
cells. (b) Genes that are downregulated in mEpiS cells in contrast to mES cells (Nanog, Gdf3, Rex1 and 
Stella) and (c) upregulated in mEpiS cells (Eomes, Fgf5, Gata6, Sox17, Foxa2 and Tcf3). Mean and 
standard deviation of three independent experiments are shown. Data was normalized to the expression of 
two housekeeping genes (Actin and L19). 
 
 
 
  
 
Figure A6. Cell culture adaptation and karyotype 
abnormalities are not associated with earlier replication 
timing profiles in hES cells. The replication timing of 
individual loci was assessed in H1-BH1 hES cells from early 
(P19) and late (P154) passage number cultures, as provided 
by Peter Andrews’s laboratory. H1-BH1 late passage cells 
were previously referred as “culture adapted” and are 
karyotypically abnormal (Baker et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
